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ABSTRACT 
 
The typhoid fever causing Salmonella Typhi remains an important public health problem in 
Africa. More importantly, the emergence of the highly antimicrobial resistant H58 Salmonella 
Typhi haplotype is of greater concern. Rapid and highly discriminatory molecular methods are 
essential for prompt and effective epidemiological investigation of typhoid fever outbreaks. 
Traditional methods, such as pulsed-field gel electrophoresis (PFGE) are time-consuming and 
offer subjective discrimination of highly homologous isolates. On the contrary, molecular 
subtyping based on multiple-locus variable-number tandem-repeats (VNTR) analysis (MLVA) is 
a rapid, PCR-based method which has been successfully used for subtyping homogenous isolates 
of the Salmonella genus. This study describes the development and application of a MLVA assay 
for molecular characterization of Salmonella Typhi isolates from sub-Saharan Africa (SSA). This 
involved evaluation of thirteen VNTR loci using a validation panel consisting of 50 diverse 
Salmonella Typhi isolates. A MLVA assay consisting of five highly variable VNTR loci was 
adopted. The developed MLVA assay was used, along with PFGE, to characterize 316 
Salmonella Typhi isolates from SSA. A total of 226 MLVA types were identified as compared to 
143 PFGE fingerprint types. MLVA typing results indicated intracontinental spread of 
Salmonella Typhi. For the rapid identification of H58 Salmonella Typhi, a conventional PCR 
targeting a mutation that is exclusive to the H58 haplotype was employed on 105 isolates from 
South Africa as well as 121 isolates from other SSA countries. Approximately 54% (105/214) of 
the Salmonella Typhi isolates from South Africa and 62% (75/121) of the isolates from other 
SSA countries were identified as H58 Salmonella Typhi. The MLVA tool was able to 
discriminate among H58 Salmonella Typhi isolates. MLVA is viable alternative to PFGE for 
subtyping Salmonella Typhi and can be used as first-line assay for routine screening of 
Salmonella Typhi isolates in SSA, providing excellent discrimination of isolates.  
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Chapter 1  
 
Literature review 
 
1.1 Background           
Bacterial food-borne pathogens are a major cause of morbidity and mortality worldwide [1-3]. 
The widespread bacteria of the genus Salmonella are an important and leading cause of 
foodborne diseases and are mostly identified as aetiological agents of foodborne disease 
outbreaks [1, 3-5]. Salmonellae are transmitted from person to person and through consumption 
of contaminated food; hence making Salmonella enterica infections a huge problem in 
developing countries where there is poor sanitation and standard hygiene practices [6]. 
Epidemiological investigations play a huge role in public health improvement [2]. During food-
borne disease outbreaks, epidemiological investigations are carried out in order to determine 
the primary sources of bacterial contamination. These can be used to link ill patients following 
consumption of contaminated food to the sources of bacterial contamination. Strong evidence 
linking exposure to incidence of infection within a population can be obtained through 
epidemiological investigations thereby improving public health management [2].  
 
Traditional surveillance methodologies for Salmonella enterica species are based on 
phenotypic characterization of the bacterial pathogen [4]. The phenotypic techniques such as 
serotyping and phage typing are very useful; nonetheless they have a limited ability to further 
characterize predominant phenotypes within a species. Presently, newer methods based on 
characterization of bacterial genome are being employed [4, 7].  
 
Molecular techniques have enhanced traditional surveillance and have become an essential tool 
for identifying, tracing and preventing dissemination of pathogenic bacteria [2]. These 
techniques have presented an exciting opportunity to learn about the genetic makeup of 
pathogenic bacteria consequently enhancing our knowledge and understanding of these 
organisms [2, 8]. It is through molecular epidemiological investigations that the true extent of 
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genetic diversity of pathogenic bacteria can be established [9]. Molecular subtyping techniques, 
in particular the application of molecular markers, are used to scrutinize variations in 
nucleotide sequences amongst bacterial isolates, and have become an integral part of 
epidemiological investigations of outbreak related isolates [8, 9]. These techniques are based on 
the premise that epidemiologically related isolates are derived from the clonal expansion of a 
single precursor, and that share characteristics that differ from epidemiologically unrelated 
isolates [4]. The application of molecular epidemiological techniques for subtyping food-borne 
bacterial pathogens is important to improve public health [2].  
 
Molecular epidemiological techniques are fundamental tools in surveillance and outbreak 
investigations of human Salmonella enterica infections [10]. The use of these techniques for 
food-borne disease outbreaks caused by Salmonellae has resulted in a plethora of subtyping 
techniques with varying ability to differentiate homogenous serovars belonging to Salmonella 
enterica species [7, 8]. Currently, macro-restriction analysis of chromosomal DNA by pulsed-
field gel electrophoresis (PFGE) is a common technique that has been used to discriminate 
Salmonellae at a DNA-level. PFGE has been used extensively for fingerprinting isolates in 
outbreak situations and is relatively inexpensive to use. Although PFGE has been used 
successfully in tracking the source of bacterial infection, this technique has limited ability to 
differentiate homogenous species and does not display equal sensitivity with different bacterial 
species [8].  
 
Amongst the Salmonella enterica species, Salmonella enterica subspecies enterica serovar 
Typhi (Salmonella Typhi) is one of the serovars known to be highly homogenous [11]. 
Salmonella Typhi is the causative agent of typhoid fever, a grave systemic infection that 
remains an important cause of morbidity and mortality in developing countries [12, 13]. 
Molecular epidemiological investigation of Salmonella Typhi isolates is critical in 
understanding dissemination of the bacteria more especially in the African context where it is 
endemic [13, 14].  
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1.2 The Salmonella bacterium      
Salmonellae belong to the family Enterobacteriaceae [15]. Isolates of this genus are Gram-
negative, non-sporulating, facultative-anaerobic bacilli and are motile by peritrichious flagellae. 
The Salmonella bacterium emerged from Escherichia coli (E. coli) approximately 100 to 150 
million years ago and has adapted to colonize various niches as it can be found as both a 
commensal and a pathogen in human and animal, and can also survive free in the environment 
[1, 15].  
 
Biochemically, Salmonella isolates are characterized by glucose gas and hydrogen sulphide 
production, citrate utilization and fermentation of arabinose, rhamnose as well as trehalose. 
Salmonella isolates test negative for urease, indole and test positive for lysine- and ornithine-
decarboxylase [16].  
 
The Salmonella genus is divided into two species namely Salmonella bongori and Salmonella 
enterica (Figure 1.1) [17]. The species Salmonella enterica can be further subdivided into 6 
subspecies including Salmonella enterica subspecies enterica, Salmonella enterica subspecies 
salamae, Salmonella enterica subspecies arizonae, Salmonella enterica subspecies diarizonae, 
Salmonella enterica subspecies houtenae and Salmonella enterica subspecies indica. The 
subspecies are further classified into serovars based on bacterial cell surface antigens [18]. 
 
According to the Kauffmann-White-Le Minor classification scheme, the serovars can be 
determined based on the immunologic reactivity of the two surface structures including the O-
antigen (lipopolysaccharide) and the H-antigens (flagella proteins) [17, 18]. The Vi-antigen 
(subtype of the capsular K antigen) is only found in some pathogenic Salmonella. This 
antigenic diversity has led to the assignment of Salmonella isolates to approximately 2500 
serovars. Salmonella enterica subspecies enterica is the most important subspecies, causing 
approximately 99% of all human and animal Salmonella infections. Clinically, this subspecies 
can be split into typhoidal Salmonella and non-typhoidal Salmonella. While the non-typhoidal 
Salmonellae are known for extra-intestinal disease and gastroenteritis, the typhoidal 
Salmonellae are characterized by invasive disease, and consist of Salmonella enterica 
  Chapter One  
Introduction                                                                      
4 
 
subspecies enterica serovar Typhi (Salmonella Typhi) and Salmonella enterica subspecies 
enterica serovar Paratyphi A, B and C (Salmonella Paratyphi A, B and C) [17, 18].  
 
Salmonella Typhi isolates share common antigenic determinants including being serologically 
positive for lipopolysaccharide antigens O9 and O12, flagella protein antigen Hd and the 
polysaccharide capsular antigen Vi [18]. In contrast to the other ~2500 serovars of Salmonella 
enterica subspecies enterica (with the exception of Salmonella Paratyphi A, B and C), 
Salmonella Typhi is exclusively adapted to the infection of human host [18, 19]. This 
specificity for human suggests that Salmonella Typhi might be younger than the split that 
occurred several million years ago between human and higher primates, and is possibly as 
young as the expansion of the anatomically modern humans from Africa which occurred 
~50,000 to 100,000 years ago [19]. 
 
 
Figure 1.1 Classification of Salmonella species [17] 
 
  Chapter One  
Introduction                                                                      
5 
 
1.2.1 Typhoid fever         
Salmonella Typhi is the aetiological agent for the life threatening systemic disease known as 
typhoid fever [20]. This invasive disease is characterized by high fever, headache, 
gastrointestinal symptoms (including abdominal pain, nausea, constipation and diarrhoea) and 
systemic infection which can be detected by isolation of the Salmonella Typhi bacterium from 
patient’s blood or bone marrow [12, 21] 
 
Recent global estimates indicate that typhoid fever causes 26.9 million illnesses annually [13, 
20]. Although not common in industrialized countries, typhoid fever remains a major public 
health problem in developing countries. Typhoid fever is endemic in Latin America, Southeast 
Asia and Africa (Figure 1.2) where the disease is exacerbated by poor living conditions [20, 22-
27]. The incidence of typhoid fever in the sub-Saharan African region has not been well 
characterized [20, 28]. In 2010, Buckle and colleagues conducted a study aimed at calculating 
the global burden of typhoid fever disease [13]. In their study, they concluded that there are 
approximately 724.6 typhoid fever cases per 100 000 population in Africa [13]. Even so, the 
true burden of typhoid fever in Africa is still unclear due to under-reporting as only severely ill 
patients seek hospital treatment and, lack of blood-culture facilities essential for diagnosis [23, 
26, 29]. These estimates have relied on limited available data from countries in the sub-Saharan 
African region [23, 26, 29] 
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1.2.2 Pathogenesis of typhoid fever     
Poor environmental sanitation and lack of provision of safe drinking water remain the main 
cause of typhoid fever endemicity in developing countries [20]. Contrary to other Salmonella 
serovars, humans are the only reservoirs for Salmonella Typhi [30]. The explanation behind 
this host specificity is still not clear. However, it has been reported that Salmonella Typhi could 
have undergone some mutation which could have led to specificity to the human host [30]. 
Typhoid fever is considered a disease of children, adolescents and elderly people [30, 31]. 
Although there are consistent reports of infections in very young children, these infections are 
generally uncommon [30]. This could be explained by the fact that young children display 
atypical response to Salmonella Typhi infection resulting in misdiagnosis [30].  
 
Salmonella Typhi infectious dose varies between 1000 and 1 million organisms [32]. Once 
ingested, the bacteria survives the gastric-acid barrier in the stomach passing through the 
epithelial cells to proliferate in the Peyer’s patch [33]. The Salmonella Typhi bacteria migrate 
into the mesenteric lymph nodes where they multiply [33, 34]. They are then released in the 
blood stream (primary bacteraemia) where they translocate to the reticuloendothelial cells of 
the liver and spleen. During the re-entry of Salmonella Typhi (secondary bacteraemia), the 
bacteria are then removed from the blood via the liver to infect the gallbladder [34]. The 
gallbladder has been reported to be the preferred site of Salmonella Typhi residence in 
persistently infected humans. Gallbladder infection by Salmonella Typhi results in excretion of 
the bacteria in urine and faeces (Figure 1.3) [34, 35]. The infection of the gallbladder might 
lead to reinfection of the small intestine with the second exposure of Peyer’s patches to the 
Salmonella Typhi bacteria. This may result in inflammation, ulceration and necrosis ultimately 
complications include endocarditis, meningitis, renal failure and pneumonia [32, 34]. 
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Figure 1.2 Salmonella Typhi infection of the epithelial cells in the intestinal tract [30] 
 
1.2.3 Salmonella Typhi carriage        
Salmonella Typhi reaching the gallbladder can establish an acute, active infection which is 
accompanied by inflammation or can persist in this organ long after the symptoms subside [32, 
36]. Bile is an important digestive secretion in the liver that serves as potent emulsifying and 
antimicrobial agent in the gastric tract, however, Salmonella Typhi has adapted to withstand 
these harsh conditions [36]. These bacteria are concentrated in the bile-concentrated 
gallbladder. Reports indicate that gallbladder damage and the presence of gallstones contribute 
to carriage of Salmonella Typhi, even though the precise role of gallstone in carriage has not 
been described [36]. There are life-threatening risk factors associated with carriage of 
Salmonella Typhi in the gallbladder including cancer of the gallbladder, pancreas, lung and 
female colorectum [36-38]. 
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Chronic typhoid fever carriage may develop as a result of acute typhoid fever infection or after 
subclinical infection with the bacterium [39]. It has been reported that subclinical cases are five 
times higher than acute cases, with about 10% of healthy individuals identified as carriers [39]. 
The infection of the gallbladder by Salmonella Typhi can result in long-term shedding of the 
bacterium through urine or faeces [34, 40]. This plays a major role in the transmission of the 
diseases. It has been reported that approximately 10% of untreated patients and 3% of treated 
patients become temporary carriers who shed the bacteria for months or years [34, 39, 40]. 
 
Since Salmonella Typhi is a human restricted pathogen, carriers are mostly responsible for 
endemic nature of typhoid fever and for community outbreaks [34]. Such was the case of a 
cook from New York City, Mary Mallon, also known as “Typhoid Mary”, who in the early 20th 
century, served as a source for typhoid fever as she shed high levels of Salmonella Typhi [41]. 
While Typhoid Mary was asymptomatic and leading a normal life, reports indicate that she 
infected approximately 54 people with typhoid fever. During those days, she had to be 
quarantined to stop her from spreading typhoid fever further [41]. 
 
1.2.4 Typhoid fever prevention and vaccines       
The provision of safe drinking water, hygienic food preparation and proper management of 
sewage systems could be the most effective way to prevent typhoid fever spread [28, 32]. This 
has been shown in a cross-sectional, laboratory-based surveillance study in the United States of 
America (USA) from the years 1999 -2006, where a dramatic decline in incidence rates and 
associated mortality of typhoid fever was observed following widespread implementation of 
municipal water and sewage treatment systems. Currently the majority of cases in the USA are 
associated with travel to typhoid fever endemic countries [28]. Unfortunately, the provision of 
safe drinking water and foodstuffs in the developing countries, particularly in rural areas, might 
not be achieved in the near future [42].  
 
The use of vaccines against typhoid fever can provide short to medium term protection against 
this disease [43]. The first typhoid fever vaccine was developed in the late 1800s [44]. This 
vaccine was developed by Almroth Wright in Britain using a heat- and phenol-treated 
Salmonella Typhi preparation. The vaccine was used by the British Army during the Anglo-
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Boer War in southern Africa in 1899 for protection against typhoid fever infection. Major 
Frederick Russell of the US Army Medical School later modified the vaccine by using 
inactivated whole-cell Salmonella Typhi. The widespread use of this vaccine continued 
amongst the soldiers and the Navy from the year 1909 [44]. It was later established that the 
efficacy of the whole-cell vaccine over a period of 3 years was 73%. Although whole-cell 
vaccines were very effective, the vaccine demonstrated a high rate of adverse effects [44, 45]. It 
is for this reason that the use of whole-cell typhoid fever vaccines was renounced [44]. 
 
Newer typhoid fever vaccines have been developed and these provide an alternative to the 
highly efficacious whole-cell vaccine [32, 46]. There are two commercially available typhoid 
fever vaccines including Ty21a (oral) and Vi polysaccharide (parental) vaccines [32, 46, 47]. 
The Ty21a vaccine is a live-attenuated vaccine given orally in adults and children six years or 
older. The vaccine has a 50% protection efficacy over 3 years and there are no significant 
adverse effects reported. The Vi vaccine is a purified Vi antigen and is administered as 
intramuscular injection in adults and children over two years of age [32]. Although this vaccine 
provides 60% efficacy over a period of two years, a booster dose is still required every after 
two years to maintain the protection against typhoid fever [46-48]. 
 
Currently, the commercially available vaccines are recommended for travellers to endemic 
regions, laboratory workers and household contacts of typhoid carriers, but are not used 
routinely [32]. Mass immunization coupled with adequate provision of safe drinking water has 
been recommended in typhoid fever endemic areas [32]. 
 
1.3 Epidemiology of typhoid in Africa        
In Africa, typhoid fever is mainly a disease of young children, adolescents and the elderly [22]. 
Even though the true burden of this disease has not been established in SSA, there have been 
several reports of typhoid fever from a number of African countries [13, 22].  
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1.3.1 Mediterranean North African countries including Morocco, Algeria, Tunisia, 
Libya and Egypt 
The incidence of typhoid fever in the Mediterranean North African countries (MNAC) is 
estimated at 10-100 cases per 100 000 populations for the years 2000 to 2005. Outbreaks in this 
area have been attributed to the consumption of sewage-contaminated and untreated water [49].  
 
1.3.1.1 MNAC: Libya 
For the years 1975 to 1980, Salmonella Typhi was identified amongst the most frequently 
reported Salmonella serotypes [50]. The incidence of typhoid fever in Libya has been estimated 
at 7-21 cases per 100 000 population between the years 2004 to 2006 [49]. 
 
1.3.1.2 MNAC: Tunisia 
Studies have shown that Salmonella Typhi was identified amongst the eight most frequently 
isolated Salmonella serotypes in Tunisia [49, 51, 52]. Typhoid fever outbreaks in this country 
were recorded in 1999 in hospitalized patients in Sousse City, and in 2004 and 2005 in 
southeast of Tunisia [52, 53]. The incidence of typhoid fever in Tunisia has been estimated at 
1-6 cases per 100 00 population per year [49]. 
 
1.3.1.3 MNAC: Morocco 
The incidence of typhoid fever in Morocco is estimated at 8-17 cases per 100 000 population 
[49, 54]. Reports indicated that for the years 1999 to 2000, Salmonella Typhi dropped from 
being the most commonly isolated Salmonella serotype to being the third most common 
serotype in Morocco. In the year 2001, no typhoid fever cases were reported in Morocco, 
however, during the year 2002, Salmonella Typhi was the fourth most commonly isolated 
Salmonella serotype [49]. 
 
1.3.1.4 MNAC: Algeria 
Salmonella Typhi has been identified amongst the most common causes of diarrhoea, 
predominately affecting male children in Algeria [49]. This pathogen was identified as the 
Salmonella serotype responsible for approximately 98% of the 3340 clinical Salmonella 
isolates recovered between the years 1986 to 1990 [55]. For the years 1985 to 2005, the 
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incidence of typhoid fever was estimated at 3-22 cases per 100 000 populations. Typhoid fever 
outbreaks in Algeria have resulted from the consumption of sewage contaminated village water 
reservoirs; and as a result, more than 100 water wells have been filled and 16 suspected 
drinking water supply points stopped in order to control typhoid fever spread in the country 
[49, 56, 57]. 
 
1.3.1.5 MNAC: Egypt 
Typhoid fever is endemic in Egypt and is most commonly a disease of children and adolescents 
aged 3 to 17 years old [58]. The incidence of typhoid fever in Egypt is estimated at 59 cases per 
100,000 populations per year [59]. Of most concern is the widespread prevalence of MDR 
Salmonella Typhi [59]. Wasfy and colleagues (2002) studied the trends of multi-drug resistance 
among Salmonella Typhi isolates from the years 1987 to 2000.  Interestingly, they reported a 
significant shift in the prevalence of MDR Salmonella Typhi from nonexistence to greater than 
60% and then decreasing to only 5% in a period of 15 years [58].  
 
1.3.2 Nigeria 
Typhoid fever is a major public health problem in Nigeria and has been rated eighth amongst 
widespread diseases affecting the population [60, 61]. Typhoid fever is endemic this country 
and affects people of all age groups [60, 62]. Reports indicate an alarmingly increasing rate of 
resistance amongst Salmonella Typhi isolates [63-67]. Adabara and colleagues (2012) studied 
the prevalence and antimicrobial susceptibility patterns of Salmonella Typhi amongst patients 
attending a Military hospital in Minna, Nigeria. Salmonella Typhi isolates were found to be 
resistant to ceftriaxone, cefuroxime, amoxicillin, ampicillin, ciprofloxacin and augmentin, all of 
which are antimicrobials of choice routinely used for the treatment of typhoid fever. 
Interestingly, these isolates were susceptible to chloramphenicol [63]. 
 
1.3.3 Ghana 
Typhoid fever has been reported to be amongst the 20 leading causes of outpatient illness in 
Ghana, accounting for 0.92% of hospital admissions [68]. Marks and colleagues (2010) 
conducted a study which included approximately 1500 children less than 15 years of age who 
were admitted to the paediatric ward of Agogo Presbyterian Hospital from September 2007 to 
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November 2008. The highest incidence of typhoid fever (290/100 000 population per year) was 
identified in children 2 to 5 years of age. The incidence of typhoid fever was estimated at 
190/100 000 population per year in children less than 5 years of age and 200/100 000 
population per year in children 5 to 8 years of age. In children older than 8 years of age the 
incidence decreased with increasing years. Resistance to ciprofloxacin and ceftriaxone was 
identified in less than 10 % of Salmonella Typhi isolates [68]. 
 
1.3.4 Democratic Republic of Congo 
Salmonella Typhi has been reported to be endemic in the Democratic republic of Congo (DRC) 
[69]. Muyembe-Tamfum and colleagues (2009) compiled the first report of multidrug-resistant 
Salmonella Typhi in Kinsasha between the years 2004 and 2005 [70]. In their study, 
Salmonella Typhi was isolated from blood of patients with peritonitis. The isolates were 
resistant to first-line antimicrobials but were susceptible to third-generation cephalosporins, 
quinolones and amoxicillin-clavulanic acid [70]. Lunguya and colleagues (2012) characterized 
201 Salmonella Typhi isolates from the DRC [69]. Infected patient age ranged from less than 4 
years of age to greater than 50 years of age with the median age of 5 years of age. Not only 
were the isolates resistant to first line antimicrobials but they also had decreased susceptibility 
to ciprofloxacin. PFGE analysis indicated 33 pulsotypes with 72% of the isolates showing a 
single profile [69].  
 
1.3.5 Ethiopia 
Typhoid fever infections have been reported in Ethiopia [22, 71, 72]. Bogale Worku (2000) 
reported typhoid fever in an Ethiopian children’s hospital between the years 1984 to 1995 [72]. 
The study showed the prevalence of typhoid fever infections amongst children aged less than 2 
years to adolescents aged 13 years with high case fatality rate of 15.7% due to chloramphenicol 
treatment of multi-drug resistant typhoid fever  [72]. 
 
1.3.6 Malawi and Mozambique 
The incidence of typhoid fever in Malawi and Mozambique is estimated at rates of 10-100 
cases per 100 000 population per year [73]. In Malawi, typhoid fever remains a significant 
public health problem and is mostly a disease of school aged children and younger adults [23, 
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74, 75]. Although previously reported as uncommon in Mozambique, Salmonella Typhi caused 
an outbreak along Mozambiquean and Malawian borders in March to November 2009 [73, 76]. 
Lutterloh and colleagues (2012) studied 42 Salmonella Typhi isolates from the outbreak and 
reported resistance to first-line antimicrobials with four isolates having additional resistance to 
nalidixic acid and decreased susceptibility to ciprofloxacin. It was concluded that the outbreak 
was caused by a single clone as 83% (35/42) of the isolates were indistinguishable by PFGE 
analysis [73].  
 
1.3.7 Cameroon 
Even though there’s only limited data regarding the incidence of typhoid fever in Cameroon, a 
report by Nkemngu and colleagues (2005) confirmed the presence of Salmonella Typhi in this 
country [77]. In this report, Nkemngu and colleagues (2005) indicated the emergence of 
multidrug resistant and nalidixic acid resistant Salmonella Typhi. This isolate was obtained 
from a 29 year old woman who presented to the St. John’s hospital with symptoms of fever, 
emesis, myalgia and hepatosplenomegaly. Salmonella Typhi was isolated from blood culture 
and the isolate was found to be resistant to first-line antimicrobials and to nalidixic acid [77].  
 
1.3.8 Uganda 
A large laboratory-confirmed outbreak of typhoid fever was reported in Uganda from 
December 2007 to July 2009 [78]. From a total of 27 laboratory confirmed cases of typhoid 
fever, 76% were resistant to ampicillin, streptomycin, sulfisoxazole, tetracycline and 
cotrimoxazole and were susceptible to chloramphenicol. Resistance to nalidixic acid and 
ciprofloxacin were not detected. PFGE analysis revealed several different pulsotypes 
suggesting that multiple sources of infection were present. PFGE analysis also showed different 
pulsotypes for isolates collected from the same patient indicating co-infection with different 
Salmonella Typhi isolates [78]. 
 
1.3.9 Kenya 
Typhoid fever in Kenya is mostly a disease of children aged 2 to 9 years of age [29, 79, 80]. 
Typhoid fever outbreaks have been well documented in this country [29, 79-83]. Kariuki and 
colleagues (2004) characterized 102 Salmonella Typhi isolates collected from three parts of 
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Kenya, including Nairobi Province, Embu district and Thika district hospital, during an typhoid 
fever outbreak which occurred during January 2000 to December 2002 [82]. Analysis of these 
isolates indicated an increase in the number of MDR Salmonella Typhi isolates.  These isolates 
were seen to be gradually replacing the sensitive phenotype. PFGE analysis of these isolates 
indicated 2 circulating strains (including MDR and fully sensitive strains) [82]. Not only is 
MDR a public health problem in Kenya, but the increase is fluoroquinolone resistant 
Salmonella Typhi isolates has become a major public health concern in the treatment of typhoid 
fever and other bacterial infections in Kenya [29, 82]. Kariuki and colleagues (2010), through 
DNA sequence-based analysis, determined that the increase in the incidence of fluoroquinolone 
resistant  Salmonella Typhi was attributed to Salmonella Typhi haplotype H58 [29]. This 
haplotype has been detected as the phylogenetic lineage of Salmonella Typhi responsible for 
the increase in antimicrobial resistant Salmonella Typhi isolates in Kenya [29]. 
 
1.3.10 Tanzania 
Salmonella Typhi was found to be the leading cause of fever in patients in Pemba Island, 
Zanzibar and Tanzania mainland between March 2009 and December 2010 [84]. The report by  
Thriemer and colleague (2012) showed that typhoid fever affected patients with ages ranging 
from 10 months to 58 years with a mean age of 17.7 years and most of these patients were 
female (61%) [84]. 
 
1.3.11 South Africa 
There have been several reports on typhoid fever outbreaks in South Africa. In the year 1992, 
Coovadia and colleagues (1992) reported the first outbreak of multidrug resistant Salmonella 
Typhi in South Africa [85]. A cluster of six typhoid fever cases were described from three 
adjacent districts in South Africa and all isolates showed resistance to first line antimicrobial 
treatment [85]. Antimicrobial susceptibility testing revealed high levels of resistance to 
ampicillin, chloramphenicol, tetracycline, trimethoprim, sulphamethoxazole and trimethoprim- 
sulphamethoxazole. These isolates were β-lactamase producers and high mortality rates (50%) 
were reported [85]. In the year 2003, national surveillance for Salmonella species was 
introduced. Data was collected through the national surveillance representing data from 
approximately 205 laboratories across the country [23]. Typhoid fever affects mainly school-
aged children and younger adults [23]. Reports of MDR Salmonella Typhi indicate an increase 
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in the number of quinolone-resistant Salmonella Typhi [86, 87]. Several other typhoid fever 
outbreaks have been reported in this country [88, 89].  During the year 2005, an outbreak of 
typhoid fever occurred in the Delmas area in Mpumalanga [88]. During this outbreak, 
approximately 600 clinically diagnosed typhoid fever cases were reported. This outbreak was 
second to the one that occurred in the same municipality during the year 1993 [88, 90]. 
Molecular epidemiological techniques showed that the isolates from the 1993 as well as the 
2005 outbreaks were related [88]. In the year 2010, an outbreak of typhoid fever was reported 
in the Pretoria district in Gauteng [89]. Eight laboratory confirmed cases of typhoid fever were 
reported during this outbreak and patients involved were students and friends of students who 
all ate at a common restaurant in the Pretoria area [89]. 
 
1.4 Diagnosis of typhoid fever       
Typhoid fever diagnosis can be difficult as the presenting symptoms are similar to those of 
Malaria and dengue fever [91]. Isolation of Salmonella Typhi bacterium from blood still 
remains the gold standard for laboratory diagnosis [92]. Even so, the lack of blood culture 
facilities in most primary health care facilities in the developing countries makes typhoid fever 
diagnosis difficult [93].  
 
The Widal test has been used in many developing countries as a tool for typhoid fever 
diagnosis [94-96]. This test was developed by F. Widal in 1896, and is based on agglutination 
reaction between Salmonella Typhi somatic lipopolysaccharide O antigen and the flagella H 
antigen. The Widal test is relatively cheap, easy to perform, requires unsophisticated facilities 
and minimal training; however, the value of the test has been questioned due to lack of 
sensitivity and specificity as the O antigen and the H antigens targeted in the test are shared by 
many Enterobacteriaceae species [91, 93, 94]. 
 
Newer diagnostic tests have been developed for typhoid fever diagnosis [91]. These include the 
TUBEX® and Typhidot® which are based on direct detection of IgM antibodies against a host 
of specific Salmonella Typhi antigens. In a study by Keddy and colleagues (2011) the Widal 
test was compared to blood culture test and newer typhoid rapid antibody tests including the 
semi-quantitative slide agglutination test, the TUBEX® and Typhidot® [97]. Although 
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acceptable as diagnostic tests, none of these rapid tests exceeded blood culture performance in 
typhoid fever diagnosis [97]. 
 
PCR has been successfully used as a tool for diagnosis of typhoid fever [91, 98, 99]. In a study 
by Hashimoto and colleagues (1995), a PCR assay targeting the sequence that encodes the Vi 
antigen (ViaB) was developed [98]. This assay was specific for Salmonella Typhi due to the 
limited distribution of the Vi antigen amongst organisms. In order to detect Salmonella Typhi 
from blood, Hashimoto and colleagues used a nested-PCR strategy combined with the PCR 
primers targeting the ViaB region, and this offered a useful tool for rapidly and specifically 
detecting Salmonella Typhi from clinical specimens. Additionally, a nested PCR that targets 
the  H1-d gene has been used to amplify Salmonella Typhi specific genes from blood [98].  
 
In another study, Song and colleagues (1993) developed a PCR targeting the flagellin gene of 
Salmonella Typhi [100]. Unlike the flagella antigen and d-antigen that are not specific 
structures of Salmonella Typhi, the flagellin gene of Salmonella Typhi has unique nucleotide 
sequences that are specific for the organism. Song and colleagues developed a nested-PCR that 
targets fragments of the flagellin gene that are specific to Salmonella Typhi. This PCR has 
become a promising tool for rapid diagnosis of typhoid fever [91, 99, 100]. 
 
Rapid detection of Salmonella Typhi isolates has been improved with the development of real-
time PCR assays [101, 102]. Real-time PCR is a fluorogenic based PCR method which utilizes 
an internal fluorogenic probe that is specific to the target gene [101]. During PCR, the 
amplification of the target gene is recognized and computationally monitored by the increase in 
fluorescence resulting from the fluorescent probe moiety. The most commonly used 
fluorogenic PCR-based method is the TaqMan® assay. This is based on a linear fluorogenic 
probe which requires the 5’ to 3’ endonuclease activity of the DNA polymerase. For the 
TaqMan® real-time PCR, the linear fluorescent moiety is conjugated to one end of the target 
sequence and a quencher moiety is attached to the other end of the target sequence. During 
PCR amplification of the target sequence, the quencher moiety is cleaved off, resulting in the 
fluorescence emission by the fluorogenic moiety. Contrary to the traditional PCR method, 
which uses agarose gels to detect amplicons of the target gene, real-time chemistries have the 
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advantage of timeous detection of target amplification by measuring kinetics of the reaction in 
early PCR phases [101-103]. 
 
Ranjbar and colleagues (2014) developed a TaqMan® real-time PCR assay for the rapid 
detection of Salmonella Typhi [101]. The PCR targeted a putative fimbrial protein (staG) of the 
Salmonella Typhi. The TaqMan® real-time PCR assay was tested against various Salmonella 
enterica serovars as well as non-Salmonella microorganisms. This PCR was highly sensitive,  
rapid and specific detection of Salmonella Typhi in clinical samples [101]. 
 
Nga and colleagues (2010) developed a real-time PCR assay for the detection of Salmonella 
Typhi and Salmonella Paratyphi A [102]. In this study, the PCR targeted sequences unique to 
Salmonella Typhi and Salmonella Paratyphi A. These unique sequences were identified by 
aligning whole genome sequences of Salmonella Paratyphi A strain ATCC9150, Salmonella 
Typhi strains Ty2 and CT18 as well as shotgun-sequenced strains. Although the real-time PCR 
exhibited high specificity for Salmonella Typhi and Salmonella Paratyphi, a lack of sensitivity 
attributed to the low physiological level of these pathogens in blood was observed. However, 
the real-time PCR assay showed 100% sensitivity on culture positive bone marrow biopsies. 
This increased sensitivity was attributed to the high bacterial loads in bone marrow biopsies 
[102].  
 
1.5 Phenotypic identification of Salmonella Typhi      
Salmonella enterica isolates are classically identified and typed using phenotypic methods such 
as biochemical profiling, serotyping, phage typing as well as antimicrobial resistance profiling. 
Microbial typing is essential for establishing and understanding clonal relations between 
microbial isolates.  
 
1.5.1 Serotyping 
Serotyping is used as the basis for the classification of Salmonella enterica isolates [8, 104]. 
This methodology does not have the capacity to fingerprint the isolates in a sensitive manner; 
however, it still remains useful in surveillance programs. Serotyping deciphers the antigenic 
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makeup of the pathogen by identifying variants of the somatic (O) and the flagella (H) antigens 
through reaction with specific antisera [8]. The O-antigen is the saccharide component of the 
lipopolysaccharide layer that is exposed on the cell surface of bacteria [104, 105]. The reaction 
of the O-antigen with specific antisera forms the basis of Salmonella serotyping. Most 
Salmonella isolates possess two different copies (phase I and phase II) of genes encoding the 
H-antigen. Even so, only one H-antigen is expressed at a time. The H-antigens are determined 
by reaction towards specific antisera. Salmonella isolates are characterized and classified by 
their antigenic properties according to the serological Kauffmann-Le Minor scheme [104, 105]. 
Currently, 2,463 Salmonella serovars have been identified [18].  
 
1.5.2 Phage typing         
Phage-typing of Salmonella isolates is a useful tool for identification and subtyping of these 
pathogens [91]. A bacteriophage is defined as a virus which specifically attacks bacteria. The 
method is based on bacterial cell lysis by a specific bacteriophage. The lysis that occurs as a 
result of the viral infection is specific and important in the identification of the bacterium. A 
plaque assay, in which a clear zone results from the bacterial lysis, is used for enumeration of 
the lytic phages [91].  
 
In 1938, Craigie and Yen developed a phage-typing scheme for Salmonella Typhi [106]. 
Following the description of the Vi antigen of the Salmonella Typhi, Craigie and Yen 
discovered bacteriophages that could only attack bacteria possessing the Vi-antigen. The Vi-
phages specifically attack bacteria that possess the Vi-antigen, such as Salmonella Typhi, and 
these phages cannot be absorbed into bacterial cells lacking the Vi-antigen. Four virulent Vi-
phages were described and designated I, II, III and IV. These phages were serologically 
different and had different physical properties. The Vi-phage II showed adaptations that would 
lyse strains similar to that which it had been last grown. Through successive adaptation of the 
Vi-antigen II, Salmonella Typhi strains could be further subdivided. Thirty three internationally 
recognized Vi types have been recorded. The Vi-phage typing scheme for Salmonella Typhi 
was published by Craigie and Yen in 1938 and has since become the method of choice for the 
epidemiological subtyping of Salmonella Typhi isolates [106, 107]. 
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The advantage of phage typing resides in the simplicity of its implementation, which requires 
only basic laboratory equipment [8]. However, the ambiguous lysis reactions are common 
drawbacks, and careful coordination between reference laboratories is required in order to 
ensure reproducibility of the assay. The method is also limited by the number of available 
phages [8] 
 
1.5.3 Antimicrobial treatment and acquired resistance     
Typhoid fever can be fatal if untreated [12]. Considering the risk of relapse and chronic 
carriage, it is essential to treat all typhoid fever cases [108]. It is recommended that patients be 
treated with antimicrobials as soon as a diagnosis has been made rather than after the 
availability of antimicrobial susceptibility test results. Treatment with appropriate 
antimicrobials is essential to prevent typhoid fever case fatalities and spread [12, 108-110]. 
 
1.5.3.1 Chloramphenicol treatment       
Following its availability in 1948, chloramphenicol became widely used as the treatment of 
choice for typhoid fever infections [111-115]. Chloramphenicol treatment of typhoid fever 
during this time resulted in a dramatic decrease in illness and mortality associated with typhoid 
fever [115]. The antimicrobial effect of chloramphenicol comes from its ability to cause prompt 
and dramatic inhibition of protein synthesis in drug sensitive isolates [115]. It is a metabolic 
antagonist as it prevents protein chain elongation by inhibiting the peptidyl transferase activity 
of the bacterial ribosome. Chloramphenicol does not block the progression of the growing 
peptide but interferes directly with substrate binding [116].  
 
Most Salmonella Typhi isolates remained sensitive to chloramphenicol treatment throughout 
the 1950s to the 1960s. Even though there were sporadic reports of typhoid fever resistance to 
chloramphenicol [117-119], it was not up until 1972 that this resistance became a public health 
problem, as epidemics caused by chloramphenicol resistant Salmonella Typhi were reported in 
Mexico and India [110, 118, 120, 121]. Subsequently, epidemics caused by chloramphenicol 
resistant Salmonella Typhi were reported in Vietnam, Korea and Peru [108, 121]. Most of the 
resistant isolates not only showed resistance to chloramphenicol, but also showed resistance to 
tetracycline, aminoglycosides and sulphonamides [121]. Chloramphenicol resistance in these 
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isolates was encoded by a plasmid that belonged to the incompatibility group H (IncH). 
Streptomycin, sulphonamides and tetracycline-resistance were also carried on this plasmid 
[108, 122]. 
 
1.5.3.2 Ampicillin treatment       
Following the introduction of ampicillin as treatment of choice for chloramphenicol resistant 
Salmonella Typhi, epidemics caused by Salmonella Typhi isolates resistant to ampicillin and 
chloramphenicol, with additional resistance to streptomycin, sulphonamides and tetracyclines 
were reported in developing countries including Pakistan and India [29, 108, 123]. Such multi-
drug resistant (MDR) isolates were subsequently isolated in Vietnam and in some countries in 
Africa including South Africa, Egypt and Kenya [29, 85, 124, 125]. 
 
1.5.3.3 Co-trimoxazole treatment       
In 1981, following the introduction of co-trimoxazole as treatment for MDR Salmonella Typhi, 
plasmid mediated resistance to chloramphenicol and trimethoprim was identified in sporadic 
Salmonella Typhi isolates [122].  
 
1.5.3.4 Multi-drug resistant Salmonella Typhi      
The emergence of multi-drug resistant (MDR) Salmonella Typhi has become a global health 
problem with serious impact on treatment of typhoid fever [126]. MDR Salmonella Typhi 
harbour incHI1 incompatibility type plasmid. Wain and colleagues (2003) described two 
incHI1 incompatibility plasmids responsible for the MDR phenotype of Salmonella Typhi, 
including the pHCM1 that encodes transferable multiple antibiotic resistance and the R27 
plasmid, a precursor of pHCM1 that encodes tetracycline resistance. The pMCH1 plasmids 
contain coding sequences (CDS) that are involved in resistance to antimicrobial agents. These 
include coding sequences which represent the transposable genetic element (Tn9) which 
determines chloramphenicol resistance, coding sequences which represent the Tn10 element 
associated with tetracycline resistance, coding sequences which are homogenous to the 
sulphonamide resistance gene, coding sequences which are identical to the trimethoprim 
resistance gene and coding sequences which are putative β-lactamases [126].  
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1.5.3.5 Ciprofloxacin treatment       
Following reports of MDR Salmonella Typhi, ciprofloxacin, a class of fluoroquinolones, 
became the treatment of choice for typhoid fever [12, 127]. Fluoroquinolones target the 
bacterial topoisomerases, in particular DNA gyrase protein (GyrA) thereby inhibiting DNA 
replication [128].  
 
Chromosomal mediated resistance is emerging as a result of selective pressure on the bacterial 
population due to uncontrolled use of fluoroquinolones [129]. In most cases, fluoroquinolone 
resistance is chromosomally encoded and is associated with single point mutations that alter the 
amino acid structure of DNA gyrase. This mutation occurs in the A subunit of DNA gyrase 
(gyrA) known as the quinolone-resistance determining-region (QRDR). In Salmonella Typhi 
isolates, a single point mutation conferring an amino acid substitution at codons Serine 83 
(Ser83 →Phe) or aspartate 87 (Asp87 → Gly or Tyr) of the gene encoding GyrA protein (gyrA) 
can confer resistance to nalidixic acid [129, 130]. The evolution of fluoroquinolone resistance 
is often preceded by mutations which induce nalidixic acid-resistance; therefore, reduced 
susceptibilities to fluoroquinolones can be predicted by the detection of resistance to nalidixic 
acid [128, 131]. The accumulation of more mutations in DNA gyrase genes may result in an 
increase in the minimum inhibitory concentration (MIC) for fluoroquinolone [132]. 
 
Currently, the rate of nalidixic acid resistance in Salmonella Typhi is increasing and there are 
an increasing number of reports on the emergence of Salmonella Typhi with decreased 
susceptibility to ciprofloxacin [29, 127, 131-133]. Recent reports implicate Salmonella Typhi 
haplotype H58 (H58 Salmonella Typhi) as the single clone that has been mostly associated with 
nalidixic acid resistance [132]. The H58 Salmonella Typhi lineage is a highly clonal haplotype 
of Salmonella Typhi that possesses the IncHI1 MDR plasmid as well as point mutations 
conferring resistance to quinolones [132]. This H58 Salmonella Typhi lineage, which first 
emerged in Southeast Asia, has now become the causative agent of most typhoid fever 
outbreaks [132, 134]. In addition, the H58 Salmonella Typhi has disseminated into parts of 
Africa and is spreading rapidly [29, 132, 133]. A study done in Kenya has shown that this 
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haplotype has replaced the antimicrobial-susceptible strains of Salmonella Typhi and has been 
associated with an increase in the incidence of MDR Salmonella Typhi [29]. From the 
phylogenetic analysis of a global collection of Salmonella Typhi isolates from 63 countries 
based on whole-genome sequences, Wong and colleagues (2015) showed cases of closely 
related Salmonella Typhi isolates from different countries clustering together, indicating the 
likelihood of spread of Salmonella Typhi isolates from one African country to another [132]. 
This is depicted in figure 1.4 which shows H58 Salmonella Typhi isolates from South Africa 
and Malawi clustering closely together. In their study, Wong and colleagues (2015) indicated a 
major on-going clonal replacement of non-H58 Salmonella Typhi haplotypes with this H58 
Salmonella Typhi clade since 1990. High predominance of this lineage has also been seen in 
Eastern and Southern Africa [132].  
 
Currently, treatment options for typhoid fever with reduced susceptibility to fluoroquinolones, 
are ceftriaxone (extended-spectrum cephalosporin) and azithromycin (macrolide) [135]. 
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Figure 1.3 Population structure of the Salmonella Typhi H58 lineage and distribution across countries 
in the Sub-Saharan African continent [132] 
 
1.6 Molecular characterization        
1.6.1 The genome of Salmonella Typhi      
The genomic features of individual species, subspecies, serovars and different isolates can be 
scrutinised using sequencing [136]. Through genomic sequencing, the genetic blue print of 
bacteria can be examined and compared to genomes of bacteria of similar phenotypic traits 
[136]. Chromosomal scrutiny of Salmonella Typhi strains CT18 and TY2 have indicated an 
incredible degree of conservation amongst Salmonella Typhi isolates [136]. It is believed that 
Salmonella Typhi belongs to a single clone that evolved from the same progenitor. The low rate 
of variation of single-nucleotide polymorphisms in Salmonella Typhi advocates the notion that 
the bacterium may be as young as 30 000 years and thereby denoting that the Salmonella Typhi 
diverged significantly later than the estimated divergence of Salmonella enterica and E. coli. 
The differentiation of Salmonella Typhi isolates is a very cumbersome process because of the 
high homogenous characteristic of the organism. Several genotypic methods have been 
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implemented in attempt to differentiate the homogenous Salmonella Typhi isolates. There is 
still a need for newer genetic tools that will improve the abilities to examine the genomic 
structure of Salmonella Typhi isolates [136]. 
 
1.6.2 Genotyping Salmonella Typhi       
Molecular characterization, in particular of Salmonella Typhi isolates, plays a very critical role 
in public health management [137]. In order to understand the factors that contribute to the 
epidemiology of Salmonella Typhi in endemic areas, it is important to propose new and 
efficient methods which can be used for rapid characterization of Salmonella Typhi isolates. 
Molecular subtyping methods, in particular the application of molecular markers, have become 
an integral part of epidemiological investigations of Salmonella Typhi infections. These 
methods are most valuable in surveillance for improving treatment, control and prevention 
measures and during outbreak investigations [11, 138]. Molecular subtyping techniques offer 
rapid, robust, portable, sensitive and objective results and can be used to differentiate 
epidemiologically unrelated Salmonella Typhi isolates [137].  
 
Several molecular subtyping methods have been explored in order to differentiate homogenous 
Salmonella Typhi isolates. PFGE, Multi-locus sequence-typing (MLST), whole-genome 
sequencing (WGS) and multiple-locus variable-number tandem-repeats analysis (MLVA) are a 
few techniques commonly used to characterize Salmonella Typhi at molecular level [137]. 
 
1.6.3 Pulsed-field gel-electrophoresis       
Macro-restriction of chromosomal DNA using PFGE is commonly used for the differentiation 
of isolates at DNA-level [8, 137]. This technique has been employed by PulseNet international 
as a primary methodology for tracking foodborne infections world-wide. PFGE has been used 
successfully to perform comparative chromosomal DNA analysis amongst Salmonella Typhi 
isolates and has been used successfully in typhoid fever outbreak investigations [87, 139-142]. 
The method relies on the digestion of chromosomal or plasmid DNA by rare cutting restriction 
endonucleases. The resulting large DNA fragments (greater than 50 000 base pairs) are 
separated by use of periodic changes in the direction of the electric field during electrophoresis.  
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PFGE has added great value in epidemiological surveillance and outbreak investigations of 
pathogenic isolates and has been used frequently for bacterial isolate characterization [10, 142]. 
The validity of PFGE has been well established for the most common bacterial pathogens 
including Salmonella, Shigella, E. coli, Campylobacter, Clostridium, Cronobacter and Listeria. 
The standardization of the PFGE protocols for these pathogens by PulseNet International has 
enhanced the ability to compare fingerprint data between laboratories [10, 137]. PulseNet 
International has also established the international fingerprinting database from which 
emerging outbreaks can be detected and from where the spread of pathogenic bacteria can be 
monitored [7]. The greatest strength of PFGE is that it is has good discriminatory power [137, 
143]. The PFGE approach scrutinizes the whole bacterial genome, for this reason, insertion and 
deletion mutations resulting from environmental pressure and from recombination can alter the 
genome by introducing new restriction sites which will, as a result, alter the PFGE pattern of 
the specific isolate [137, 143]. The acquisition of mobile genetic elements, such as resistance 
plasmid, may also introduce new restriction sites thereby altering the PFGE pattern of the 
isolate [143].  
 
The successful use of PFGE in outbreak investigations of typhoid fever has been documented 
[10, 89, 139-142]. In 2010, Smith and colleagues used PFGE to study and track a typhoid fever 
outbreak from South Africa to Australia [89]. A cluster of six typhoid fever cases were reported 
from patients who had previously visited a common restaurant. PFGE analysis of these isolates 
revealed an indistinguishable PFGE fingerprint type (pulsotypes) indicating that the outbreak 
was caused by a single Salmonella Typhi isolate. Epidemiological investigations revealed an 
additional typhoid fever case from a Canadian barman who had worked at the same restaurant 
while on a working holiday in South Africa. The barman, who was later identified as the index 
case, departed from South Africa and journeyed to Australia where he was diagnosed and 
treated with typhoid fever on arrival. The PFGE pattern of this Salmonella Typhi isolate was 
obtained through the PulseNet International networks and was later found to be 
indistinguishable to the isolates from the Pretoria outbreak [89]. 
  
Although PFGE has been successfully used in outbreak detection of Salmonella isolates, the 
subtyping capabilities of this technique are limited in Salmonella Typhi isolates [144, 145]. 
Studies have shown that Salmonella Typhi frequently undergoes changes in the chromosomal 
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gene order [146]. Chromosomal rearrangement involves the movement or reshuffling of DNA 
throughout the genome, from one location to another. The chromosome in Salmonella Typhi 
show significant rearrangement in gene order in the wild-type isolates [146]. Therefore, a 
single Salmonella Typhi isolate may have multiple PFGE patterns [145]. This phenomenon was 
demonstrated in a study by Echieta and Usera (1998) were 85 Salmonella Typhi isolates 
belonging to eight different typhoid fever outbreaks that occurred in Spain between 1989 and 
1994 were analysed. In five of the eight outbreaks, the strains were indistinguishable by PFGE. 
However, the remaining three outbreaks presented two PFGE patterns. The detection of two 
PFGE types in the very same outbreak isolate was due to chromosomal rearrangements [145]. 
 
Other major drawbacks with PFGE are that the technique is technically demanding, time-
consuming and labour-intensive [137]. Additionally, the technique does not display equal 
sensitivity with different bacterial species. Analysis of the PFGE patters can suffer from some 
subjectivity, making it prone to errors [137]. 
 
1.6.4 Multi-locus sequence-typing       
Multi-locus sequence-typing (MLST) is a well-established technique aimed at exploiting the 
unambiguous nature of nucleotide sequence data for bacterial characterization [10, 135, 147]. 
MLST has become a common tool used for epidemiological studies and for the analysis of the 
molecular evolution of pathogens [17, 135, 137]. The technique is based on the analysis of 
sequence data from a selection of house-keeping genes [143, 147]. The alleles from the house-
keeping gene are assigned allele numbers based on a complete match to alleles in the global 
database. The combination of these allele numbers from the selected house-keeping genes 
makeup a sequence type and a clonal complex [143, 147].  
 
In the year 2002, Kidgell and colleagues published an MLST scheme for studying the clonality 
of Salmonella Typhi isolates [19]. This MLST scheme involved PCR amplification of 
fragments (432 to 501 bp) from a selection of 7 housekeeping genes including aroC 
(chorismate synthase), dnaN (DNA polymerase III beta subunit), hemD (uroporphyrinogen III 
cosynthase), hisD (histidinol dehydrogenase), pure (phosphoribosylaminoimidazole 
carboxylase), sucA (alpha ketoglutarate dehydrogenase) and thrA (aspartokinase+homoserine 
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dehydrogenase) [8, 10, 19]. These 7 housekeeping genes were selected from the Salmonella 
Typhi CT18 genome based on their scattered position, that they are flanked by genes with 
known functions and that the selected housekeeping genes as well as their flanking regions are 
selectively neutral. Following amplification of the 7 housekeeping genes, the PCR products 
were purified and resulting fragments subjected to nucleotide sequencing [10, 19]. The trimmed 
sequences from the 7 housekeeping genes were submitted to a publically accessible database 
(http://mlst.warwick.ac.uk/mlst/dbs/Senterica) which currently contains more than 2300 
isolates that have been characterized [17]. For each locus, alleles were assigned arbitrary 
numbers and based on the combination of allele numbers from all 7 housekeeping genes (allelic 
profile) the sequence type was determined [137, 148]. 
 
The success of MLST in discriminating bacterial isolates has been shown to be dependent on 
the number of the housekeeping genes selected [8, 143]. In a study conducted by Fakhr and 
colleagues (2005), MLST analysis of 85 Salmonella enterica subspecies enterica serovar 
Typhimurium (Salmonella Typhimurium) isolates using only 4 housekeeping genes including 
manB (phosphomannomutase), glnA (glutamasesynthetase), pduF (1-2-propanediol utilization 
factor) and spaM (virulence gene), showed no diversity amongst the isolates [10, 143]. On the 
contrary, an MLST scheme consisting of 7 housekeeping genes was successful in 
discriminating Salmonella Typhimurium isolates and identifying the highly invasive MLST 
sequence type (ST) 313 clone, which has emerged as a huge public health problem in sub-
Saharan Africa [148].  
 
Even so, MLST has been found to be poorly suited for the discrimination of Salmonella Typhi 
isolates [19, 149]. In a study conducted by Dahiya and colleagues (2013), MLST analysis of 30 
Salmonella Typhi isolates using seven housekeeping genes distinguished the isolates into 2 
MLST sequence types, namely ST1 and ST2 [149]. Kidgell and colleagues (2002), used seven 
housekeeping genes to distinguish 26 Salmonella Typhi isolates into 3 MLST sequence types 
including ST1, ST3 and ST8[19]. Since Salmonella Typhi is homogenous, MLST analysis of 
this pathogen is uninformative [135].  
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PFGE has been found to be more discriminatory than MLST [10, 143]. MLST analysis is 
limited only to parts of a series of genes while PFGE screens the entire genome. With MLST 
analysis, little or no variation in nucleotide sequences outside of the housekeeping genic region 
can render no discrimination between isolates. Yet, insertions, deletions and plasmid presence 
can alter PFGE profile resulting in diversity in PFGE patterns [10, 143].  
 
Since MLST is sequenced-based, it is considered to be objective and reproducible, and allows 
for inter-laboratory comparison [10, 148]. The ability for MLST to detect slowly accumulating 
mutations within a bacterial species renders this technique a valuable tool for international and 
national surveillance [149]. However, due to its labour-intensive, time-consuming and low 
discriminatory power for Salmonella Typhi, MLST is not suitable for epidemiological typhoid 
fever surveillance and outbreak investigations [10, 150]. 
 
1.6.5 Multiple-locus variable-number tandem-repeats analysis   
In recent years, variable-number tandem-repeats (VNTR) have been used with increasing 
frequency for the molecular subtyping of pathogenic bacteria [151-154]. These are short 
nucleotide sequences organized as tandem repeats at specific loci. These repeated sequences 
are widespread throughout the genome of bacteria and can vary in repeat number from strain to 
strain. VNTR are a good source of polymorphism believed to have resulted mostly from 
slipped-strand mispairing during replication. It has been reported that insertion and deletion 
mutation are more prevalent in DNA templates that contain repeated sequences. Replication 
slippage can be induced at a repeat sequence when the template strand and its copy shift their 
relative position leading to part of the template being copied twice or missed out. The resulting 
template is a new polynucleotide strand with larger or smaller number of repeat units. Thus, 
replication slippage generates new length variants, adding to the collection of alleles already 
present in the bacterial population hence making VNTR highly diverse. Variation within 
VNTR has also been attributed to DNA recombination between homogenous repeat sequences 
[151-154].  
 
Multiple-locus variable-number tandem-repeats analysis (MLVA) is an assay in which several 
VNTR loci can be combined to generate strain specific profiles used to discriminate genetically 
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homogenous strains [155]. The MLVA typing of VNTR is rapid, reliable and can provide 
greater discriminatory capacity as VNTR are highly diverse [155]. The MLVA procedure is a 
PCR-based method involving amplification of several VNTR loci, followed by fragment size 
determination using capillary electrophoresis with an internal size standard and then 
determination of the actual number of repeats at each locus [156].  
 
MLVA has been used successfully and has been very effective in subtyping genetically 
homogenous strains [157-160]. Recently, there has been great success in the development of 
highly-discriminatory MLVA assays for subtyping Salmonella enterica serovars including 
Salmonella Typhimurium and Salmonella enterica subspecies enterica serovar Enteritidis 
(Salmonella Enteritidis) [151-154]. In a recent report by Liu and colleagues (2016), MLVA 
was used to study the molecular epidemiology of Salmonella Enteritidis infection in the 
Guangdong province, China [161]. A seven-locus MLVA assay was used to characterize 147 
sporadic Salmonella Enteritidis isolates into 33 MLVA types showing higher discrimination as 
compared to PFGE from which 29 pulsotypes were identified. Liu and colleagues (2016) also 
used the MLVA assay to detect outbreaks and find their sources successfully. Seven 
Salmonella Enteritidis isolates collected during the year 2014 were found to possess a common 
MLVA type. Epidemiological investigations determined this to be an outbreak of Salmonella 
Enteritidis infection with six epidemiologically related isolates. Liu and colleagues (2016) 
determined the source of infection to be a bread countertop prepared with contaminated cakes 
[161]. 
 
Wuyts and colleagues (2013) evaluated the added value of MLVA typing for surveillance and 
outbreak detection of Salmonella Typhimurium isolates [162]. Isolates in this study were 
collected from Belgium where Salmonella Typhimurium has been identified as the most 
frequently isolated Salmonella serovar from humans with an average of 1,985 isolates per year. 
Of the 5,698 isolates collected between the years 2010 and 2012, approximately 1,420 isolates 
were randomly selected for analysis. A five-locus MLVA assay characterized the isolates into 
414 MLVA types. The MLVA assay identified 30 MLVA types that were common throughout 
the three-year period, and also identified unique MLVA types in each year of study. MLVA 
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showed high discriminatory power and showed the ability to improve public health surveillance 
[162]. 
 
1.6.6 Whole-genome sequencing       
Whole-genome sequencing (WGS) technique has revolutionized molecular typing of 
pathogenic bacteria by providing rapid and accurate identification of variation in the bacterial 
genome [137, 163-165]. This has become the most powerful and most highly recommended 
tool for epidemiological investigation [163, 166]. The most remarkable aspect of WGS is its 
ability to combine typing results which could have been obtained from several different typing 
techniques in order to give accurate discrimination of bacterial pathogens [163]. 
 
Contrary to the Sanger sequencing technique where genome sequencing projects took years 
before completion, the current WGS techniques provide rapid and high throughput technology 
[167]. WGS technique involves extraction of bacterial genomic DNA, which can be done using 
commercially available kits. It uses a shotgun sequencing approach for the sequencing of large 
genomic DNA fragments [168]. Shotgun sequencing involves enzymatic or mechanical 
breakdown of DNA into multiple segments that are sequenced using the chain termination 
method to produce short reads (500–700bp). High-throughput data in form of short reads are 
assembled based on overlapping regions to form contigs. Contigs are joined together to form a 
complete sequence [165, 168, 169].  
 
Through sequencing of one bacterial genome, a large amount of data can be obtained including 
antimicrobial resistance profile, MLST sequence types, virulence genes, serotype prediction as 
well as single-nucleotide polymorphisms (SNP) [165, 168]. WGS provides a complete 
unambiguous typing of different bacterial pathogens due to its potential to resolve single-base 
differences between genomes [165, 168]. 
 
There are high-throughput sequencing platforms developed for WGS analysis with the capacity 
for large scale DNA sequencing [170]. Through the use of these platforms, sequence data can 
be determined from amplified DNA fragments without the need for cloning of DNA fragments. 
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There are several numbers of WGS platforms that are commercially available, including the 
Illumina Solexa technology, ABI SOLiD and the Ion torrent technology. These platforms differ 
on base read-length generated as well as error rates. The Illumina/Solexa genome analyzer 
(Figure 1.5) is one of the most commonly used platforms [167, 170].  
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Figure 1.4 Outline of the whole genome sequencing workflow (Illumina platform). (I) Following 
genomic DNA fragmentation, (II) the library is applied on to a solid surface of a flow cell. The attached 
fragments form bridge molecules which are amplified by means of isothermal amplification resulting in 
a cluster of identical fragments. The DNA fragments are amplified following denaturation and annealing 
of sequencing primers. (III) The amplified DNA fragments are subjected to sequencing-by-synthesis 
using 3’labelled nucleotides[167].  
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1.6.6.1 Analysis of whole genome sequence data 
 
1.6.6.1.1 Whole genome MLST 
Phylogenetic analysis of whole-genome sequencing data includes MLST and single nucleotide 
polymorphism (SNP) analysis [171, 172]. Contrary to the traditional MLST which begins with 
a PCR amplification step using primers that are specific for the targeted house-keeping genes 
and followed by Sanger sequencing of each gene, whole-genome MLST (wgMLST) provides a 
more discriminatory and rapid alternative [171]. WgMLST is regarded as the gene-by-gene 
approach and involves in silico comparison of whole genome allelic variants between isolates. 
The added advantage of using wgMLST is that the number of targeted loci is not limited [173]. 
Analysis of the large amount of data generated through in silico MLST can be performed using 
user-friendly software and tools available on the Center for Genomics Epidemiology 
(http://www.genomicepidemiology.org) server as well as the CLC Genomics workbench tool 
[174]. 
 
1.6.6.1.2 Whole-genome SNP 
SNPs represent the most abundant source of genetic variation within bacterial genomes and are 
considered good markers to study diversity [174]. SNPs occur as a result of substitution 
mutations as they emerge in strains within the same serotype [174, 175]. Contrary to the 
taxonomically informative or canonical SNP-based approaches, whole-genome SNP (wg-SNP) 
analysis provides a robust and unbiased method to resolve closely related species [175]. SNPs 
from whole-bacterial genomes can be identified using online pipelines, such as the genobox 
available on the Centre for Genomic Epidemiology server. Once the SNPs have been identified, 
genetic diversity of strains can be analysed through the construction of phylogenetic SNP trees 
[175]. WgSNP analysis has been found to be a superior method for clustering outbreak related 
isolates of Salmonella as better resolution between outbreak and sporadic isolates has been 
observed [172, 176, 177].  
 
Taylor and colleagues (2015), showed the ability of WGS to distinguish between 
epidemiologically linked and unrelated isolates [172]. In their study, Taylor and colleagues 
(2015) analysed 28 Salmonella Enteritidis isolates from seven distinct food-borne outbreaks as 
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well as 27 sporadic isolates. SNP-based phylogenetic tree analysis showed all isolates within 
the same outbreak to be closely related with zero to three SNP differences identified between 
the isolates. Clusters of outbreak isolates differed from the nearest non-outbreak isolates by an 
average of 42 SNPs and they differed from sporadic isolates by an average of 60 SNPs. 
Furthermore, wgSNP analysis was able to distinguish between isolates from different outbreaks 
thus showing that the outbreaks did not originate from a common source [172]. 
 
WGS has proven to be a superior molecular method used to distinguish between 
epidemiologically linked and unrelated isolates. However, the challenge that still remains with 
WGS is the requirement of skilled bioinformatics experts to aid in extraction and analysis of 
data that is important for clinical microbiology, infection control and public health [178]. In 
order for WGS to be used for routine diagnostics and surveillance, sequence data needs to be 
transformed to clinically relevant information which can be easily understood by public health 
professionals and clinicians with limited bioinformatics skills [137, 163, 178, 179]. Although 
online analysis tools are available for use by non-bioinformatics experts, these tools only 
provide data similar to PFGE, MLST, serotyping, antimicrobial resistance profiling, virulence 
genes and SNP determination. The ability to formulate novel research questions is 
tremendously diminished without the skills provided by bioinformatics experts. With the skills 
of bioinformatics experts, data produced by WGS can be invaluable for developments of new 
subtyping techniques and conventional typing methods can be optimized [137, 163, 178, 179]. 
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1.7 The importance of studying the molecular epidemiology of Salmonella Typhi in the 
sub-Saharan African region 
Typhoid fever has proven to be a public health problem in Africa [29, 49, 78, 84, 85]. More 
concerning is the increase in the number of isolates showing resistance to current treatment 
regimes. Currently, fluoroquinolones are recommended for treatment of typhoid fever, but the 
emergence of the super-strain H58 Salmonella Typhi and the spread thereof has made treatment 
of typhoid fever a challenge [87, 180, 181]. The H58 Salmonella Typhi has become a huge 
public health problem in Africa, yet very little is known about the emergence, evolution and 
transmission of the H58 lineage across Africa. Of great concern is the on-going H58 
Salmonella Typhi lineage epidemic that has been reported across Africa [132]. Several studies 
recommend the use of Azithromycin which has proven to be effective against fluoroquinolone 
resistant Salmonella Typhi [182, 183]. Even so, reports of Azithromycin resistant Salmonella 
Typhi are emerging [184, 185]. Increasing resistance of Salmonella Typhi isolates to newly 
used antimicrobials presents a public health challenge. Fundamental stringent control measures 
within SSA countries are required [14]. Undoubtedly, the use of molecular techniques can 
provide the ultimate method to discriminate these isolates. Furthermore, through the use of 
standardized molecular methods, the genetic makeup of the organism could be compared 
within the countries in the continent providing information to model transmission dynamics and 
inform vaccine trial to control dissemination from one country to another [14, 132]. MLVA has 
proven to be a highly discriminatory yet affordable molecular method which has potential to be 
used in African countries for subtyping Salmonella Typhi isolates [155].  
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1.8 Aim 
The aim of the research presented in this dissertation was to design a highly-discriminatory 
MLVA typing assay for the analysis of Salmonella Typhi strains. The assay was used to study 
the population structure of these Salmonella Typhi isolates (including Salmonella Typhi H58) 
and compare the discriminatory capacity of MLVA with that of PFGE.  
 
1.8.1 Specific objectives 
a) To use VNTR markers to explore their potential in the characterization of Salmonella 
Typhi isolates 
b) To establish a highly-discriminatory MLVA assay consisting of five VNTR markers for 
the typing for Salmonella Typhi isolates 
c) To compare MLVA genotyping data to the commonly used PFGE genotyping data 
d) PCR screen Salmonella Typhi isolates for Salmonella Typhi H58-specific mutations 
e) To investigate the whether H58 Salmonella Typhi is associated with particular a MLVA 
profile 
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Chapter 2   
 
General materials and methods 
2.1 Surveillance programs 
2.1.1 National Surveillance 
The Centre for Enteric Diseases (CED) of the National Institute for Communicable Diseases 
(NICD), a division of the National Health Laboratory Services (NHLS), serves as a reference 
centre for enteric pathogens (including Salmonella) in South Africa. There are approximately 
200 laboratories (NHLS and Private) across the country that participates in the national 
laboratory surveillance through the Group for Enteric, Respiratory and Meningeal Disease 
Surveillance network in South Africa (GERMS-SA). For each year of surveillance 
demographic details are captured for all isolates, including information about the patient, 
isolate collection date and site, and the information is stored in a centralized GERMS-SA 
Microsoft Access database [186]. All laboratories submit Salmonella isolates to the CED on 
Dorset Egg transport media. The case definition for typhoid fever is the isolation of Salmonella 
Typhi from any normally-sterile sites (e.g. blood, cerebrospinal fluid (CSF) and tissue) as well 
as gastrointestinal sites (e.g. stools and rectal swabs) by positive culture. 
 
2.1.2 Typhoid Fever Surveillance in Africa Program (TSAP) 
Typhoid Fever Surveillance Program (TSAP) in Africa is a multi-country surveillance network 
aimed at establishing the true burden of typhoid fever in the African continent [187]. The TSAP 
study was conducted in public healthcare facilities in Burkina Faso, Ethiopia, Ghana, Guinea 
Bissau, Kenya, Madagascar, Senegal, South Africa, Sudan and Tanzania [187, 188]. The case 
definition for typhoid fever includes positive blood culture from patients presenting to sentinel 
sites around Africa with a history of fever for 72 hours or a recorded axillary temperature of 
>37.5°C or rectal 38°C [189].  Participating sites submit a subculture Salmonella Typhi to the 
CED onto Cary & Blair transport media. 
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2.2 Phenotypic characterization of Salmonella Typhi isolates    
Upon receipt at the CED, all Salmonella isolates from transport media (Dorset Egg and Cary & 
Blair) were subcultured onto non-selective 5% blood agar plates (Diagnostic Media Products 
(DMP), Sandringham, South Africa) using sterile loop. The blood agar plates were incubated at 
37°C for 18-24 hours. The automated VITEK-2 compact system (BioMérieux, Marcy L’Étoile, 
France) was used to confirm biochemical identification.  
 
Specific anti-sera (Statens Serum Institut, Copenhagen, Denmark; Remel Europe Ltd, Dartford, 
Kent, UK; and BioMérieux, Marcy-I’Ètoile, France) were used to serotype Salmonella Typhi 
isolates according to the Kauffman-Le Minor scheme [104]. Pure heavy growths of Salmonella 
Typhi were frozen in 10% skim milk (DMP) at -70°C for further analysis. 
 
2.3 Crude genomic DNA extraction 
Bacterial isolates were cultured on 5% blood agar (Diagnostic Media Products) and incubated 
overnight at 37°C. Half a loopful of bacterial culture was suspended in autoclaved TE Buffer 
(10 mM Tris: 1 mM EDTA, pH 8.0) and incubated for 25 minutes at 95°C. The boiled 
suspensions were centrifuged in a table-top centrifuge at 12000 rpm for 3 minutes. 
Approximately 50 µl of the supernatant was transferred into a clean 1.5 ml Eppendorf tube and 
were used as the template DNA for PCR assays. The supernatants were stored in the freezer at -
20°C. 
 
 
2.4 Real-time PCR serotyping of Salmonella Typhi isolates 
The real-time PCR assay targeted DNA sequences that were unique to Salmonella species as 
well as sequences unique to Salmonella Typhi. The ttrRSBCA gene, which is located near the 
Salmonella pathogenicity island 2, required for tetrathionate respiration in Salmonella, was 
selected for specific detection of Salmonella isolates [103]. For Salmonella Typhi, the 
STY0201 gene, encoding a putative fimbral-like adhesion protein located at position 210,264 in 
the Salmonella Typhi CT18 chromosomal genome (Accession number NC_003198) was 
selected [102]. Primers and probes targeting these genes were used as previously described 
(Table 2.1). 
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Table 2.1  Primer and probe sequences for Salmonella species and Salmonella Typhi specific genes 
 
All PCRs were carried out on an Applied Biosystems 7500 real-time PCR system (Applied 
Biosystems, Weiterstadt, Germany). Each 50µl PCR reaction contained 25 µl TaqMan Gene 
Expression Master Mix, 12 µl internal positive control mix and 1µl DNA template. The final 
primer concentrations were 1µM and 2µM for the Salmonella species and Salmonella Typhi 
assays, respectively. 
 
2.5 Pulsed-field gel electrophoresis (PFGE)     
PFGE analysis is still commonly used for molecular characterization of most bacterial strains, 
including molecular subtyping of Salmonella. Analysis of Salmonella Typhi isolates by PFGE 
is carried out as part of routine surveillance in the CED and is performed using the standardized 
PulseNet protocol for Salmonella, E. coli and Shigella sonnei [190]. 
 
2.5.1 The PFGE reference standard – Salmonella Braenderup (strain H9812) 
Normalization and accurate comparison of PFGE gel images required a well-characterized size 
standard [191]. A Salmonella enterica subspecies enterica serotype Braenderup (Salmonella 
Braenderup) strain H9812 was included as a size standard on at least three lanes in all PFGE 
gels. This strain was digested with XbaI restriction enzyme and produced an even distribution 
of band sizes.  
Isolate Gene PCR primer/probe sequences Amplico
n size 
Reference 
Salmonella 
species 
ttrRSBCA 
Forward (ttr-6 ): 
CTCACCAGGAGATTACAACATGG 
95 bp [103] Reverse (ttr-4): AGCTCAGACCAAAAGTGACCATC 
Probe (ttr-5): 6FAM - 
CACCGACGGCGAGACCGACTTT-BHQ1 
Salmonella 
Typhi 
STY0201 
Forward: CGCGAAGTCAGAGTCGACATAG 
131 bp [102] 
Reverse: AAGACCTCAACGCCGATCAC 
Probe: Cy5 - 
CATTTGTTCTGGAGCAGGCTGACGG-BBQ 
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2.5.2 Preparation of bacterial plugs 
Overnight bacterial culture was resuspended into 2ml of cell suspension buffer (Appendix A) to 
a turbidity of approximately 0.7 (MicroScan Turbidity Meter, Dade Behring, West Sacramento, 
CA). 400µl of the bacterial suspension was mixed with 20µl of Proteinase K (20mg/ml stock) 
and heated to 37°C.  A volume of 280 µl of 1% SeaKem® Gold agarose (Lonza, Rockland, 
USA) was then added to the bacterial suspension and the mixture was dispensed into plugs 
moulds and allowed to solidify for 15 min at room temperature.  
 
For bacterial cell lyses, plugs were incubated at 55°C for 2 hours in 5 ml cell lysis buffer 
(Appendix A). Following cell lysis, plugs were washed twice with preheated dH2O for 15 min 
at 55°C and four times with Tris-EDTA (TE) buffer (Appendix A) for 15 min at 55°C.  
 
2.5.3 Restriction enzyme digestion of genomic DNA and electrophoresis of DNA 
fragments 
For the restriction enzyme digestion of genomic DNA, 2-2.5 mm slices of agarose plugs were 
incubated for 15 min at 37°C in 100µl of XbaI restriction buffer [Roche Diagnostics GmbH, 
Mannheim, Germany] (Appendix A). The plugs were then incubated at 37°C for 3 hours in 
150µl of restriction enzyme master mix containing 50 units of XbaI restriction enzyme 
(Appendix A). The plugs were placed on a comb in a casting stand and allowed to air-dry for 3-
5 min. 1% SeaKem Gold agarose (Appendix A) was poured into the casting stand and the gel 
was allowed to polymerize for 20 min at room temperature.  
 
PFGE was performed in a CHEF-DR III electrophoresis chamber (Bio-Rad Laboratories, 
Hercules, CA) filled with 3L of 0.5x Tris-borate EDTA [TBE] (Appendix A) buffer cooled to 
14°C. The PFGE was run at 6 V/cm at an angle of 120° with an initial switch time of 2.2 sec, a 
final switch time of 63.8 sec and a run time of 19 hours. 
 
2.5.4 Staining of agarose gels 
The gel was stained in 0.5x TBE buffer containing 1 mg/ml ethidium bromide [EtBr staining 
solution] (Appendix A) for 20 minutes and destained three times with dH2O at 20 minute 
intervals. The gel image of PFGE patterns was captured using the Quantity 1-D analysis 
software (Bio-Rad Laboratories, Hercules, CA) and saved in TIFF format to enable electronic 
transfer into the BioNumerics software for further analysis.  
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2.5.5 BioNumerics analysis of PFGE bands 
The generated TIFF image was imported into the BioNumerics (version 6.5) Software (Applied 
Maths, Sint-Martens-Latem, Belgium) for analysis. The analysis of the image involved marking 
of PFGE bands of the isolates and these were normalized against the Salmonella Braenderup 
strain H9812 PFGE bands. Dendrograms of the patterns were created using the unweighted pair 
group method with arithmetic averages (UPGMA), with analysis of banding patterns 
incorporating the Dice-coefficient at an optimization setting of 1.5% and a position tolerance 
setting of 1.5% for the band migration distance. In this study, a cluster was defined as a group 
of isolates with indistinguishable PFGE patterns.  
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Chapter 3  
 
Development and validation of multiple-locus variable-number tandem-
repeats analysis for molecular sub-typing of Salmonella Typhi isolates 
 
3.1 Introduction 
MLVA is a DNA-based molecular subtyping method widely used to study the molecular 
epidemiology of pathogenic bacteria [192]. This molecular subtyping method has been 
successfully used for phylogenetic profiling as well as epidemiological investigations of 
Salmonella enterica species. MLVA uses PCR assisted amplification of VNTR loci and 
fragment size determination of the PCR amplicons by capillary electrophoresis with an 
internal size standard. This method has been used to study outbreaks as well as 
epidemiologically unrelated isolates, and has been very effective in typing homologous 
clones [138, 155]. 
 
Numerous approaches have been made in an effort to improve molecular subtyping of 
Salmonella Typhi using MLVA [11, 193-195]. The availability of two fully sequenced 
Salmonella Typhi genomes (CT18 and Ty2) motivated the determination of VNTRs in the 
Salmonella Typhi genome, from which MLVA assays have been designed. In 2003, Lui 
and colleagues identified five VNTR markers (designated TR1 to TR5) for molecular 
subtyping of Salmonella Typhi isolates from Asian countries. Only three markers (TR1, 
TR2 and TR3) showed variations amongst 59 Salmonella Typhi isolates [11]. In 2004, 
Ramisse and colleagues identified five other VNTR markers (designated Sal02, Sal06, 
Sal10, Sal15 and Sal20) which were used together with two previously reported VNTR 
markers (TR1 and STTR5) to distinguish 27 French Salmonella Typhi isolates into twenty-
five MLVA profiles [194]. Octavia and Lan (2009), identified two more VNTR markers 
(TR4500 and TR4699) and together with five previously reported markers (Sal02, Sal16, 
Sal20, TR1 and TR2) distinguished 73 global Salmonella Typhi isolates into 70 MLVA 
profiles [193]. The latest report published by Tien and colleagues (2011) proposed the use 
of two novel VNTR markers (Sty2 and Sty3) in addition to nine previously reported VNTR 
markers (TR4500, TR4600, Sal02, Sal06, Sal16, Sal20, TR1, TR2 and TR5) to establish 
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accurate genetic relationships amongst closely related Salmonella Typhi isolates from 
Taiwan [195]. Although these MLVA assays were able to distinguish between Salmonella 
Typhi isolates, there is still no standardized set of VNTR loci for the molecular subtyping 
of homologous Salmonella Typhi strains. 
 
3.1.1 The study aim 
The aim of this current study was to design a highly-discriminatory MLVA typing assay 
for the analysis of Salmonella Typhi isolates from SSA. The assay will be used to study the 
population structure of these Salmonella Typhi isolates and compare the discriminatory 
capacity of MLVA with PFGE. 
 
 
3.1.1.1 Objectives 
a. To use VNTR markers to explore their potential in studying the molecular 
epidemiology of Salmonella Typhi isolates 
b. To establish a highly-discriminatory MLVA assay consisting of five VNTR 
markers for the typing for Salmonella Typhi isolates 
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3.2 Materials and Methods 
 
3.2.1 Selection of bacterial isolates for the setting up of MLVA assay  
A total of 50 isolates were selected from a potential 1080 Salmonella Typhi isolates from 
the culture collection at the CED (Chapter 2, section 2.1) for the evaluation of the MLVA 
assay. The isolates in the validation panel were selected to given a good representation of 
the diverse Salmonella Typhi PFGE pulsotypes within the CED database, different 
specimen collection dates and geographic areas within the SSA region including various 
provinces in South Africa (Eastern Cape, Free State, Gauteng, Kwa-Zulu Natal, Limpopo, 
Mpumalanga, Northern Cape, North West and Western Cape provinces) as well as 
sporadic isolates from Zimbabwe and Ivory Coast. Isolates associated with previous South 
African Salmonella Typhi outbreaks were also included in the panel.  
 
3.2.2 Genotyping Salmonella Typhi from sub-Saharan Africa using MLVA 
  
3.2.2.1 Genomic DNA extractions 
Crude DNA extraction was performed using the boiling method as described in section 2.3 
of chapter 2. 
 
3.2.2.2 Selection of VNTR loci and PCR primers for MLVA assay 
For this study, VNTR loci from previously published literature were evaluated as markers 
to explore their potential in determining the strain relatedness of the Salmonella Typhi 
isolates. A total of 13 VNTR loci (Table 3.2) were identified and selected for analysis. The 
lengths of the repeat sequences at each VNTR locus ranged from three base pairs (bp) to 
26bp. MLVA was performed incorporating previously described VNTR primers [11, 193-
195].  
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3.2.2.3 Screening for length polymorphism of VNTR using simplex PCR 
The evaluation of length polymorphism at each VNTR locus began with simplex PCR 
amplification of the VNTR loci on the 50 Salmonella Typhi isolates. PCRs were performed 
using the Qiagen multiplex PCR kit (Qiagen, Hilden, Germany). The evaluation of each 
VNTR was carried out using the conventional PCR method and the forward primers were 
labelled with fluorophores. Each of the forward primers were labelled with one of four 
fluorophores, including FAM (blue), VIC (green), NED (yellow) or PET (red). Each 25µl 
reaction contained 12.5µl of the Qiagen master mix, 2.5µl Qiagen Q-solution, l µl of each 
of the forward and reverse primers, 1µl bacterial lysate suspension and autoclaved distilled 
water (dH2O) to adjust the final volume to 25µl (Appendix B). PCR amplification of the 
VNTR loci was performed in an Applied Biosystem 2720 cycler (Applied Biosystems, 
Weiterstadt, Germany) and the PCR conditions included an initial denaturation at 95ºC for 
15 min followed by 35 cycles of a three step cycle protocol: 94ºC for 60 sec, 55°C for 90 
sec and 72ºC for 90 sec, and a final extension at 72ºC for 10 min. PCR amplicons were 
diluted 1:35 in sterile distilled water. Two microliter aliquots of the dilutions were mixed 
with 11µl Hi-Di formamide solution (Applied Biosystems) and 0.2µl GeneScan 600 LIZ® 
size standard v2.0 (Applied Biosystems). These samples were evaluated by capillary 
electrophoresis on the Applied Biosystems 3500 genetic analyser (Applied Biosystems, 
Weiterstadt, Germany) and fragments sizes were analysed using the Gene-Mapper 
Software (Applied Biosystems). DNA fragments were automatically allocated to length 
bins and alleles were assigned based on the bin fragment sizes. The VNTR fragment sizes 
(in base pairs) were entered into the BioNumerics 6.5 software (Applied Maths, Sint-
Martens-Latem, Belgium) as character values and a dendrogram was constructed using a 
categorical coefficient with a 1.5 tolerance and an unweighted pair group method 
(UPGMA). Length polymorphism at each VNTR locus was defined as insertion or deletion 
of a repeat sequence. For example, VNTR locus TR2 has an 8bp repeat sequence, 
therefore, a deletion or insertion of 8bp in this VNTR locus would be considered as 
variation.    
 
3.2.2.4 VNTR measure of diversity 
The discriminatory power at each VNTR locus was determined by Simpson’s DI. The 
Simpson’s DI does not only depend on the number of alleles present at each locus but also 
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takes into consideration the equitability with which the alleles are distributed at each locus. 
VNTR loci with a Simpson’s DI closer to 1 are better markers to differentiate the strains 
for epidemiological purposes [196, 197]. In order to determine the measure of diversity 
and the degree of polymorphism at each VNTR locus, the Simpson's index of diversity 
(Simpson's DI) and 95% confidence intervals (CIs) were calculated using an online tool 
available at the Public Health England (PHE) website (http://www.hpa-
bioinformatics.org.uk/cgi-bin/DICI/DICI.pl). The Simpson's DI for the MLVA assay as 
well as PFGE was calculated and the Wallace coefficient was determined in order to assess 
the congruence between the MLVA assay and PFGE analysis, via an online tool 
(https://www.comparingpartitions.info/). 
 
3.2.2.5 Nucleotide sequencing of VNTR loci 
Nucleotide sequencing was performed in order to determine the presence of repeat 
sequences as well as to determine the size of the flanking regions in each of the seven most 
variable VNTR loci. For each VNTR locus, PCR amplicons of ten Salmonella Typhi 
isolates representing various fragment sizes were selected. These PCR amplicons served as 
template DNA in a PCR cycle sequencing reaction using the BigDye Terminator Cycle 
Sequencing Kit (Applied Biosystems, Foster City, CA, USA) (Appendix C) and an 
Applied Biosystems 3500 genetic analyser. DNASTAR Lasergene (version 8.0) software 
(DNASTAR Inc., Madison, WI, USA) was used to analyse DNA sequences and multiple-
sequence alignments were constructed using the BioEdit software package, version 7.2.5 
(Ibis Biosciences, Carlsbad, Calif, USA). 
 
3.2.2.6 Development of a 5-loci MLVA assay 
The five VNTR loci that were confirmed to harbour repeat sequences, had conserved 
flanking regions and had the highest degree of polymorphism were selected for the 
development of the MLVA multiplex PCR assay. Each 25 µl reaction contained 1 µl of the 
bacterial lysate suspension, 12.5 µl of the Qiagen master mix, 2.5 µl Qiagen Q-solution 
and primer concentrations as shown on (Table 3.2). The forward primers for TR1, TR2, 
Sal02, Sal20 and TR4699 were labelled with PET, 6-FAM, 6-FAM, VIC and NED 
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fluorophores, respectively. PCR amplicons were diluted 1:35 in sterile distilled water and 
reactions were subsequently carried out as described above (section 3.2.2.3).  
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3.3 Results 
The MLVA method for subtyping Salmonella Typhi isolates was developed for capillary 
electrophoresis and tested within this study.  
 
3.3.1 Screening for length polymorphism of VNTR loci using simplex PCR 
A validation panel consisting of 50 Salmonella Typhi isolates was used to evaluate 13 potential 
VNTR loci.  At total of 34 PFGE patterns (Figure 3.1) were represented in the validation panel. 
The validation panel consisted of two representative isolates from Zimbabwe, one isolate from 
Ivory Coast and 47 isolates from South Africa. Amongst isolates from South Africa, nine were 
collected from Gauteng, ten from Mpumalanga, eight from Kwa-Zulu Natal, seven from Western 
Cape, five from Eastern Cape, three from Limpopo, two from Free State, another two from North 
West and one isolate from Northern Cape provinces (Figure 3.2). Included in this panel were two 
representative isolates from Mpumalanga collected during the 2005 typhoid fever outbreak as well 
as two representative isolates from a typhoid fever outbreak that occurred in Gauteng, 2010.  
 
All of the 13 previously published VNTR loci selected were able to produce a PCR product at an 
annealing temperature of 55°C. Five VNTR loci were monomorphic and showed no variation 
amongst the isolates (Table 3.1). The remaining eight VNTR loci were polymorphic and showed 
variations between the isolates and were further evaluated for inclusion in the MLVA assay. 
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Figure 3.1 Dendrogram analysis of PFGE patterns of 50 Salmonella Typhi strains from sub-Saharan 
Africa. Highlighted in Yellow are strains isolated from Mpumalanga during the typhoid fever outbreak in 
2005. Highlighted in blue are strains isolated during the typhoid fever outbreak in Pretoria, Gauteng 2010. 
Highlighted in green are strains isolated from Zimbabwe  
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Figure 3.2 Geographical areas in sub-Saharan Africa as source of Salmonella Typhi strains included in the 
development of the MLVA assay 
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Table 3.1 VNTR loci showing no size variation amongst a panel of 50 Salmonella Typhi strains 
Isolate # Strain number VNTR locus 
TR4 
VNTR locus 
TR5 
VNTR locus 
Sal06 
VNTR locus 
Sal10 
VNTR locus 
Sal15 
1 TMI83959 418 173 171 190 187 
2 TMI86813 418 174 171 189 187 
3 TMI87197 418 174 171 190 187 
4 TMI87199 418 174 171 190 187 
5 TMI87513 418 174 171 190 187 
6 TCD105056 418 174 171 190 187 
7 TCD110945 418 174 171 190 187 
8 TCD111848 418 174 171 190 187 
9 TCD139882 418 174 171 189 187 
10 TCD146495 418 174 171 190 187 
11 TCD152229 419 175 171 190 187 
12 TCD167127 419 174 170 189 187 
13 TCD173225 419 175 170 190 187 
14 TCD179358 419 175 170 190 187 
15 TCD186374 419 174 172 191 187 
16 TCD185048 419 174 170 190 187 
17 TCD193597 419 175 172 191 187 
18 TCD197403 419 174 178 191 187 
19 TCD232204 419 175 171 190 187 
20 TCD241722 419 174 171 191 187 
21 TCD240006 419 174 170 191 187 
22 TCD281699 419 174 171 191 187 
23 TCD279436 419 174 171 191 187 
24 TCD298424 420 174 171 190 187 
25 TCD316823 419 175 178 192 187 
26 TCD375103 419 174 172 191 187 
27 TCD402284 419 175 172 192 187 
28 TCD409778 419 175 171 191 187 
29 TCD421690 419 175 172 192 187 
30 TCD422011 419 175 178 192 187 
31 TCD428468 419 175 172 192 187 
32 TCD458017 419 175 172 192 187 
33 TCD460486 419 175 172 192 187 
34 TCD461595 419 175 172 192 187 
35 TCD488042 419 175 172 192 187 
36 TCD525862 419 174 172 191 187 
37 TCD530747 419 174 172 191 187 
38 TCD537014 419 175 177 190 187 
39 TCD558851 418 175 172 192 187 
40 TCD619382 419 175 172 192 187 
41 TCD632685 419 175 172 191 187 
42 TCD671445 419 175 171 191 187 
43 TCD717480 419 175 172 192 187 
44 TCD723719 419 175 172 192 187 
45 TCD734935 419 175 172 191 187 
46 TCD734886 419 175 172 191 187 
47 TCD687093 419 175 171 191 187 
48 TCD674832 419 174 171 191 187 
49 TCD678877 418 175 171 191 187 
50 TMI1647764 418 171 171 190 187 
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3.3.2 Measure of diversity at each VNTR locus 
In this study, the Simpson’s DI for the 13 VNTR loci ranged from 0.00 to 0.940 and averaged at 
0.529 (Table 3.2). The most variable VNTR loci were TR2, TR4699 and Sal02 with Simpson’s DI 
of 0.940, 0.921 and 0.916 respectively. Five more VNTR loci that were variable included TR1, 
Sal16, Sal20, TR3 and TR4500 exhibiting Simpson’s DI of 0.868, 0.839, 0.730, 0.684 and 0.607 
respectively. Even though TR3 showed a higher Simpson’s DI of 0.684, this locus was excluded 
from the study as it contained a long repeat sequence (26 bp repeat length); preference was given 
to short repeat sequences which show more variability [198]. The remaining five VNTR loci had 
low diversity indices with the Simpson’s DI ranging from 0.00 to 0.339. Of these, three (VNTR 
locus TR4, Sal10 and Sal 15) were monomorphic and showed no variation amongst the isolates 
(Table 3.1). The two other VNTR loci (TR5, Sal06) were found unsuitable for the MLVA assay as 
they showed poor variation and had low diversity indices of 0.039 and 0.339.  
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 Table 3.2 Simpson's diversity indices and primers selected for the amplification of 13 Salmonella Typhi VNTR loci 
VNTR 
Locus 
Diversity 
Index 
Confidence 
Interval 
Repeat sequence VNTR Primer sequences VNTR Primer 
references 
TR2 0.940 0.916 - 0.964 CCAGTTCC Forward: CCCTGTTTTTCGTGCTGATACG 
Reverse: CAGAGGATATCGCAACAATCGG 
[11] 
TR4699 0.921 0.892 - 0.950 TGTTGG Forward: CGGGCAATTCGAGATAGGTA 
Reverse: AACCTCCCTGTATCTACCAA 
[193] 
Sal02 0.916 0.896 - 0.936 TACCAG Forward: CGATAGACAGCACCAGCAGA 
Reverse: TCGCCAATACCATGAGTACG 
[195] 
TR1 0.868 0.836 - 0.900 AGAAGAA Forward: GCCAACGATCGCTACTTTTT 
Reverse: CAAGAAGTGCGCATACTACACC 
[193, 194] 
Sal16 0.839 0.805 - 0.874 ACCATG Forward: TGCAGTTAATTTCTGCGATCA 
Reverse: CCTTCCGGATGTATGTGACC 
[195] 
Sal20 0.730 0.657 - 0.804 CAG Forward: CAGCCGACACAACTTAACGA 
Reverse: ACTGTACCGTGCGCGTTT 
[193] 
TR3 0.684 0.605 - 0.763 CGCGGGGATCGGTTTATCCCCGCTGG 
 
Forward: CGAAGGCGGAAAAAACGTCCTG  
Reverse: TGCGATTGGTGTCGTTTCTACC 
[11] 
TR4500 0.607 0.530 - 0.684 GGACTC Forward: CGTTGCTGCTCCGAAAT 
Reverse: GCGGTGAAGTGGAAAAAG 
[193] 
Sal06 0.339 0.185 - 0.494 CTCAAT Forward: TTGGTCGCGGAACTATAACTG 
Reverse: CTTCGTCTGATTGCCACTCC 
[194] 
TR5 0.039 0.000 - 0.114 CGTCACG Forward: TGAAAACCGGCTCGTAGCAGTG 
Reverse: CATACGGTTACTGCGGATTGG 
[11] 
Sal15 0.000 0.000 - 0.132 No data published Forward: GTGACCGGTTGAGTTTGCAT  
Reverse: GGCAGGTTGTACCAGTTCGT 
[194] 
Sal10 0.000 0.000 - 0.132 ACGCCGCTGCCG Forward: AAGCGACGTTCTTCTGCAAC  
Reverse: TGGAATATGATGGCATGACG 
[194] 
TR4 0.000 0.000 - 0.132 GAAATAAAAAATG Forward: AAAAGCCCGTCTAGTCTTGCAG  
Reverse: ATCCTTCGGTATCGGGGTATCC 
[11] 
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3.3.3 MLVA validation by nucleotide sequencing 
The seven VNTR loci (TR1, TR2, Sal02, Sal16, Sal20, TR4500 and TR4699) that were 
determined to be highly variable using the Simpson’s DI were selected for nucleotide 
sequencing in order to verify that variation observed in these loci occurred within the 
tandem repeat regions. 
 
VNTR locus TR1 
Variation at VNTR TR1 was determined to be in the tandem repeat regions. The flanking 
regions for this VNTR locus were consistent for all ten Salmonella Typhi isolates that were 
sequenced and determined to be 39bp (forward flanking) and 116bp (reverse flanking) in 
size (Appendix D1). 
 
VNTR locus TR2 
Nucleotide sequencing showed variation within the tandem repeat region of the VNTR 
locus TR2. The forward and reverse flanking regions for VNTR locus TR2 were 
determined to be 191bp and 105bp respectively (Appendix D2).  
 
VNTR locus Sal02 
Nucleotide sequencing of the ten Salmonella isolates revealed variation in the VNTR locus 
Sal02 was within the tandem repeat region as the forward and reverse flanking regions for 
this VNTR locus were consistent and determined to be 136bp and 59bp, respectively 
(Appendix D3). 
 
VNTR locus TR4699 
Nucleotide sequencing of the ten Salmonella Typhi isolates determined the forward and 
reverse flanking regions for VNTR locus TR4699 to be 38bp and 137bp in size. The 
flanking regions were consistent for all ten isolates and variation in this VNTR locus was 
observed within the tandem repeat region (Appendix D4). 
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VNTR locus Sal16 
Through nucleotide sequencing, the reverse flanking region for VNTR locus Sal16 was 
determined to be 49bp in size and was consistent amongst the ten Salmonella Typhi 
isolates that were sequenced. The determination of the forward flanking regions was 
challenging as variable sizes were observed. Three different sizes for the forward flanking 
region were observed and determined to be 126bp, 138bp and 162bp. Nucleotide 
sequencing revealed an additional tandem repeat region upstream of the VNTR locus Sal16 
repeat region consisting of a 12bp repeat sequence, ACCACCATTACG (Appendix D5).  
 
VNTR Locus TR4500 
Nucleotide sequencing of the VNTR locus TR4500 showed that variation observed in this 
locus was not within the tandem repeat region but was observed in the flanking regions. A 
seven base pair ‘TTGCCAC’ insertion sequence was identified in several Salmonella 
Typhi isolates. Although the size of the forward flanking region was consistent at 76bp, the 
size of the reverse flanking region varied between two sizes including, 195bp and 202bp 
(Appendix D6).  
 
VNTR locus Sal20 
Nucleotide sequencing of VNTR locus Sal20 showed that variation in this locus occurs 
within the tandem repeat region as the sizes of the forward and reverse flanking regions 
were consistent and determined to be 83bp and 80bp respectively (Appendix D7) 
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3.3.4 Optimisation of the multiplex MLVA assay consisting of five VNTR loci 
The development of the final MLVA multiplex PCR assay involved pooling the PCR 
amplicons of five highly variable VNTR loci into a single PCR reaction. The use of 
capillary electrophoresis for analysis of PCR amplicon sizes required labelling of forward 
VNTR primers with fluorescent dyes in order to enable differentiation of each of the 
VNTR loci PCR amplicons. Four fluorescent dyes were available for selection and these 
included VIC, FAM, NED and PET. VNTR loci with overlapping PCR amplicon sizes 
were assigned different fluorescent dyes. The selection of the fluorescent dyes was based 
on assessment of VNTR PCR amplicon sizes of the 50 Salmonella Typhi isolates from the 
simplex PCR assays in order to determine the size range of each VNTR locus (Figure 3.3).  
 
The development of the multiplex PCR assay began by incorporating equal amounts of 
VNTR primer concentrations in the PCR reaction. This resulted in various VNTR 
amplicons exhibiting stronger signals than others. According to the GeneScan guide, 
fluorescent dyes have variable signal strength, with VIC and FAM having stronger signals 
than NED and PET [199]. Consequently, the primer concentrations of the various VNTR 
loci were adjusted to show equal signal strength on the electropherogram (Figure 3.4). 
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Table 3.3 Features of seven highly polymorphic Salmonella Typhi VNTR loci 
VNTR 
Locus 
Gene Product Repeat 
sequence 
Unit 
length 
Forward 
offset (bp) 
Reverse offset 
(bp) 
MLVA multiplex 
PCR primer 
concentrations  
Reference(s) 
TR1 - Intergenic region between yedD 
and yedE   
AGAAGAA 7 39 116 1.2 µM [11, 193] 
TR2 - Intergenic region between arcD  
and yffB  
CCAGTTCC 8 191 105 1.2 µM [11, 193] 
TR4699 sefC Outer membrane fimbral usher 
protein  
TGTTGG 6 38 137 0.8 µM [193] 
Sal02 citT Citrate carrier  TACCAG 6 136 59 1 µM [193, 194] 
Sal16 - Intergenic region between 
STY3169 (pseudogene) and 
STY3172  
ACCATG 6 90 91, 97, 103, 
109, 115, 127 
- [193] 
Sal20 ftsN Cell division protein  CAG 3 83 80 0.5µM [193, 194] 
TR4500 STY4635 Hypothetical protein  GGACTC 6 76 195, 202 - [193] 
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Figure 3.3 Bar diagram showing selection of fluorescent dyes based on amplicon size ranges for the 
five VNTR loci 
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Figure 3.4 Electropherogram showing all five VNTR loci incorporated in a multiplex PCR for MLVA assay 
of Salmonella Typhi isolates 
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3.3.5 Subtyping of Salmonella Typhi isolates using the developed MLVA multiplex 
PCR assay 
The MLVA multiplex PCR assay developed in this study was used to type 50 Salmonella 
Typhi validation isolates. Length bins were allocated DNA fragments and bin numbers 
were assigned based on the bin fragment sizes. The fragment sizes for each of the five 
VNTR loci were combined in a string consisting of integers to form a MLVA profile and 
each MLVA profile was assigned a MLVA type (STyMT). As an example, for isolate 
TCD111848, the fragment sizes for VNTR locus TR1, TR2, Sal02, Sal20 and TR4699 
were determined to be 239bp, 383bp, 169bp, 185bp and 325bp respectively. Therefore, the 
MLVA profile for isolate TCD111848 is 239-383-168-1845-253 and this profile was 
designated MLVA type STyMT-206.  
 
The MLVA assay was able to segregate the isolates into 47 MLVA types (Figure 3.5). 
Three clusters (consisting of isolates with indistinguishable MLVA profiles) were 
identified from the dendrogram. One of the clusters consisted of the two representative 
isolates from the Gauteng, 2010 outbreak [89]. Another cluster consisted of two 
representative isolates collected during typhoid fever outbreaks in Mpumalanga, 2005. The 
third cluster consisted of sporadic isolates which were collected in the year of the 
Mpumalanga 2005 outbreak. These isolates were unrelated to the two representative 
isolates from the Mpumalanga outbreak. MLVA profiles of the two representative isolates 
from Zimbabwe were unrelated to each other and unrelated to profiles from South African 
isolates. MLVA profiles for isolates from Ivory Coast were also determined and found to 
be unrelated to profiles from South Africa and Zimbabwe. 
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Figure 3.5 MLVA cluster analysis of Salmonella Typhi isolates from sub-Saharan Africa 
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3.3.6 Discriminatory power of MLVA assay 
The established MLVA assay targeted five VNTR loci including TR1, TR2, Sal02, Sal20 
and TR4699. The discriminatory power of the MLVA assay was calculated using the 
Simpson’s DI applied to the Salmonella Typhi isolate panel. Of the 50 Salmonella Typhi 
isolates that were analysed, 47 MLVA types were identified. For the MLVA assay, 
Simpson’s DI was calculated at 0.998 (95% confidence interval (CI) 0.995 – 1.000) [Table 
3.3]. This was a high value compared to the Simpson’s DI for PFGE analysis of the same 
strains which was calculated at 0.984 (95% CI 0.974 – 0.994). With non-overlapping CIs, 
the difference in Simpson’s DI for MLVA and PFGE were statistically significant (P = 
0.013). 
 
The Wallace coefficient was calculated in order to assess the congruence between the 
MLVA assay and PFGE analysis. This coefficient indicates the probability that 2 strains 
that cluster together by one subtyping method could also be clustered together using 
another subtyping method [200]. The Wallace coefficient between MLVA assay and PFGE 
pulsotypes was 67% (Table 3.4). In contrast, the Wallace coefficient showed that PFGE 
could only poorly (9%) predict the results of the MLVA typing method.  
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Table 3.3 Simpson’s Index of diversity for MLVA assay and PFGE 
  Name   Number of 
patterns  
Diversity Index Confidence Interval 
PFGE Pattern 34 0.982 (0.970-0.994) 
MLVA assay 47 0.998 (0.994-1.000) 
 
 
 
 
Table 3.4 Wallace coefficient and analytical 95% CI of MLVA assay versus PFGE 
 PFGE Pattern MLVA assay 
PFGE Pattern  0.091 
(0.000-0.278) 
MLVA assay 0.667  
(0.333-1.000) 
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3.4 Discussion 
Epidemiological investigations are important for the control and prevention of typhoid 
fever outbreaks. Similarly, molecular subtyping of isolates serves as an important 
epidemiological investigation tool used to improve surveillance and epidemiological 
investigations. The MLVA typing scheme has been successfully used in outbreak 
investigation of many pathogenic bacteria. This is a fast and straightforward method with 
less complicated laboratory protocols compared to the widely used PFGE analysis method. 
MLVA uses PCR assisted amplification of VNTR loci and size determination of the PCR 
amplicons by capillary electrophoresis. Fragment analysis by capillary electrophoresis is 
performed for accurate determination of PCR amplicons sizes in base pair.  
 
In this study, we present a MLVA assay based on five highly polymorphic VNTR loci for 
studying the genetic diversity of Salmonella Typhi isolates from SSA. VNTR locus TR1 
located on the intergenic region between yedD and yedE carried a seven base pair repeat 
motif, AGAAGAA [193]. This VNTR locus was first characterized by Liu and colleagues 
[11]. In their study, Liu and colleagues found VNTR locus TR1 to be highly variable in 
typing Salmonella Typhi isolates from Asian countries. VNTR locus TR1 was also 
explored in other studies and was found to be highly variable, exhibiting Simpson’s DI 
ranging between 0.87 to 0.90 [193-195]. In our study, VNTR locus TR1 exhibited a 
Simpson’s DI of 0.87 (Table 3.2). Due to high variations observed, VNTR locus TR1 was 
selected for inclusion in our MLVA assay. 
 
VNTR locus TR2 was also first characterized by Liu and colleagues (2013) [11]. This 
VNTR locus is located in the intergenic region between arcD and yffB genes and carries an 
eight base pair sequence motif, CCAGTTCC. Several studies including the study by Liu 
and colleagues (2013) described VNTR locus TR2 as a highly variable VNTR locus [11, 
193-195] with an average Simpson’s DI of 0.95. In our study, VNTR locus TR2 exhibited 
Simpson’s DI of 0.94. VNTR locus TR2 was the most variable VNTR locus compared to 
other VNTR loci evaluated in our study and was therefore selected for inclusion in our 
MLVA assay. 
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VNTR locus Sal02 was first described in 2004 by Ramisse and colleagues [194]. This 
VNTR locus is located on the citT gene encoding the Citrate carrier [193] and carries a six 
bp repeat sequence, TACCAG. VNTR locus Sal02 was previously identified as highly 
polymorphic VNTR locus, with Simpson’s DI ranging from 0.87 to 0.92 [11, 193-195]. 
Similarly, in our study, VNTR locus Sal02 showed a high Simpson’s DI of 0.92 (Table 
3.2).  Therefore, this VNTR locus was also selected for inclusion in our MLVA assay. 
 
VNTR locus TR4699 was first described by Octavia and Lan in 2009 [193]. This VNTR 
locus is located on a sefC gene encoding the outer membrane fimbral usher protein and 
carries a TGTTGG repeat [193]. Octavia and Lan (2009) found this VNTR locus to be 
highly variable with a Simpson’s DI of 0.95. VNTR locus TR4699 was also explored in a 
study by Tien and colleagues (2012) and was found to be highly variable with a Simpson’s 
DI of 0.92 [195]. In our study, VNTR locus TR4699 also showed a high Simpson’s DI of 
0.92 and was selected for inclusion in our MLVA assay. 
 
VNTR locus Sal16 is located in the intergenic region between the pseudogene STY3169 
and STY3172 [193]. This VNTR locus has a six bp repeat motif, ACCATG. Octavia and 
Lan (2009) found VNTR locus Sal16 to be highly variable with a Simpson’s DI of 0.83. In 
a previous report, VNTR locus Sal16 was found to be inconsistent for Salmonella enterica 
subspecies enterica serovar Typhimurium strain LT2 [194]. Reports indicate that the 
inconsistencies in this VNTR locus are due to genome sequencing errors [193, 194]. In our 
study, VNTR locus Sal16 exhibited a high Simpson’s DI of 0.84. Even though high 
Simpson’s DI was observed for this VNTR locus, nucleotide sequencing revealed an 
additional tandem repeat region upstream of the VNTR locus Sal16 tandem repeat region. 
This region carried a 12bp repeat motif, ACCACCATCACG. Due to this region being a 
tandem repeat region, it is predisposed to high rates of polymorphism which will result in 
alteration of the product size of the VNTR locus Sal16. As a result, the correct number of 
repeat units for this VNTR locus cannot be determined. Designing new forward primers for 
VNTR locus Sal16 would not have eliminated the problem as the two tandem repeat 
regions are separated only by 12bp sequence, ACCACCATTACG. Consequently, VNTR 
locus Sal16 was not selected for inclusion in our MLVA assay. 
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VNTR locus TR4500 was first described in a study by Octavia and Lan [193] with an aim 
to develop a MLVA assay for the analysis of Salmonella Typhi strains from Australia. This 
VNTR locus is located on gene STY4635 of the Salmonella Typhi bacterium, and is a 
hypothetical protein with a consensus sequence consisting of six nucleotides, GGACTC 
[193]. Octavia and Lan (2009) found VNTR locus TR4500 to be highly variable with 
Simpson’s DI of 0.691. In our study, VNTR locus TR4500 exhibited a Simpson’s DI of 
0.607, slightly lower than the Simpson’s DI reported by Octavia and colleagues. A seven 
bp ‘TTGCCAC’ insertion sequence was identified in several Salmonella Typhi isolates. 
Due to this insertion, the correct number of repeat units for each isolate could not be 
determined as not all isolates harboured the seven bp sequence. The designing of new 
primers could not be considered as an option due to the fact that the insertion sequence is 
adjacent to the tandem repeat region. It is for this reason that the VNTR locus TR4500 was 
excluded from our MLVA assay. 
 
VNTR locus Sal20 was first described by Ramisse and colleagues (2004) in France [194]. 
Their study was aimed at developing a MLVA assay for analysis of Salmonella enterica 
subspecies enterica isolates. They identified VNTR locus Sal20 as one of the most variable 
VNTR loci exhibiting a Simpson’s DI of 0.81 [194].  VNTR locus Sal20 carries a three bp 
sequence, CAG, and is located on the ftsN gene coding for the cell division protein in 
Salmonella Typhi isolates [193]. This VNTR locus was found to be more variable in 
Salmonella Typhi than in other Salmonella species [194]. In our study, VNTR locus Sal20 
showed a Simpson’s DI of 0.730 and showed variation amongst the Salmonella Typhi 
isolates. This VNTR locus was included in our MLVA assay.  
 
The diversity at each VNTR locus is a function of both the number of alleles as well as 
their distribution frequency within a population and, high diversity indices indicate more 
variable VNTR loci. The combination of the five highly variable VNTR loci in the MLVA 
assay resulted in a highly discriminatory molecular typing scheme. We assessed the 
discriminatory power of the MLVA assay developed for Salmonella Typhi using a panel of 
50 isolates from SSA previously characterized by PFGE. The panel used in this study 
consisted of diverse collection of isolates that were epidemiologically unrelated as well as 
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closely related isolates. PFGE analysis of these isolates showed 34 unique pulsotypes. 
However, high discriminatory levels were achieved with the MLVA assay presented in this 
study. The MLVA assay consisting of the selected five VNTR loci (TR1, TR2, Sal02, Sa20 
and TR4699) was able to differentiate the 50 Salmonella Typhi isolates into 47 MLVA 
types. The Simpson’s DI for the MLVA assay was 0.998 indicating high discrimination 
abilities. The combination of VNTR loci with high diversity levels enabled differentiation 
of closely related and unrelated isolates as clusters of isolates from recent outbreaks in 
South Africa namely; Delmas, Mpumalanga outbreak in 2005 and the Pretoria, Gauteng 
outbreak in 2010. The MLVA assay was also able to distinguish between isolates from 
Ivory Coast, South Africa and Zimbabwe.  
 
To evaluate congruence between MLVA and PFGE, the Wallace coefficient was 
calculated. The Wallace index between MLVA and PFGE was 67%, indicating good 
correlation between MLVA and PFGE. However, there was lower probability that isolates 
assigned to the same cluster by PFGE would be assigned to the same cluster by MLVA. 
MLVA assay showed higher discrimination of Salmonella Typhi isolates than PFGE. 
Although capillary electrophoresis is required in order to correctly determine PCR 
amplicon sizes, the speed and simplicity in processing as well as data interpretation makes 
MLVA a more suitable molecular subtyping technique. 
 
The limitation in this study was the restricted number of isolates used to validate the 
MLVA assay. Testing a large number of isolates could help establish the discriminatory 
capacity of the MLVA assay in typing isolates from local and intercontinental outbreaks. 
Additionally, Salmonella Typhi isolates from other African countries were represented in 
low numbers. Numerous requests were put out to other African countries for Salmonella 
Typhi isolates; however, this was met with no response or false promises to send. The 
stability of the VNTR loci was not established. Further studies are required to determine 
whether VNTR loci remain stable in Salmonella Typhi isolates that have gone through a 
series of laboratory processing.  
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3.5 Conclusion 
Our study describes a MLVA assay consisting of five VNTR markers for the rapid analysis of 
Salmonella Typhi isolates from SSA which can assist epidemiological investigations of strain 
relatedness and detection of typhoid fever outbreaks in SSA. The assay represents a high-
throughput typing method that is a rapid and highly discriminatory molecular tool that may be a 
viable alternative to PFGE for subtyping Salmonella Typhi isolates from SSA. We have shown 
that the MLVA assay developed in this study is suitable to characterize Salmonella Typhi from 
the SSA as isolates from Ivory Coast, Zimbabwe and South Africa were discriminated using 
this MLVA assay. The assay was also able to differentiate between outbreak strains and 
epidemiologically unrelated strains as well as identify isolates that were closely related to the 
outbreak strains.  
 
This MLVA assay was validated using isolates from SSA as we only had African strains to 
work with, and specifically wanted to ensure that it would be applicable to African laboratories. 
Even so, the implementation of this assay in laboratories across the world will enable inter-
laboratory comparison of Salmonella Typhi strains. 
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Chapter 4  
 
The prevalence of H58 Salmonella Typhi in sub-Saharan Africa 
 
4.1 Introduction 
In sub-Saharan Africa (SSA), the spread of Salmonella Typhi is exacerbated by the lack of 
safe drinking water and good hygiene practices [28, 201]. Even more concerning is the spread 
of the highly clonal H58 Salmonella Typhi (H58 haplotype) which has been documented in 
some parts of Africa [29, 132]. These report the spread and transmission of H58 Salmonella 
Typhi from Asia to sub-Saharan Africa. Kariuki and colleagues (2010) studied the 
association of typhoid fever with a dominant MDR Salmonella Typhi haplotype [29]. In their 
study, WGS and bioinformatics approaches were used to discriminate Salmonella Typhi 
isolates into distinct phylogenetic lineages. Approximately 1500 single nucleotide variations 
on the Salmonella Typhi genome were interrogated using a novel SNP typing method. The 
H58 Salmonella Typhi was found to be the predominant strain in Kenya accounting for 
approximately 76% of all Salmonella Typhi isolates. In their study, Kariuki and colleagues 
(2010) also demonstrated the H58 haplotype, previously shown to be widespread in Asia, was 
predominant in Kenya, and was replacing the antimicrobial-susceptible strains [29]. 
 
Wong and colleagues (2015) conducted a phylogeographical analysis of the H58 Salmonella 
Typhi [132]. In their study, whole-genome sequences of approximately 1,850 global 
Salmonella Typhi isolates were analysed. A simple SNP-based typing scheme stratifying the 
Salmonella Typhi population into haplotypes was used to map the isolates into phylogeny. 
Through this typing scheme, they determined that 47% of the global Salmonella Typhi 
population belonged to the H58 haplotype. They also showed that there was inter- and 
intracontinental transmission events of the H58 haplotype as a number of very closely related 
isolates from different countries were identified. Their data suggested that South East Asia 
was the early hub for the H58 haplotype from which it was propagated to many locations 
around the world including East Africa. Data also indicated that the H58 haplotype was 
predominant amongst the eastern and southern African typhoid fever isolates. The detection 
of the H58 haplotype in Kenya, Tanzania, Malawi and South Africa provided compelling 
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evidence for multiple introductions of H58 Salmonella Typhi from South East Asia into the 
African continent. In their study, Wong and colleagues (2015) revealed evidence of an 
unreported wave of transmission of the H58 haplotype from Kenya to Tanzania and on to 
Malawi and South Africa (Figure 4.1). This demonstrated an on-going epidemic of H58 
typhoid fever across the SSA countries [132]. 
 
The surveillance of the H58 Salmonella Typhi in SSA is key in controlling the dissemination 
of this pathogen in the continent. The most reliable genotypic method that has been used to 
identify the H58 Salmonella Typhi isolates is WGS [29, 132]. However, for routine use in 
most laboratories in the SSA region, implementation of this methodology would be difficult 
due to lack of required equipment, lack of expertise and lack of funds. In a study by Holt and 
colleagues (2008), WGS analysis of approximately 20 Salmonella Typhi isolates identified 
20 genomic deletions suitable for genotyping Salmonella Typhi isolates [128, 202]. Amongst 
the H58 haplotype, a 993bp deletion affecting the STY 1507 and STY 1508 genes was 
identified. A polymerase chain reaction (PCR) assay targeting this deletion was then 
described and has been found suitable for the identification of isolates belonging to H58 
haplotype [202]. 
 
4.1.1 Aim 
In our current study, we used the recently developed conventional PCR-based typing assay 
[202] for the rapid and easy detection of H58 haplotype amongst Salmonella Typhi isolates 
from SSA. 
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Figure 4.1 Inter and intracontinental transfer of H58 Salmonella Typhi [132]
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4.2 Materials and Methods 
 
4.2.1 Crude DNA extraction 
Genomic DNA extractions were performed as described in Chapter 2 (section 2.3). 
 
4.2.2 Serotype confirmation of Salmonella Typhi isolates 
4.2.2.1 Serotyping of Salmonella Typhi isolates by slide agglutination 
All Salmonella isolates collected through the GERMS-SA programme were subjected to 
traditional slide agglutination serotyping as part of routine surveillance (See Chapter 1 
section 2.3). Specific antisera (Statens Serum Institut, Copenhagen, Denmark and 
BioMérieux, Marcy-I’Étoile, France) were used to serotype Salmonella Typhi isolates using 
the Kauffmann-Le Minor scheme (Appendix E). 
 
4.2.2.2 Real time PCR serotyping of Salmonella Typhi isolates 
Real-time PCR was employed in order to confirm the serotypes of Salmonella Typhi isolates 
collected through the TSAP study.  The real-time PCR was performed as described in 
Chapter 2 (section 2.4). 
 
4.2.3 Conventional PCR identification of H58 Salmonella Typhi 
Salmonella Typhi isolates from the GERMS-SA and TSAP programmes were subjected to 
conventional PCR in order to determine the prevalence of H58 Salmonella Typhi. PCR 
identification of the H58 haplotype was carried out using a conventional PCR method 
adapted from that described previously [202]. The PCR primers described by Murgia and 
colleagues (2016) were designed to produce an 107bp amplicon to indicate presence of the 
deletion in H58 Salmonella Typhi isolates and an 1100bp amplicon to indicate absence of the 
deletion in non-H58 Salmonella Typhi isolates. Primer sequences are shown in Table 4.1. 
 
PCR reactions were performed using Amplitaq® Gold DNA polymerase, GeneAmp® 10X 
PCR buffer and Magnesium chloride (MgCL2) (Applied Biosystems, Foster City, California) 
incorporating 1.5 units of enzyme per reaction. Reactions were performed in a final volume 
of 25 µl, consisting of MgCL2 and deoxynucleotide triphosphate (dNTP) (Celtic molecular 
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diagnostics) at concentrations of 2 mM and 200 µM respectively; with primer concentrations 
at 1.2 µM each. A no template control (NTC) was included in the reactions to rule out 
possible contamination. Salmonella Typhi NCTC 8385 was used as a positive control for 
non-H58 Salmonella Typhi and a Salmonella Typhi clinical strain number TCD0186374 was 
used as a positive control for H58 Salmonella Typhi. All reactions were carried out in 0.2 ml 
thermo-tubes (Thermo Scientific) and were performed in a Bio-Rad (iCycler) thermal cycler 
(Bio-Rad). The thermal cycling conditions were as follows: Initial denaturation at 94 °C for 2 
minutes, followed by 30 cycles at 94 °C for 30 seconds, 60 °C for 30 seconds, 70 °C for 1 
minute, and a final extension at 72 °C for 5 minutes.  
 
Table 4.1 PCR primers selected for specific amplification of H58 Salmonella Typhi 
Primer Primer sequence Position on chromosome of 
Salmonella Typhi CT18 
H58-Forward GCAGGCAAAATCGAAATCAG 1466515 – 1466534 
H58-Reverse CAAACCGTTGAATCGGAAGT 1467614 – 1457595  
 
 
4.2.4 Gel electrophoresis  
A 3 µl volume of loading dye (2.5% Bromophenol blue solution) (Sigma-Aldrich, St Louis, 
MO USA) was added to the 25 µl of PCR product (Appendix F). A 6 µl volume of the mixed 
solution was loaded on a 1.5% SeaKem LE agarose gel (Whitehead Scientific, Rockland, 
USA) containing 10 mg/ml ethidium bromide (Sigma-Aldrich) (Appendix A).  
 
Gel electrophoresis was performed in 1X TAE buffer Tris (Merck): Acetate (Merck): EDTA 
(Merck) at 140 V (voltage) for 50 min (Appendix F). The gel image was visualized using the 
Quantity 1-D analysis software (Bio-Rad Laboratories, Hercules, CA). 
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4.3 Results 
 
4.3.1 Group for Enteric, Respiratory and Meningeal Disease Surveillance network in 
South Africa (GERMS-SA study) 
 
4.3.1.1 Annual typhoid fever isolates 
A total of 214 Salmonella Typhi isolates were collected from patients hospitalized with 
typhoid fever across South Africa from January 2012 to December 2014. An increase was 
observed in the annual number of isolates collected with most of the isolates (45%) collected 
during the year 2014 (Figure 4.2). 
 
 
Figure 4.2. Temporal distribution of 214 Salmonella Typhi isolates from the GERMS-SA 
study for the period 2012-2014. 
 
4.3.1.2 PCR screening of H58 Salmonella Typhi 
Of the 214 isolates that were collected during the study period, 195 isolates were viable; these 
isolates were subjected to the H58 Salmonella Typhi conventional PCR. Of the 195 isolates 
that were processed, 107bp amplicons were identified in 54% (n=105) of the isolates. This 
confirmed the presence of a 993bp deletion which is only present in all H58 Salmonella 
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Typhi isolates. For the remaining isolates (n=90), 1100bp amplicons were identified; these 
isolates belonged to non-H58 Salmonella Typhi haplotype groups.  
 
There was an increase in the number of H58 Salmonella Typhi isolates identified from the 
year 2012 to 2014. In the year 2012, 50% (n/N=28/56) of the isolates were identified as H58 
Salmonella Typhi. This number slightly decreased to 43% (n/N=25/58) in 2013; however, 
during the year 2014, 64% (n/N=52/81) of the isolates were identified as H58 Salmonella 
Typhi (Figure 4.3). The identification of H58 Salmonella Typhi in more than half the number 
of the isolates (54%) collected between 2012 and 2014 is concerning. The association of H58 
Salmonella Typhi with MDR as well as reduced susceptibility to fluoroquinolones means that 
current treatment regimes, such as ciprofloxacin, cannot be used for routine typhoid fever 
treatment. This then means that more expensive antimicrobial drugs would be required as 
alternatives. 
 
 
Figure 4.3 Number of H58 Salmonella Typhi isolates identified in South Africa from 2012 - 
2014.  
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4.3.1.3 H58 Salmonella Typhi by geographical area 
Typhoid fever cases were reported in all but one province (n=8) in South Africa (Figure 4.4). 
Most typhoid fever cases were reported from Gauteng, followed by Western Cape, Kwa-Zulu 
Natal and Mpumalanga (Figure 4.5).  
 
The H58 Salmonella Typhi was identified in all eight provinces (Figure 4.4). This strain was 
predominant in Gauteng and Western Cape provinces accounting for 57% (n/N=43/75) and 
61% (n/N=27/44), respectively, of the Salmonella Typhi isolates collected from these 
provinces. Even though the H58 Salmonella Typhi was identified in the Kwa-Zulu Natal 
province, findings indicated that non-H58 haplotypes were the predominant cause of typhoid 
fever, accounting for 62% of isolates collected in this province.  
 
4.3.1.4 Prevalence of H58 Salmonella Typhi in age groups 
The H58 Salmonella Typhi was identified in all age groups and caused a slightly higher 
number of illnesses than other Salmonella Typhi haplotypes except in age groups 6–10 and 
11–15 and 55+ years (Figure 4.6). Even though the H58 Salmonella Typhi was not the 
principal cause of infection in the 6-10 years age group, approximately 36% of the isolates in 
this age group belonged to the highly resistant haplotype. Additionally, 83% (n=5) of typhoid 
fever illness in in children aged 0-5 years was caused by the resistant H58 haplotype.  
 
Chapter 4 
Results 
76 
 
 
Figure 4.4 Geographical distribution of H58 and non-H58 Salmonella Typhi within 
provinces in South Africa for the years 2012 to 2014 
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Figure 4.5 Bar graph representing Salmonella Typhi haplotypes identified in eight provinces 
in South Africa for the years 2012 to 2014. 
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Figure 4.6 The Bar graph depicts haplotype specific typhoid fever infections by age group in South 
Africa, for the years 2012 to 2014. 
 
4.3.2 Multi-Country Typhoid Fever Surveillance in sub-Saharan Africa Program 
(TSAP Study) 
 
4.3.2.1 Real-time PCR confirmation of serotype 
Real-time PCR assay targeting a gene unique to Salmonella species and an additional gene 
unique to Salmonella Typhi was used to confirm the serotype of Salmonella Typhi isolates 
collected from eight countries in the SSA. A total of 121 isolates were identified as 
Salmonella Typhi. Most of the isolates were collected from Kenya (n=56), followed by 
Ghana (n=34) and Burkina Faso (n=12) (Figure 4.7).  
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Figure 4.7 The bar graph showing the number of Salmonella Typhi isolates detected in SSA 
countries through the TSAP study for the years 2012 to 2014 
 
4.3.2.2 PCR Screening of H58 Salmonella Typhi 
All 121 Salmonella Typhi isolates were subjected to the H58 Salmonella Typhi conventional 
PCR. Of these, 75 isolates (62%) belonged to the H58 haplotype. The H58 Salmonella Typhi 
was identified in all but one of the SSA countries in the TSAP study (Figure 4.8). A total of 
two Salmonella Typhi isolates were collected from Guinea Bissau during the study period. 
These isolates were identified as non-H58 Salmonella Typhi.  
 
The results from the conventional PCR also indicated that the H58 haplotype was 
predominant in both Kenya and Tanzania, as non-H58 Salmonella Typhi isolates were not 
identified. Of the two isolates collected from Senegal, only one belonged to the H58 
haplotype. Three of the five isolates from Madagascar and two of three isolates from Ethiopia 
were identified as H58 Salmonella Typhi. Although the H58 haplotype was identified in 
Burkina Faso and Ghana, this highly resistant strain is not the predominant cause of typhoid 
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fever in these countries. Most of the Salmonella Typhi isolates in Burkina Faso (92%, n=11) 
and Ghana (85%, n=29) were identified as non-H58 Salmonella Typhi isolates (Figure 4.9). 
 
Figure 4.8 Pie charts showing the prevalence H58 Salmonella Typhi isolates in SSA 
countries. 
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Figure 4.9 Map of Africa depicting the presence of H58 Salmonella Typhi in countries 
involved in typhoid fever surveillance through TSAP and GERMS-SA studies.
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4.4 Discussion 
In this study, a simple and inexpensive PCR assay was employed for the rapid identification 
of H58 Salmonella Typhi. The PCR assay targeted a 993bp deletion which is highly 
conserved in the H58 haplotype and was suitable for accurate identification of this haplotype. 
All H58 Salmonella Typhi isolates were identified and distinguishable from non-H58 
Salmonella Typhi isolates. This proved to be a useful molecular tool for the preliminary 
screening of Salmonella Typhi isolates and can be accessible to most laboratories in the 
developing countries. 
 
Data from SSA has suggested the presence of the H58 haplotype in some parts of the 
continent. Approximately 62% of the Salmonella Typhi isolates collected through the TSAP 
study belonged to H58 haplotype. Data also indicated that all isolates from Kenya (n=56) 
belonged to this haplotype. The emergence of the H58 haplotype in Kenya was first described 
in 2010 by Kariuki and colleagues, where they reported that approximately 75% of 
Salmonella Typhi isolates from Kenya belonged to the H58 haplotype [29]. It is very 
concerning that isolates collected from the TSAP surveillance site in Kenya were all 
identified H58 Salmonella Typhi isolates. This correlates with observations by Kariuki and 
colleagues that the H58 haplotype has rapidly spread in Kenya and is replacing the 
antimicrobial susceptible Salmonella Typhi [29]. Over-the-counter sales of fluoroquinolones 
without prescription in Kenya is a contributing factor to the misuse of antimicrobials which 
has resulted in emergence of antimicrobial resistant pathogens [22].  
 
The H58 Salmonella Typhi seems to be spreading beyond the borders of Kenya. All isolates 
(n=7) collected in Tanzania for the period of the study belonged to the H58 haplotype. 
Additionally, 67% (n=2) of the isolates collected from Ethiopia were H58 Salmonella Typhi. 
There were H58 Salmonella Typhi isolates detected from Madagascar. Approximately 60% 
(n=3) of isolates collected from Madagascar belonged to the H58 haplotype. The majority of 
isolates collected in Ghana and Burkina Faso belonged to the non-H58 Salmonella Typhi 
haplotypes and accounted for approximately 85% (n=29) and 92% (n=11) of all isolates, 
respectively. Of the two isolates collected from Senegal during the study period, one 
belonged to the H58 haplotype. The H58 Salmonella Typhi was not detected in Guinea 
Bissau. Our data is in agreement with that of Wong and colleagues (2015) indicating 
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predominance of the H58 Salmonella Typhi in the eastern and southern parts of Africa; which 
suggests an on-going clonal replacement of the non H58 haplotypes. 
 
In South Africa, an increase in the number of H58 Salmonella Typhi was observed for the 
years 2012 to 2014. During the period of the study, the number of H58 Salmonella Typhi 
isolates in South Africa increased from 50% in 2012 to 64% in 2014. This was particularly 
alarming as H58 Salmonella Typhi is known for its MDR characteristic coupled with reduced 
susceptibility to fluoroquinolones. The H58 haplotype was identified in patients of all age 
groups, but was predominant amongst patients aged 25-34 and 35-44 years. Interestingly, the 
H58 haplotype was identified as the predominant cause of infection in children aged 0-5 
years. Fluoroquinolones are generally not recommended for treatment of typhoid fever in 
children under the age of 18 years due to major problems associated with bones, joints and 
join tissues [203]. Therefore, it is not unexpected that the majority of typhoid fever cases in 
this age group are not caused by the H58 Salmonella Typhi. Exposure to the H58 Salmonella 
Typhi in age groups 0-5 years, 6-10 years and 11-15 years could be as a result of contact with 
adult carriers and not necessarily of selection pressure. Qin and colleagues (2006) studied 
ciprofloxacin resistance in gram-negative bacilli from the faecal microflora of children that 
were not exposed to the antimicrobial agent [203]. In their study, they demonstrated that 
resistant bacteria belonging to species that would normally be susceptible to fluoroquinolones 
can be found in the intestinal tracts of individuals who were not exposed to fluoroquinolones. 
This suggested that bacteria that are resistant to clinically useful antimicrobial agents can be 
acquired by humans without experiencing selective pressure due to either direct or indirect 
exposure to the antimicrobial agents. Therefore, since fluoroquinolones are not used for the 
treatment of typhoid fever in children, the presence of the H58 haplotype in this age group 
could be through contact with adult typhoid carriers rather than antimicrobial selection 
pressure. 
 
H58 Salmonella Typhi was mostly identified in Gauteng and in the Western Cape provinces 
(Figure 4.5). The reason for the detection of high typhoid fever incidences in these provinces 
could include; (a) that many of the South African population relocate to these provinces to 
seek employment opportunities as the unemployment rate in Gauteng and Western Cape 
provinces is higher than anywhere else in the country; (b) the Gauteng and Western Cape 
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province are two of the most popular tourist destinations in South Africa; (c) additionally, 
over the years, the Gauteng Province has become home to many refugees from many 
impoverished countries in the SSA. Even though H58 Salmonella Typhi was detected in 
Mpumalanga, Kwa-Zulu Natal and the Eastern Cape, other haplotypes of Salmonella Typhi 
were detected, accounting for more than half the isolates collected over the study period.  
 
Study limitations 
There were no cases of typhoid fever reported from the Northern Cape Province during the 
study period; this could be due to a couple of reasons including (1) underreporting of 
laboratory-confirmed cases to the GERMS-SA laboratory-based surveillance program and (2) 
various provinces in SA could be involved in more intense surveillance as compared to 
others. Similarly, the difference in the number of isolates collected from the various countries 
in SSA could be an effect of variation in surveillance efforts and not a reflection of the 
burden of typhoid fever disease in those countries.  
 
We could not perform statistical calculations for the difference in number of H58 Salmonella 
Typhi isolates identified in various age groups as well as in different provinces in SA, as 
there were not enough variables. This would have been possible if we compared the number 
of H58 Salmonella Typhi isolates in age groups or provinces per year. This was not done in 
our study. 
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4.5 Conclusion 
The predominance of H58 Salmonella Typhi in South Africa as well as other parts of the SSA 
region is concerning. In this country, the spread and transmission of typhoid fever is believed to 
be fuelled by lack of access to clean water and proper sanitation especially in countries where 
stringent legislations regarding over-the-counter sales of antimicrobials exists. The increase in 
the number of H58 Salmonella Typhi threatens successful treatment of typhoid fever. The 
inappropriate and misuse of antimicrobials, fuelled by over-the counter sale of antimicrobials, 
is believed to contribute greatly to antimicrobial resistance. The enforcement of legislations 
that restrict over-the-counter dispensation of antimicrobials without prescription could greatly 
reduce emergence of highly resistant strains which occur as a result of antimicrobial selection 
pressure. 
 
There is evidence of intracontinental spread of H58 Salmonella Typhi in the SSA. Therefore, 
continued surveillance of typhoid fever is crucial for monitoring disease spread and to inform 
prevention and control strategies.
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Chapter 5  
 
Multiple-locus variable-number tandem-repeats analysis of Salmonella 
Typhi isolates collected from eight sub-Saharan African countries, 2012 - 
2014 
 
5.1 Introduction 
MLVA typing has been used successfully for molecular typing of Salmonella Enteritidis as 
well as Salmonella Typhi [153, 154]. In this study, we used MLVA typing to study the 
molecular epidemiology of Salmonella Typhi isolates collected from eight countries from 
within SSA including, Burkina Faso, Ethiopia, Ghana, Guinea Bissau, Kenya, Madagascar, 
Senegal, South Africa (through GERMS-SA and TSAP surveillance programs) and Tanzania 
through the TSAP study. The TSAP is a network of 13 sentinel sites within ten countries in 
SSA (Figure 5.1) [187]. This program was established in SSA with the aim of introducing 
standardized multi-country surveillance for typhoid fever and invasive non-typhoidal 
Salmonella. Along with their collaborators, the TSAP has managed to strengthen local 
surveillance by improving disease surveillance, diagnosis of bacterial disease analysis and 
reporting systems [187].  
 
5.1.1 The study objectives: 
a) To use MLVA assay to investigate the molecular epidemiology of Salmonella Typhi 
isolates from SSA 
b) To investigate whether H58 Salmonella Typhi is associated with a particular MLVA 
profile 
c) To compare MLVA molecular subtyping data to the PFGE genotyping data 
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Figure 5.1 Thirteen TSAP sentinel sites[187]
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5.2 Materials and Methods 
 
5.2.1 Salmonella Typhi isolates 
A total of 316 Salmonella Typhi isolates from eight countries in the SSA continent were 
analysed. The isolates were collected through two surveillance studies, GERMS-SA and 
TSAP described in Chapter 2, section 2.1. 
 
5.2.2 Pulsed-field gel-electrophoresis (PFGE) 
PFGE was performed as described in Chapter 2 (section 2.5).  
 
5.2.3 Multiple-locus variable-number tandem-repeats analysis (MLVA) 
MLVA typing was performed by multiplex PCR amplification of the five most variable 
VNTR loci as described in Chapter 3 (section 3.2.2.6).  
 
A minimum spanning tree (MST) was generated in order to display the distance in relation 
between the Salmonella Typhi isolates. The distance was calculated based on the number of 
different VNTR loci between two MLVA profiles. For instance: if two MLVA profiles 
differed at one VNTR locus, the distance between them would be ‘one’, thus indicating close 
relation between the MLVA types. Furthermore, if two MLVA profiles differed at two 
VNTR loci, the distance between these MLVA types would be ‘two’, and so forth. The 
majority of isolates in this study differed by either one or two VNTR loci. There was no 
apparent major cluster in the MST; however, six small clusters consisting of four to sixteen 
isolates with indistinguishable MLVA profiles were identified.  
 
5.2.4 Data analysis 
The Simpson's DI and 95% confidence intervals (CIs) were calculated using an online tool 
available at (www.comparingpartitions.info). The congruence between the MLVA assay and 
PFGE analysis the Wallace coefficient was determined, via an online tool 
(www.comparingpartitions.info). 
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5.3 Results 
5.3.1 Diversity of Salmonella Typhi isolates analysed by MLVA 
Three hundred and sixteen Salmonella Typhi isolates from SSA were analysed using a 
MLVA assay consisting of five VNTR loci. All five VNTR loci were amplified in one 
multiplex PCR reaction using fluorescently labelled primers. The PCR amplicons were 
separated based on fragment size by multicolour capillary electrophoresis Genetic analyzer. 
The loci sizes for each VNTR locus were inferred numbers based on bin fragment size. The 
loci sizes for each VNTR locus were then combined into a string of integers referred to as a 
MLVA profile. As an example, 197-487-309-196-241 is a string of integers representing 
amplicon fragment sizes for VNTR loci TR1-TR2-Sal02-Sal20-TR4699 respectively. This 
particular string of integers or MLVA profile was assigned MLVA type STyMT-86 (i.e. 
Salmonella Typhi MLVA type-86). Altogether, 226 MLVA types were identified amongst 
the Salmonella Typhi isolates from SSA (Appendix G).   
 
The MST revealed two major clonal complexes (clonal complex I and clonal complex II) 
which consisted of the majority of isolates (n/N=252/316) (Figure 5.2). It was evident that the 
Salmonella Typhi isolates from the different SSA countries were distributed throughout the 
MST and not limited to one clonal complex as no branching was completely dominated by 
isolates from the same country. Similarly, the H58 clone was not limited to a single clonal 
complex (Figure 5.3). This haplotype was dispersed throughout the MST indicating that 
heterogeneity exists within the H58 clonal group. Even so, the majority of isolates 
(n/N=83/135) in clonal complex I belonged to non-H58 Salmonella Typhi haplotype.  
 
5.3.2 MLVA typing of isolates from South Africa 
MLVA typing of 195 isolates from South Africa indicated that diversity exists amongst the 
Salmonella Typhi isolates (Figure 5.4). In total, 155 MLVA types were identified amongst 
the South African Salmonella Typhi isolates. Although no major clusters were identified, 
seven small clusters consisting of three to four isolates were identified. These were STyMT-
121, STyMT-114, STyMT-102, STyMT-130, STyMT-132, STyMT-136 and STyMT-139. 
Analysis of Salmonella Typhi isolates using MLVA did not indicate predominance of any 
MLVA type in the country. There was high variability observed amongst the isolates from 
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South Africa with 66 MLVA types identified in Gauteng, 34 in Kwa-Zulu Natal, 30 in 
Western Cape, 24 in Mpumalanga, 9 in Eastern Cape, 2 in Limpopo and 1 in North West.  
 
Several MLVA types were shared between provinces and included STyMT-100, STyMT-
107, STyMT-114 and STyMT-136 identified in isolates from Gauteng and Western Cape; 
STyMT-112, STyMT-132 and STyMT-261 identified in Gauteng and Mpumalanga; MLVA 
types STyMT-102 and STyMT-139 identified in Gauteng and Eastern Cape; MLVA type 
STyMT-134 identified in Kwa-Zulu Natal and Limpopo; and MLVA type STyMT-111 
identified in Eastern Cape and Western Cape provinces. 
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Figure 5.2 Minimum spanning tree calculated for MLVA profiles of Salmonella Typhi isolates from 
SSA collected over a three year period (n=316). Each node represents a different MLVA profile. 
Node colour denotes country of isolate origin. Branch thickness indicated difference in the number of 
loci between MLVA profiles. Thick solid lines connect nodes that differ at one VNTR locus, thin 
lines connect nodes that differ at two VNTR loci, dashed lines connect nodes that differ at three 
VNTR loci and dotted lines connect nodes that differ at four or more VNTR loci. 
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Figure 5.3 Minimum spanning tree calculated for MLVA profiles of Salmonella Typhi isolates from 
SSA collected over a three year period (n=316). Each node represents a different MLVA profile. Blue 
coloured node colour denote non-H58 Salmonella Typhi isolates and red coloured nodes denote H58 
Salmonella Typhi isolates.  
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Figure 5.4 Minimum spanning tree calculated for MLVA profiles of Salmonella Typhi isolates from 
South Africa collected over a three year period (n=195). Each node represents a different MLVA 
profile. Node colours denote province of isolate origin.  
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5.3.3 Annual distribution of MLVA types amongst Salmonella Typhi in South Africa 
A total of 57 Salmonella Typhi isolates collected during the year 2012 were analysed using 
MLVA assay. There were 45 MLVA types identified from these isolates (Figure 5.5A). There 
was no evidence of a predominant MLVA type; however, small clusters consisting of two to 
four isolates were identified and these were MLVA types STyMT-121, STyMT-112, 
STyMT-239, STyMT-125 and STyMT-100. MST revealed a clonal complex consisting of 
isolates that belong to the H58 haplotype. The H58 Salmonella Typhi was associated with 
MLVA type and these included MLVA types STyMT-239, STyMT-112, STyMT-127, 
STyMT-125 and STyMT-100 which consisted of two to four isolates each (Figure 5.5 B).  
 
From the 58 Salmonella Typhi isolates collected during the year 2013, 52 MLVA types were 
identified (Figure 5.6 A). MST revealed two clonal complexes from which small clusters 
consisting of two isolates each were identified; these were STyMT-102, STyMT-136, 
STyMT-113, STyMT-56, STyMT-127, STyMT-261 and STyMT-87. The H58 clone was not 
limited to a single clonal complex as isolates belonging to this haplotype were dispersed 
throughout the MST (Figure 5.6 B). The MST revealed MLVA types consisting of both the 
H58 as well as non-H58 haplotype isolates. These MLVA types were identified as STyMT-
261, STyMT-113 and STyMT-56. MLVA types which were associated with the H58 
haplotype were STyMT-136 and STyMT-127 consisting of two isolates each. 
 
A total of 73 MLVA types were identified from 85 Salmonella Typhi isolates collected 
during the year 2014 (Figure 5.7 A). Similar to the years 2012 and 2013, there was no 
evidence of a predominant MLVA type; however, small clusters consisting of two to three 
isolates each were identified. These MLVA type included, STyMT-132, STyMT-139, 
STyMT-173, STyMT-133, STyMT-111, STyMT-146, STyMT-59, STyMT-114 and STyMT-
134. The MST revealed MLVA clusters consisting of both H58 and non-H58 Salmonella 
Typhi isolates, and these included STyMT-139, STyMT-173, STyMT-114 and STyMT-111 
(Figure 5.7 B). MLVA types which were exclusively associated with the H58 haplotype 
included STyMT-132, STyMT-134 and STyMT-59. 
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During each year of the study, distinct MLVA types were detected; however, nine MLVA 
types were identified throughout the study period. MLVA types STyMT-114 and STyMT-
130 were observed every year throughout the study; MLVA types STyMT-121, STyMT-132 
and STyMT-159 were observed during the years 2012 and 2014; MLVA type STyMT-128 
was observed during 2012 and 2013 and finally, MLVA types STyMT-102, STyMT-107 and 
STyMT-136 were observed during the years 2013 and 2014.  
 
Figure 5.5 Minimum spanning tree calculated for MLVA profiles of Salmonella Typhi isolates from 
South Africa collected during the year 2012 (n=57). Each node represents a different MLVA profile. 
(A) Node colours denote province of isolate origin and (B) Blue coloured node colour denote non-
H58 Salmonella Typhi isolates and red coloured nodes denote H58 Salmonella Typhi isolates.  
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Figure 5.6 Minimum spanning tree calculated for MLVA profiles of Salmonella Typhi isolates from South Africa collected during the year 2013 (n=58). 
Each node represents a different MLVA profile. (A) Node colours denote province of isolate origin and (B) Blue coloured node colour denote non-H58 
Salmonella Typhi isolates and red coloured nodes denote H58 Salmonella Typhi isolates.  
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Figure 5.7 Minimum spanning tree calculated for MLVA profiles of Salmonella Typhi isolates from South Africa collected during the year 2014 (n=73). 
Each node represents a different MLVA profile. (A) Node colours denote province of isolate origin and (B) Blue coloured node colour denote non-H58 
Salmonella Typhi isolates and red coloured nodes denote H58 Salmonella Typhi isolates.  
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5.3.4 MLVA typing of isolates from other sub-Saharan African Countries 
 
5.3.4.1 Burkina Faso 
MLVA typing was performed on 12 isolates collected in Burkina Faso during the years 2012 
to 2014 (Figure 5.8 A). A total of ten MLVA types were identified. The MST did not reveal a 
predominant MLVA type. Even so, a cluster consisting of three isolates belonging to MLVA 
type STyMT-206 was identified. Salmonella Typhi isolates from this country showed 
heterogeneity. Only one MLVA type, STyMT-184, was associated with the H58 haplotype 
(Figure 5.8 B). H58 Salmonella Typhi was not predominant in Burkina Faso.  
 
 
Figure 5.8 Minimum spanning tree calculated for MLVA profiles of Salmonella Typhi isolates from 
Burkina Faso collected over a three year period (n=12). Each node represents a different MLVA 
profile. (A) Node colours denote MLVA profiles and (B) Blue coloured node colour denote non-H58 
Salmonella Typhi isolates and red coloured nodes denote H58 Salmonella Typhi isolates. 
 
5.3.4.2 Ethiopia 
The three Salmonella Typhi isolates collected from Ethiopia during the study period showed 
diversity amongst the isolates. MLVA typing revealed three distinct MLVA types that 
differed at two or more VNTR loci. The H58 haplotype was associated with two MLVA 
types, namely STyMT-170 and 171; however, this is not irrefutable as only a small number 
of isolates was collected from this country. 
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5.3.4.3 Ghana 
A total of 34 Salmonella Typhi isolates from Ghana were analysed using the MLVA assay 
(Figure 5.9 A). Of these, 30 MLVA types were detected. Even though there was no 
predominant MLVA type identified, small clusters consisting of two isolates each were 
identified. The five MLVA types consisting of small cluster of isolates included STyMT-223, 
STyMT-236, STyMT-195 and STyMT-49. We identified five MLVA types that were 
associated with the H58 clone, namely MLVA types STyMT-200, STyMT-158, STyMT-181, 
STyMT-180 and STyMT-220; even so, this is not absolute as only one isolate was identified 
for each MLVA type. Analysis of more isolates could confirm this finding or reveal non-H58 
isolates belonging to these MLVA types (Figure 5.9 B). MLVA type STyMT-49 consisted of 
both the H58-clone and a non-H58 haplotype isolate. 
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Figure 5.9 Minimum spanning tree calculated for MLVA profiles of Salmonella Typhi isolates from 
Ghana collected over a three year period (n=34). Each node represents a different MLVA profile. (A) 
Node colours denote MLVA profiles and (B) Blue coloured node colour denote non-H58 Salmonella 
Typhi isolates and red coloured nodes denote H58 Salmonella Typhi isolates. 
 
5.3.4.4 Guinea Bissau 
Diversity was observed amongst the two isolates collected from Guinea Bissau during the 
study period. Two MLVA types were identified, namely STyMT-188 and STyMT-252, and 
these differed at 4 VNTR loci. The H58 clone was not associated with any MLVA type in 
this country as this clone was not identified in Guinea Bissau.  
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5.3.4.5 Kenya 
MLVA typing was performed on 56 Salmonella Typhi isolates collected in Kenya during the 
year 2012 to 2014 (Figure 5.10 A). A total of 27 MLVA types were observed. The MST 
revealed that MLVA type STyMT-86 was predominant in Kenya. This MLVA type consisted 
of a cluster of 16 isolates. Several other clusters were identified amongst MLVA types 
STyMT-256 and STyMT-84 consisting of six and four isolates, respectively; MLVA types 
STyMT-80, STyMT-82, STyMT-83, STyMT-67 and STyMT-93 consisted of two isolates 
each. Kenyan Salmonella Typhi isolates appear to be more clonal that isolates from the rest 
of the continent (Figure 5.10 B). Given that all isolates from Kenya belong to the H58 clone, 
this haplotype was dispersed throughout the MST. 
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Figure 5.10 Minimum spanning tree calculated for MLVA profiles of Salmonella Typhi isolates from Kenya collected over a three year period (n=56). Each 
node represents a different MLVA profile. (A) Node colours denote MLVA profiles and (B) Blue coloured node colour denote non-H58 Salmonella Typhi 
isolates and red coloured nodes denote H58 Salmonella Typhi isolates. 
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5.3.4.6 Madagascar 
Four MLVA types were identified amongst the five Salmonella Typhi isolates collected from 
Madagascar. MLVA type STyMT-189 consisted of two isolates. The H58 clone was not 
limited to a single MLVA type. MLVA type STyMT-189 consisted of isolates belonging to 
both the H58 clone as well as non-H58 haplotype. 
 
5.3.4.7 Senegal 
Diversity was observed amongst two Salmonella Typhi isolates collected in Senegal. These 
MLVA types differ at four VNTR loci. Within this group of isolates, the H58 clone was 
associated with MLVA type STyMT-210. 
 
5.3.4.8 Tanzania 
 
MLVA typing showed that Salmonella Typhi isolates from Tanzania were highly clonal. 
There were two MLVA types identified from the seven isolates subjected to MLVA typing. 
These two MLVA types differ at two VNTR loci. MLVA type STyMT-101 was found to be 
predominant in Tanzania. Isolates belonging to the H58 clonal group were observed in both 
MLVA types. All isolates from Tanzania belonged to this clonal group 
 
5.3.5 Intracontinental transmission of Salmonella Typhi isolates 
MLVA typing revealed evidence of intracontinental transmission of typhoid fever (Figure 
5.11). Similar MLVA types were identified in different SSA countries. MLVA type STyMT-
101 was identified in Senegal, Tanzania and Madagascar. The majority of isolates from 
Tanzania belong to this MLVA type. This may suggests that isolates are transmitted between 
Tanzania, Senegal and Madagascar. MLVA type STyMT-132 was identified in both Ghana 
and South Africa and MLVA type STyMT-48 in Ghana, South Africa and Burkina Faso. 
Isolates belonging to MLVA type STyMT-107 were identified in Kenya and in South Africa 
while MLVA types STyMT-49, STyMT-83 and STyMT-195 were common in Kenya and 
Ghana.  
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Figure 5.11 Outline map of Africa showing intracontinental distribution and transmission of 
Salmonella Typhi isolates based on MLVA assay. 
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5.3.6 Comparison of PFGE analysis of Salmonella Typhi isolates from SSA to MLVA 
typing 
PFGE analysis of Salmonella Typhi isolates from SSA was performed using XbaI in order to 
study the diversity and strain relatedness of these isolates. Digestion of the genomic DNA 
using XbaI revealed 143 unique pulsotypes from which 44 clusters were identified. PFGE 
clusters were defined as a group of two or more isolates with indistinguishable pulsotypes. 
PFGE analysis revealed five major clusters consisting of nine or more Salmonella Typhi 
isolates. 
 
5.3.6.1 PFGE Cluster I 
PFGE Cluster I consisted of ten Salmonella Typhi isolates from South Africa (Figure 5.12). 
The PFGE fingerprint pattern of these isolated was designated as STyPT-10. Even though 
isolates within this cluster had the same pulsotype, six MLVA types were identified within 
this group. These included STyMT-105 (n=1), STyMT-121 (n=4), STyMT-100 (n=2), 
STyMT-125 (n=1), STyMT-63 (n=1), STyMT-69 (n=1). Isolates within this cluster differed 
at up to four VNTR loci. 
 
5.3.6.2 PFGE Cluster II 
PFGE analysis revealed high homogeneity amongst Salmonella Typhi isolates from Kenya 
(Figure 5.12 and Figure 5.13). Pulsotype STyPT14 consisted only of Kenyan Salmonella 
Typhi isolates. This was found to be the predominant PFGE fingerprint pattern in Kenya 
consisting of 36 of the 56 isolates (64%). Within this cluster, 20 MLVA types were 
identified. The most common MLVA type within PFGE cluster II was STyMT-86 (n=8) 
followed by STyMT-256 (n=3) and STyMT-84 (n=3). Interestingly, some isolates within this 
group differed at all five VNTR loci; even so, these were found to be indistinguishable by 
PFGE analysis.  
 
5.3.6.3 PFGE Cluster III 
PFGE analysis suggested that isolates from South Africa are highly clonal, and that an 
association exists between Salmonella Typhi isolates from South Africa, Tanzania and 
Madagascar (Figure 5.13 and Figure 5.14). Of the 42 isolates that belonged to PFGE Cluster 
III, four were from Tanzania, one from Madagascar and 37 from South Africa. This was 
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identified as the largest cluster and dendrogram analysis indicated that STyPT-22 was the 
predominant PFGE fingerprint type in South Africa. This pulsotypes consisted of isolates 
belonging to 30 different MLVA Types. The most common MLVA types identified within 
this cluster were STyMT-101 (n=4) and STyMT-132 (n=3). This cluster consisted of isolates 
that differed at one to all five VNTR loci. 
 
5.3.6.4 PFGE Cluster IV 
PFGE Cluster IV consisted of 12 Salmonella Typhi isolates from South Africa (Figure 5.14). 
Within this group, 12 unique MLVA types were identified. Most isolates within this cluster 
differed at two VNTR loci; however; isolates that differed at all five VNTR loci were 
identified. Dendrogram analysis suggests that pulsotypes STyPT-25 is the second most 
common PFGE fingerprint type in South Africa. 
 
5.3.6.5 PFGE Cluster V 
PFGE Cluster V consisted of isolates from Ghana (n=2), South Africa (n=2) and Burkina 
Faso (n=5) (Figure 5.15). A total of 7 unique MLVA types were identified in this cluster. The 
most common MLVA Type within this group of isolates was STyMT-206, identified in most 
of the isolates from Burkina Faso (n=3). Isolates within this cluster differed at one to all five 
VNTR loci. 
 
Dendrogram analysis revealed a group of isolates clustered together by MLVA typing but 
found to be genetically diverse by PFGE (Figure 5.12, Figure 5.13, Figure 5.14 and Figure 
5.16). A total of seven isolates belonging to MLVA type STyMT-101 were dispersed 
throughout out the dendrogram and were found to be unrelated by MLVA.   
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Figure 5.12 Dendrogram analysis of PFGE patterns of Salmonella Typhi isolates from SSA showing 
PFGE clusters I and II. The green border line indicates Salmonella Typhi isolates that were 
indistinguishable by MLVA assay but diverse by PFGE analysis 
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Figure 5.13 Dendrogram analysis of PFGE patterns of Salmonella Typhi isolates from SSA showing 
PFGE clusters II and III. The green border line indicates Salmonella Typhi isolates that were 
indistinguishable by MLVA assay but diverse by PFGE analysis 
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Figure 5.14 Dendrogram analysis of PFGE patterns of Salmonella Typhi isolates from SSA showing 
PFGE clusters III and IV. The green border line indicates Salmonella Typhi isolates that were 
indistinguishable by MLVA assay but diverse by PFGE analysis 
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Figure 5.15 Dendrogram analysis of PFGE patterns of Salmonella Typhi isolates from SSA showing 
PFGE cluster V.  
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Figure 5.16 Dendrogram analysis of PFGE patterns of Salmonella Typhi isolates from SSA. The 
green border line indicates Salmonella Typhi isolates that were indistinguishable by MLVA assay but 
diverse by PFGE analysis 
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5.3.7 Comparison of the discriminatory power of MLVA assay with PFGE analysis 
In order to estimate the discriminatory power of the two subtyping techniques, Simpson’s DI 
was applied to the Salmonella Typhi isolates from SSA. A total of 226 MLVA types were 
identified from the 316 Salmonella Typhi isolates that were analysed. For the MLVA assay, 
Simpson’s DI was calculated at 0.995 (95% CI 0.992 – 0.997). In contrast, Simpson’s DI for 
PFGE analysis of the same isolates was calculated at 0.959 (95% CI 0.943 – 0.972). The 
difference in Simpson’s DI for MLVA and PFGE were statistically significant as non-
overlapping CIs were observed (p-value <0.001). As expected, several MLVA profiles were 
observed for isolates that shared the same PFGE profile; however, the reverse was observed 
in some cases where several pulsotypes were observed for isolates of the same MLVA type 
(Figures 5.6, 5.7, 5.8 and 5.10) 
 
The congruence between the MLVA assay and PFGE analysis was assessed by calculating 
the Wallace coefficient. Through calculating the Wallace coefficient, the probability that 2 
isolates that cluster together by one subtyping method could also be clustered together using 
another subtyping method was determined. The Wallace coefficient between MLVA assay 
and PFGE pulsotypes was determined to be 52%; however, the probability that two isolates 
that belong to the same MLVA type could have the same pulsotypes was determined to be 6 
%. The p-value between the Wallace indices was determined to be <0.001. This indicates that 
the MLVA assay exhibited more discriminatory power than PFGE analysis. 
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Table 5.1 Simpson's Index of Diversity 
Method Partitions Simpson’s ID CI (95%) P-value 
PFGE 143 0.959 (0.947 – 0.972) 
<0.001 
MLVA 226 0.995 (0.992 – 0.997) 
 
 
Table 5.2 Wallace coefficient and analytical 95% CI 
 MLVA assay PFGE analysis P-value 
MLVA assay  0.516 (0.353 – 0.678) 
<0.001 
PFGE analysis 0.062 (0.025 – 0.099)  
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5.4 Discussion 
In this study, MLVA assay was applied to a total of 316 Salmonella Typhi isolates from SSA. 
The MST was generated in order to study the diversity and show relations between the 
isolates. MLVA showed high discrimination of the isolates as 226 MLVA types were 
observed from the 316 isolates that were processed. The SSA community of Salmonella 
Typhi isolates were found to be diverse by MLVA analysis as no major clusters were 
observed. These results showed that MLVA was able to provide good discrimination even for 
the highly clonal Salmonella Typhi.  
 
MLVA assay was able to discriminate isolates from South Africa as 155 MLVA types were 
identified from 195 isolates. Although no major clusters were observed, six clusters 
consisting of three to four isolates belonging to the same MLVA type were identified. There 
was evidence of inter-provincial transmission of Salmonella Typhi isolates as several MLVA 
types were observed in more than one province. Even though distinct MLVA types were 
observed during each year of the study, MST showed three MLVA types that were common 
throughout the study period. Additionally, MST revealed common MLVA types that were 
observed between the years 2012 and 2013, between 2012 and 2014 and between 2013 and 
2014.   
 
MLVA typing of Salmonella Typhi isolates from seven other SSA countries revealed 
heterogeneity amongst the isolates. There were no apparent major clusters observed in 
Burkina Faso, Ethiopia, Ghana, Guinea Bissau, Madagascar and Senegal. MLVA analysis 
revealed diversity amongst Salmonella Typhi isolates from these countries and only a few 
clusters consisting of two to three isolates identified.  
 
Although high diversity was observed amongst Kenyan Salmonella Typhi isolates, isolates 
belonging to MLVA type STyMT-86 were the predominant. Approximately 30% of all 
isolates from Kenya belonged to STyMT-86. This could indicate that Salmonella Typhi 
STyMT-86 is a dominant clonal type responsible for most typhoid fever infections in Kenya. 
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MLVA indicated that Salmonella Typhi isolates from Tanzania were highly clonal. This was 
contrary to what was observed in other SSA countries where Salmonella Typhi isolates were 
found to be heterogeneous. Only two MLVA types were identified amongst isolates from 
Tanzania with the majority of isolates (85%, n=6) belonging to MLVA type STyMT-101. 
 
MLVA typing revealed intra-continental transmission of isolates as common MLVA types 
were identified between SSA countries. Common MLVA types were identified between 
Senegal, Tanzania and Madagascar, between Kenya and South Africa, between South Africa 
and Ghana, between Ghana and Kenya; and finally between Ghana, Burkina Faso and South 
Africa. This correlates with observation by Wong and colleagues (2015) that there is an on-
going epidemic of typhoid fever in Africa [132]. Interestingly, MLVA assay did not reveal 
evidence of transmission of isolates between Kenya and its neighbouring country, Tanzania.  
 
The MST showed that H58 Salmonella Typhi isolates were dispersed and were not limited to 
any clonal complex. Even so, the majority of these isolates were found in clonal complex I. 
Although preliminary data suggests that correlation exists between MLVA type and the H58 
haplotype, analysis of a greater number of isolates is required in order to qualify this 
observation. Nonetheless, MLVA typing showed that the H58 haplotype is not limited to one 
particular MLVA type, as MLVA types representing both H58 Salmonella Typhi and non-
H58 Salmonella Typhi isolates were identified. 
 
PFGE analysis of the 316 isolates from SSA revealed 143 pulsotypes. PFGE analysis 
revealed five major clusters consisting of nine isolates or more. Clustering based on PFGE 
revealed grouping that was dissimilar to that of MLVA. PFGE cluster I was exclusive to ten 
Salmonella Typhi isolates from South Africa. Although PFGE analysis found these isolates to 
be indistinguishable, six MLVA types were identified within this group. Similarly, the 12 
South African Salmonella Typhi isolates in PFGE cluster IV were found to be highly diverse 
by MLVA typing as 12 MLVA types were identified within this group of isolates. PFGE 
cluster II consisted of 64% of the isolates from Kenya. This suggested that the Kenyan 
Salmonella Typhi isolates were highly clonal; however, MLVA typing revealed high 
diversity amongst the isolates as 20 MLVA types were identified within this group. 
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PFGE clusters III and V exhibited evidence of intracontinental transmission of Salmonella 
Typhi isolates. PFGE cluster III consisted of isolates from South Africa, Tanzania and 
Madagascar. This suggested transmission of isolates from Tanzania to both South African 
and Madagascar. On the contrary, MLVA typing did not reveal similarities between isolates 
from Tanzania and South Africa or Madagascar and South Africa; however PFGE analysis 
correlates with MLVA typing in indicating that transmission of isolates between Tanzania 
and Madagascar exist. Although PFGE analysis found the 42 isolates within this cluster to be 
indistinguishable, MLVA typing indicated high diversity as 30 MLVA types were identified. 
PFGE cluster V consisted of isolates from South Africa, Burkina Faso and Ghana. Although 
MLVA typing found isolates within this group to be highly diverse, MLVA typing correlates 
with PFGE in showing that there is transmission of isolates between South Africa, Burkina 
Faso and Ghana. 
 
In order to qualify the degree of similarity between MLVA and PFGE in clustering of 
isolates, both the Simpson DI and congruence between the typing methods were calculated. 
The Simpson DI is the most commonly used mathematical measure to estimate the 
discriminatory ability of subtyping methods [138]. This measures the probability that two 
epidemiologically unrelated isolates will be characterized as diverse by the typing method 
evaluated. The Simpson’s DI is subjective towards the relative abundance of each subtype in 
the population studied. The Simpson’s DI indicated that MLVA exhibited higher 
discriminatory power than PFGE.  
 
The Wallace coefficient was calculated in order to determine the probability that isolates 
clustered together by MLVA typing will also cluster together by PFGE analysis. The 
directional congruence as indicated by Wallace coefficient from MLVA to PFGE was 53% 
suggesting that there was a high probability that isolates assigned to a cluster by MLVA 
typing would be assigned to the same cluster by PFGE. On the contrary, calculation of the 
Wallace coefficient indicated that isolates assigned to the same cluster by PFGE analysis a 
low probability to be assigned to the same cluster by MLVA typing. 
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The discriminatory capacity of MLVA and PFGE analysis of Salmonella Typhi was assessed 
in other studies [195, 204]. Tien and colleagues (2012) compared the discriminatory 
capacities of MLVA and PFGE by subtyping 125 Salmonella Typhi isolates from Taiwan 
collected during the years 1996 to 2009 [195]. MLVA analysis distinguished the isolates into 
109 MLVA types while PFGE analysis of the same revealed 71 pulsotypes. MLVA assay 
was found to be more discriminatory, exhibiting Simpson’s DI of 0.996, as compared to 
PFGE 0.980, showing Simpson’s DI [195]. In a recent study by Wang and colleagues (2016), 
an 8-loci MLVA assay was used to discriminate against 103 Salmonella Typhi isolates from 
China [204]. In their study, the discriminatory capacity was evaluated against that of PFGE 
using XbaI restriction enzyme. MLVA assay characterized the 103 isolates into 93 MLVA 
types while PFGE characterized the same isolates into 88 pulsotypes. MLVA exhibited high 
Simpson’s DI values of 0.9981 as compared to Simpson’s DI value of 0.9968 exhibited by 
PFGE analysis [204] 
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5.5 Conclusion 
In this study, MLVA typing showed high levels of diversity amongst Salmonella Typhi isolates 
from SSA. MLVA typing clearly discerned closely related and epidemiologically unrelated 
isolates. This molecular epidemiological method showed higher discriminatory power that 
PFGE analysis. Clear differences between the distributions of isolates by MLVA typing and 
PFGE analysis were observed. While PFGE analysis showed that Salmonella Typhi isolates 
from SSA were highly clonal while MLVA revealed that heterogeneity existed amongst these 
isolates. PFGE was found to be suitable for establishing the major phylogenetic relationships 
between isolates, while MLVA typing was found to be more appropriate in determining the 
relationships of very closely related isolates. Rapid identification and characterization of 
typhoid fever outbreaks using MLVA analysis can improve effective initiation of public health 
intervention measures.  
 
For epidemiological purposes, the following MLVA interpretations could be implemented: 
Isolates with identical MLVA profiles are considered to be highly related; isolates exhibiting 
MLVA profiles that differ at 1 locus are considered to be related; and isolates exhibiting 
MLVA profiles that differ at 2 or more loci are considered to be unrelated. We suggest using 
MLVA in conjunction with PFGE in typhoid fever surveillance and outbreak investigations for 
the accumulation of data regarding phylogenetic relationships and for further characterization 
of epidemiologically related isolates.  
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Chapter 6  
 
General Discussions and Conclusions 
 
This study focused on the use of MLVA subtyping tool for the molecular characterization of 
Salmonella Typhi isolates, particularly in the SSA context. Salmonella Typhi, the aetiological 
agent of typhoid fever, is endemic in this region and remains a public health problem. Very 
little data exists about the molecular epidemiology of Salmonella Typhi in SSA. The lack of 
genetic diversity amongst Salmonella Typhi isolates has presented a significant challenge in 
developing suitable molecular subtyping methodology for characterizing this pathogen.  
 
In this study, we explored the use of VNTRs as molecular markers for the differentiation of 
Salmonella Typhi isolates by developing a MLVA assay consisting of five VNTR loci. We also 
used a simple conventional PCR to study the prevalence of a highly resistant Salmonella Typhi 
strain in the SSA region. Furthermore, the developed MLVA assay was used to discriminate 
Salmonella Typhi isolates from SSA and the discriminatory capacity of MLVA was compared 
to that of PFGE analysis of the same isolates. 
 
6.1 Development of a five loci MLVA assay 
PFGE has been commonly used for molecular subtyping of bacterial pathogens; however, it has 
presented with a series of limitations including labour intensity as well as suboptimal 
discrimination of pathogens, especially with the highly homogenous Salmonella Typhi isolates. 
Newer technologies, such as WGS applications provide remarkable discrimination of 
Salmonella Typhi isolates, however, using WGS applications as a routine methodology in the 
SSA region is still many years away; the high costs of WGS including expensive equipment 
and expensive running costs, and the requirements for specialized laboratory personnel with 
technical knowhow, makes this an unrealistic option at present. Conversely MLVA has 
attracted intense interest due to its high discriminatory capabilities combined with the 
advantage of being rapid, cost effective and a reliable method that is easy to implement. 
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A total of 13 potential VNTRs were selected and evaluated using a panel of 50 diverse 
Salmonella Typhi isolates. Of these, six were monomorphic and showed no variation among 
the isolates. The remaining seven were subjected to nucleotide sequencing and only five were 
found to have consistent and conserved flanking regions. These five VNTR loci (TR1, TR2, 
Sal02, Sal20 and TR4699) were included and used in the development of the MLVA assay. 
This MLVA assay was used to type the panel of 50 Salmonella Typhi isolates. MLVA showed 
great discrimination of the isolates as 47 MLVA and showed high Simpson DI of 0,998 (CI 
0,994-1,000). 
 
6.2 The use of conventional PCR to study the prevalence of H58 Salmonella Typhi  
We explored the use of a low-cost conventional PCR assay that did not require specialized 
equipment and was suitable for the rapid identification of H58 Salmonella Typhi isolates. The 
H58 Salmonella Typhi haplotype has been associated with MDR and resistance to the current 
typhoid fever treatment regime, ciprofloxacin. This strain is wide-spread in South East Asia 
and is spreading into SSA. The ability for laboratories in the SSA region to rapidly identify this 
highly resistant Salmonella Typhi strain is crucial for successful treatment of typhoid fever. 
The conventional PCR targeted a deletion in the STY1507 gene that is present in all H58 
haplotype isolates. This PCR was used to screen Salmonella Typhi isolates for the prevalence 
of the H58 haplotype. 
 
Approximately 54% (105 of 195) Salmonella Typhi isolates from South Africa were identified 
as H58 Salmonella Typhi.  From the other eight countries (Burkina Faso, Ethiopia, Ghana, 
Guinea Bissau, Kenya, Madagascar, Senegal, South Africa and Tanzania) in the SSA region, 
approximately 62% (75 of 121) Salmonella Typhi isolates were identified as H58 Salmonella 
Typhi.  Results from the PCR assay indicate that the H58 Salmonella Typhi is now widespread 
in SSA and seems to be replacing the antimicrobial susceptible Salmonella Typhi.  
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6.3 MLVA offers higher discriminatory power than PFGE analysis for molecular 
subtyping Salmonella Typhi isolates from SSA 
The MLVA assay developed in this study was used for the molecular subtyping of Salmonella 
Typhi isolates from nine countries in the SSA region, including Burkina Faso, Ethiopia, Ghana, 
Guinea Bissau, Kenya, Madagascar, Senegal, South Africa and Tanzania. These isolates were 
also subjected to PFGE analysis and discriminatory power of MLVA and PFGE compared. 
From a total of 316 Salmonella Typhi isolates from SSA, 226 MLVA types were identified; 
while PFGE analysis of the same isolates revealed 143 PFGE fingerprint patterns. MLVA was 
able to resolve all isolates from SSA and indicated intracontinental transmission of Salmonella 
Typhi isolates. Throughout the SSA region, MLVA showed no evidence of geographical 
association with MLVA type.  
 
For the South African Salmonella Typhi isolates, MLVA indicated interprovincial transmission 
of isolates. Additionally, MLVA showed a number of isolates that were present throughout the 
study period. MLVA typing also provided insight into the province related epidemiology of 
isolates in South Africa. There was evidence of interprovincial transmission of typhoid fever. 
However, no single MLVA type was predominant around the country; suggesting that different 
Salmonella Typhi populations exist and are circulating throughout the country. 
 
MLVA types that were exclusively associated the H58 Salmonella Typhi were identified, and 
MLVA types representing both H58 Salmonella Typhi and non-H58 Salmonella Typhi isolates 
were also observed. The H58 Salmonella Typhi isolates were diverse and not limited to one 
clonal complex. The diversity amongst the H58 Salmonella Typhi isolates suggest that the 
emergence of the H58 haplotype could occur as a result of clonal transmission events of the 
pathogen as well as antimicrobial selective pressure.  
 
There was a significant difference in the discriminatory power of MLVA as compared to 
PFGE. The Simpson’s DI was for the MLVA assay was calculated at 0.995 (95% CI 0.992 – 
0.997) as compared to 0.959 (95% CI 0.943 – 0.972) for PFGE analysis. The MLVA assay 
showed higher discriminatory of Salmonella Typhi isolates than PFGE and could be better 
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suited for would as an effective molecular epidemiological investigation tool for Salmonella 
Typhi outbreaks in SSA 
 
6.4 Concluding remarks 
Typhoid fever remains a dreadful disease in the SSA region. In order to obtain important 
epidemiological information such as transmission routes of typhoid fever outbreaks, the 
application of molecular subtyping tools is essential.  This dissertation represents one of the 
first studies to explore the use of a MLVA assay for molecular subtyping of the SSA 
Salmonella Typhi population. We have shown that MLVA assay consisting of five highly 
polymorphic VNTR has provided an excellent discrimination of Salmonella Typhi isolates.  
 
The MLVA assay as well as the simple, low-cost and effective protocol used to identify the 
H58 haplotype in this study could be applied in laboratories across the continent. Laboratories 
in SSA are resource poor and cannot afford to implement established methods such as PFGE 
and WGS. MLVA serves as a more affordable method which involves the use of equipment 
that most laboratories have and can be used for outbreak investigation. To the best of our 
knowledge, capillary electrophoresis equipment is available in Kenya, Gambia, Ivory Coast and 
Uganda to which the MLVA assay can be implemented. The adoption of these molecular 
methodologies by reference laboratories in the SSA region could be helpful in monitoring the 
spread of typhoid fever across the SSA and to emphasise the role of specific clones as the cause 
of typhoid fever infection. The MLVA assay could also assist in understanding the role of 
imported cases of typhoid fever into SSA countries and their contribution to the burden of 
disease. This could promote effective and appropriate disease control strategies to prevent the 
emergence and spread of this pathogen.  
 
The provision of clean water coupled with improvements in sanitation in the SSA countries 
could curb the spread of typhoid fever on the continent. Additionally, given that typhoid 
carriers play a huge role in the transmission of typhoid fever, it is then evident that a huge gap 
exists within the surveillance system, as molecular characterization and discrimination of 
isolates is based on isolates collected only from patients reporting to the hospitals as well as 
laboratory confirmed cases that are submitted for laboratory-based surveillance. It would be of 
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great interest and benefit to use MLVA typing to study the association between Salmonella 
Typhi isolates collected from typhoid carriers and those collected from hospital admitted 
patients. It is important that MLVA typing data should be coupled with epidemiological data in 
order to make meaningful interpretation that could be used to implement effective control 
measures. 
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Appendix A 
 
Preparation of reagents for PFGE 
 
A.1 Cell suspension buffer  
100 mM Tris, pH 8.0 (Merck Chemical Ltd., Nottingham, England and Wales) 
100 mM EDTA, pH 8.0 (Sigma-Aldrich, Inc.) 
 
A.2 Tris: EDTA (TE) Buffer   
10 mM Tris, pH 8.0 (Merck) 
1 mM EDTA, pH 8.0 (Sigma) 
 
A.3 Proteinase K (20mg/ml stock) 
20mg Proteinase K powder (Roche Diagnostics GmbH, Mannheim, Germany) 
1ml TE buffer 
 
A.4 10% Sodium dodecyl sulphate 
10 g sodium dodecyl sulphate (SDS) (Merck) 
100 ml deionized water (dH2O) 
 
A.5 1% SeaKem® Gold agarose: 1% SDS (for agarose plugs) 
0.25 g SeaKem® Gold agarose (Lonza, Rockland, USA) 
22.5 ml TE buffer  
2.5 ml 10% SDS (Merck) 
Boil to dissolve. Keep at 55-60°C while in use 
 
A.6 Cell Lysis Buffer  
50 mM Tris, pH 8.0 (Merck) 
50 mM EDTA, pH 8.0 (Sigma) 
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1% N-Lauroylsarcosine, Sodium salt (Sarcosyl)  
0.1 mg/ml Proteinase K (Roche) 
 
A.7 XbaI Restriction Enzyme buffer µl/plug slice 
20 µl of 10X H restriction buffer (Roche) 
180µl of sterile dH2O 
 
A.8 XbaI Restriction Enzyme Master Mix: (50U/plug slice)  
20 µl of 10X H restriction Buffer (Roche) 
5 µl of XbaI Enzyme (10U/µl) (Roche) 
175µl of sterile dH2O 
 
A.9 0.5X Tris-borate EDTA (TBE) buffer 
50 ml 10X TBE Buffer (Merck) 
900 ml dH2O 
 
A.10 1% SeaKem® Gold Agarose in 0.5X TBE  
1.5 g of SeaKem® Gold Agarose (Lonza) 
150 ml of 0.5X TBE 
Boil to dissolve  
 
A.11 Ethidium bromide solution (10 mg/ml)  
1 g Ethidium bromide  
100 ml distilled H2O 
 
A.12 Ethidium bromide (EtBr) staining solution 
25 µl of ethidium bromide stock solution (10 mg/ml) (Merck) 
250 ml of TBE buffer (Merck)
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Appendix B 
 
PCR amplification of VNTR loci 
B.1 Preparation of 20 µM primer working solutions from 100 µM stock solutions  
c1v1=c2v2  
100 µM x v1=20 µM X 100 µl 
v1=20 µl (Add 20 µl of primer stock solution to 80 µl of distilled H2O) 
 
B.2 Simplex PCR setup for VNTR loci screening 
 
 
 
 
 
 
 
 
B.3 Multiplex PCR setup for MLVA typing  
B.3.1 The forward and reverse multiplex primer mix 
VNTR primers  Forward primer mix 
(Volume) 
Reverse primer mix 
(Volume) 
TR1 6 µl 6 µl 
TR2 6 µl 6 µl 
Sal02 5 µl 5 µl 
Sal20 3.5 µl 3.5 µl 
TR4699 4 µl 4 µl 
Distilled H2O 75.5 µl 75.5 µl 
Final volume 100 µl 100 µl 
PCR reaction mix 
 
Qiagen multiplex PCR kit (Qiagen, Hilden, Germany) 
Distilled H2O 7 µl 
Qiagen master mix 
Q solution 
Forward primer (20 µM) 
Reverse Primer (20 µM) 
12.5 µl 
2.5 µl 
1 µl 
1 µl 
DNA template 1 µl 
Final volume 25  µl 
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B.3.2 Multiplex PCR setup for MLVA typing 
 
 
 
 
 
 
 
 
B.4 Determination of primer concentration in PCR reaction 
Primer concentration in primer mix 
 
c1v1=c2v2 
(Concentration in working solution)(Volume added to primer mix) = (Concentration in 
primer mix) (Primer mix final volume) 
 
Example: VNTR TR1 
20 µM x 6 µl= c2 X 100 µl  
c2= 1.2 µM 
VNTR TR1 primer concentration in primer mix = 1.2 µM 
 
PCR reaction mix 
 
Qiagen multiplex PCR kit (Qiagen, Hilden, Germany) 
Distilled H2O 7 µl 
Qiagen master mix 
Q solution 
Forward primer mix 
Reverse Primer mix 
12.5 µl 
2.5 µl 
1 µl 
1 µl 
DNA template 1 µl 
Final volume 25  µl 
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Appendix C 
 
Sequencing of VNTR loci using the ABI Prism®BigDye® Terminator cycle 
sequencing kit  
 
C.1 Nucleotide sequencing of VNTR loci 
 
 
 
 
C.2 Cycle sequencing PCR conditions 
 
PCR cycle Temperature Time Number of cycles 
Initial denaturation 95 °C 2 min 1 
Denaturation 
Annealing 
Extension 
95 °C 
50 °C 
60 °C 
30 sec 
30 sec 
4 min 
 
25 
 6 °C ∞ 1 
 
PCR reaction mix 
 
ABI Prism®BigDye® Terminator v3.1 Cycle Sequencing Kit 
(Applied Biosystems) 
Distilled H2O 7.5 µl 
5X Sequencing buffer 
BigDye terminator reaction mix 
Forward primer (5 µM) 
Reverse Primer (5 µM) 
1.5 µl 
3 µl 
1 µl 
1 µl 
DNA template 1 µl 
Final volume 15 µl 
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Appendix D 
 
VNTR sequence alignments 
 
D.1 Sequence alignment: VNTR locus TR1 
 
Multiple sequence alignment of the VNTR locus TR1 sequences from ten Salmonella Typhi 
isolates. Sequences highlighted in Yellow and in Green indicate the forward and reverse 
primers respectively. Sequences highlighted in Purple indicate the tandem repeat region. 
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                      10         20         30         40         50              
TCD105056    GCCAACGATC GCTACTTTTT TCATCATTCA TCCTGCATCA GAAGAAAGAA  
TCD461595    GCCAACGATC GCTACTTTTT TCATCATTCA TCCTGCATCA GAAGAAAGAA  
TCD458017    GCCAACGATC GCTACTTTTT TCATCATTCA TCCTGCATCA GAAGAAAGAA  
TCD409778    GCCAACGATC GCTACTTTTT TCATCATTCA TCCTGCATCA GAAGAAAGAA  
TCD488042    GCCAACGATC GCTACTTTTT TCATCATTCA TCCTGCATCA GAAGAAAGAA  
TCD316823    GCCAACGATC GCTACTTTTT TCATCATTCA TCCTGCATCA GAAGAAAGAA  
TCD281699    GCCAACGATC GCTACTTTTT TCATCATTCA TCCTGCATCA GAAGAAAGAA  
TCD241722    GCCAACGATC GCTACTTTTT TCATCATTCA TCCTGCATCA GAAGAAAGAA  
TCD240006    GCCAACGATC GCTACTTTTT TCATCATTCA TCCTGCATCA GAAGAAAGAA  
TCD537014    GCCAACGATC GCTACTTTTT TCATCATTCA TCCTGCATCA GAAGAAAGAA  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                      60         70         80         90        100             
TCD105056    GAAAGAAGAA AGAAGAAAGA AGAAAGAAGA AAGAAGAATT GTGGCATTAA  
TCD461595    GAAAGAAGAA AGAAGAAAGA AGAAAGAAGA AAGAAGAAAG AAGAAAGAAG  
TCD458017    GAAAGAAGAA AGAAGAAAGA AGAAAGAAGA AAGAAGAATT GTGGCATTAA  
TCD409778    GAAAGAAGAA AGAAGAAAGA AGAAAGAAGA AAGAAGAAAG AAGAAAGAAG  
TCD488042    GAAAGAAGAA AGAAGAAAGA AGAATTGTGG CATTAAAGCC CTGACGCCGC  
TCD316823    GAAAGAAGAA AGAAGAAAGA AGAAAGAAGA AAGAAGAAAG AAGAAAGAAG  
TCD281699    GAAAGAAGAA AGAAGAAAGA AGAAAGAAGA AAGAAGAAAG AAGAAAGAAG  
TCD241722    GAAAGAAGAA AGAAGAAAGA AGAAAGAAGA AAGAAGAAAG AAGAAAGAAG  
TCD240006    GAAAGAAGAA AGAAGAAAGA AGAAAGAAGA AAGAAGAAAG AAGAAAGAAG  
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TCD537014    GAAAGAAGAA AGAAGAAAGA AGAAAGAAGA AAGAAGAAAG AAGAAAGAAG  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     110        120        130        140        150         
TCD105056    AGCCCTGACG CCGCCAGCCT TTCCAGGCGC TGGCCGCAAT TTGATCCAGT  
TCD461595    AAAGAAGAAA GAAGAAAGAA GAAAGAAGAA TTGTGGCATT AAAGCCCTGA  
TCD458017    AGCCCTGACG CCGCCAGCCT TTCCAGGCGC TGGCCGCAAT TTGATCCAGT  
TCD409778    AATTGTGGCA TTAAAGCCCT GACGCCGCCA GCCTTTCCAG GCGCTGGCCG  
TCD488042    CAGCCTTTCC AGGCGCTGGC CGCAATTTGA TCCAGTCGGT ATTACCGCTT  
TCD316823    AAAGAAGAAA GAAGAAAGAA GAAAGAAGAA TTGTGGCATT AAAGCCCTGA  
TCD281699    AAAGAAGAAA GAAGAATTGT GGCATTAAAG CCCTGACGCC GCCAGCCTTT  
TCD241722    AAAGAAGAAA GAAGAAAGAA GAAAGAAGAA AGAAGAAAGA AGAAAGAAGA  
TCD240006    AAAGAAGAAA GAAGAATTGT GGCATTAAAG CCCTGACGCC GCCAGCCTTT 
TCD537014    AAAGAAGAAA GAAGAAAGAA GAAAGAAGAA AGAAGAATTG TGGCATTAAA  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     160        170        180        190        200         
TCD105056    CGGTATTACC GCTTATTAGG TGTAGGCAAA TTCTGTGATC GGTGTAGTAT  
TCD461595    CGCCGCCAGC CTTTCCAGGC GCTGGCCGCA ATTTGATCCA GTCGGTATTA  
TCD458017    CGGTATTACC GCTTATTAGG TGTAGGCAAA TTCTGTGATC GGTGTAGTAT  
TCD409778    CAATTTGATC CAGTCGGTAT TACCGCTTAT TAGGTGTAGG CAAATTCTGT  
TCD488042    ATTAGGTGTA GGCAAATTCT GTGATCGGTG TAGTATGCGC ACTTCTTGA.  
TCD316823    CGCCGCCAGC CTTTCCAGGC GCTGGCCGCA ATTTGATCCA GTCGGTATTA  
TCD281699    CCAGGCGCTG GCCGCAATTT GATCCAGTCG GTATTACCGC TTATTAGGTG  
TCD241722    ATTGTGGCAT TAAAGCCCTG ACGCCGCCAG CCTTTCCAGG CGCTGGCCGC  
TCD240006    CCAGGCGCTG GCCGCAATTT GATCCAGTCG GTATTACCGC TTATTAGGTG 
TCD537014    GCCCTGACGC CGCCAGCCTT TCCAGGCGCT GGCCGCAATT TGATCCAGTC  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     210        220        230        240        250         
TCD105056    GCGCACTTCT TGA....... .......... .......... ..........  
TCD461595    CCGCTTATTA GGTGTAGGCA AATTCTGTGA TCGGTGTAGT ATGCGCACTT  
TCD458017    GCGCACTTCT TGA....... .......... .......... ..........  
TCD409778    GATCGGTGTA GTATGCGCAC TTCTTGA... .......... ..........  
TCD488042    .......... .......... .......... .......... ..........  
TCD316823    CCGCTTATTA GGTGTAGGCA AATTCTGTGA TCGGTGTAGT ATGCGCACTT  
TCD281699    TAGGCAAATT CTGTGATCGG TGTAGTATGC GCACTTCTTG AA........  
TCD241722    AATTTGATCC AGTCGGTATT ACCGCTTATT AGGTGTAGGC AAATTCTGTG  
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TCD240006    TAGGCAAATT CTGTGATCGG TGTAGTATGC GCACTTCTTG A......... 
TCD537014    GGTATTACCG CTTATTAGGT GTAGGCAAAT TCTGTGATCG GTGTAGTATG  
 
 
             ....|....| ....|....| ....|.. 
                     260        270           
TCD105056    .......... .......... ....... 
TCD461595    CTTGA..... .......... ....... 
TCD458017    .......... .......... ....... 
TCD409778    .......... .......... ....... 
TCD488042    .......... .......... ....... 
TCD316823    CTTGA..... .......... ....... 
TCD281699    .......... .......... ....... 
TCD241722    ATCGGTGTAG TATGCGCACT TCTTGA. 
TCD240006    .......... .......... ....... 
TCD537014    CGCACTTCTT GA........ ....... 
 
 
D.2 Sequence Alignment: VNTR locus TR2 
 
Multiple sequence alignment of the VNTR locus TR2 sequences from ten Salmonella Typhi 
isolates. Sequences highlighted in Yellow and in Green indicate the forward and reverse 
primers respectively. Sequences highlighted in Purple indicate the tandem repeat region. 
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                      10         20         30         40         50              
TCD139882    TCCCTGTTTT TCGTGCTGAT ACGTCGCCGC TTCCCGCTGA AGCCGCGCCC  
TCD723719    TCCCTGTTTT TCGTGCTGAT ACGTCGCCGC TTCCCGCTGA AGCCGCGCCC  
TMI87197     TCCCTGTTTT TCGTGCTGAT ACGTCGCCGC TTCCCGCTGA AGCCGCGCCC  
TMI87199     TCCCTGTTTT TCGTGCTGAT ACGTCGCCGC TTCCCGCTGA AGCCGCGCCC  
TCD298424    TCCCTGTTTT TCGTGCTGAT ACGTCGCCGC TTCCCGCTGA AGCCGCGCCC  
TCD316823    TCCCTGTTTT TCGTGCTGAT ACGTCGCCGC TTCCCGCTGA AGCCGCGCCC  
TCD422011    TCCCTGTTTT TCGTGCTGAT ACGTCGCCGC TTCCCGCTGA AGCCGCGCCC  
TCD671445    TCCCTGTTTT TCGTGCTGAT ACGTCGCCGC TTCCCGCTGA AGCCGCGCCC  
TCD723719    TCCCTGTTTT TCGTGCTGAT ACGCCGCCGC TTCCCGCTGA AGCCGCGCCC  
TCD674832    TCCCTGTTTT TCGTGCTGAT ACGTCGCCGC TTCCCGCTGA AGCCGCGCCC  
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             ....|....| ....|....| ....|....| ....|....| ....|....|  
                      60         70         80         90        100             
TCD139882    GGAATAAGCT CCTGGCCAGC CTGATACGAG GTGTCGGGCA CAAAAAAGGC  
TCD723719    GGAATAAGCT CCTGGCCAGC CTGATACGAG GTGTCGGGCA CAAAAAAGGC  
TMI87197     GGAATAAGCT CCTGGCCAGC CTGATACGAG GTGTCGGGCA CAAAAAAGGC  
TMI87199     GGAATAAGCT CCTGGCCAGC CTGATACGAG GTGTCGGGCA CAAAAAAGGC  
TCD298424    GGAATAAGCT CCTGGCCAGC CTGATACGAG GTGTCGGGCA CAAAAAAGGC  
TCD316823    GGAATAAGCT CCTGGCCAGC CTGATACGAG GTGTCGGGCA CAAAAAAGGC  
TCD422011    GGAATAAGCT CCTGGCCAGC CTGATACGAG GTGTCGGGCA CAAAAAAGGC  
TCD671445    GGAATAAGCT CCTGGCCAGC CTGATACGAG GTGTCGGGCA CAAAAAAGGC  
TCD723719    GGAATAAGCT CCCGGCCAGC CTGATACGAG GTGTCGGGCA CAAAAAAGGC  
TCD674832    GGAATAAGCT CCTGGCCAGC CTGATACGAG GTGTCGGGCA CAAAAAAGGC  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     110        120        130        140        150         
TCD139882    GACTTTCGTT GAGTCGCCTT TTCTTATCCC CTATGGGAGC GCGGTGCCTT  
TCD723719    GACTTTCGTT GAGTCGCCTT TTCTTATCCC CTATGGGAGC GCGGTGCCTT  
TMI87197     GACTTTCGTT GAGTCGCCTT TTCTTATCCC CTATGGGAGC GCGGTGCCTT  
TMI87199     GACTTTCGTT GAGTCGCCTT TTCTTATCCC CTATGGGAGC GCGGTGCCTT  
TCD298424    GACTTTCGTT GAGTCGCCTT TTCTTATCCC CTATGGGAGC GCGGTGCCTT  
TCD316823    GACTTTCGTT GAGTCGCCTT TTCTTATCCC CTATGGGAGC GCGGTGCCTT  
TCD422011    GACTTTCGTT GAGTCGCCTT TTCTTATCCC CTATGGGAGC GCGGTGCCTT  
TCD671445    GACTTTCGTT GAGTCGCCTT TTCTTATCCC CTATGGGAGC GCGGTGCCTT  
TCD723719    GACTTTCGTT GAGTCGCCTT TTCTTATCCC CTATGGGAGC GCGGTGCCTT  
TCD674832    GACTTTCGTT GAGTCGCCTT TTCTTATCCC CTATGGGAGC GCGGTGCCTT  
 
 
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     160        170        180        190        200         
TCD139882    CCAGGCATTT ATTTACGAAG CATGACTTCG ATAAAATCTT TCCAGTTCCC  
TCD723719    CCAGGCATTT ATTTACGAAG CATGACTTCG ATAAAATCTT TCCAGTTCCC  
TMI87197     CCAGGCATTT ATTTACGAAG CATGACTTCG ATAAAATCTT TCCAGTTCCC  
TMI87199     CCAGGCATTT ATTTACGAAG CATGACTTCG ATAAAATCTT TCCAGTTCCC  
TCD298424    CCAGGCATTT ATTTACGAAG CATGACTTCG ATAAAATCTT TCCAGTTCCC  
TCD316823    CCAGGCATTT ATTTACGAAG CATGACTTCG ATAAAATCTT TCCAGTTCCC  
TCD422011    CCAGGCATTT ATTTACGAAG CATGACTTCG ATAAAATCTT TCCAGTTCCC  
TCD671445    CCAGGCATTT ATTTACGAAG CATGACTTCG ATAAAATCTT TCCAGTTCCC  
TCD723719    CCAGGCATTT ATTTACGAAG CATGACTTCG ATAAAATCTT TCCAGTTCCC  
TCD674832    CCAGGCATTT ATTTACGAAG CATGACTTCG ATAAAATCTT TCCAGTTCCC  
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             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     210        220        230        240        250         
TCD139882    CAGTTCCCCA GTTCCCCAGT TCCCCAGTTC CCCAGTTCCC CAGTTCACGT  
TCD723719    CAGTTCCCCA GTTCACGTTC AATCATAATA GCCTCTCTTA TTATTATGGG  
TMI87197     CAGTTCCCCA GTTCCCCAGT TCCCCAGTTC CCCAGTTCCC CAGTTCCCCA  
TMI87199     CAGTTCCCCA GTTCCCCAGT TCCCCAGTTC CCCAGTTCCC CAGTTCCCCA  
TCD298424    CAGTTCCCCA GTTCCCCAGT TCCCCAGTTC CCCAGTTCCC CAGTTCCCCA  
TCD316823    CAGTTCCCCA GTTCCCCAGT TCCCCAGTTC CCCAGTTCCC CAGTTCCCCA  
TCD422011    CAGTTCCCCA GTTCCCCAGT TCCCCAGTTC CCCAGTTCCC CAGTTCCCCA  
TCD671445    CAGTTCCCCA GTTCCCCAGT TCCCCAGTTC CCCAGTTCCC CAGTTCCCCA  
TCD723719    CAGTTCCCCA GTTCACGTTC AATCATAATA GCCTCTCTTA TTATTATGGG  
TCD674832    CAGTTCCCCA GTTCCCCAGT TCCCCAGTTC CCCAGTTCCC CAGTTCCCCA  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     260        270        280        290        300         
TCD139882    TCAATCATAA TAGCCTCTCT TATTATTATG GGTATTCTAC GTAGTTAGCG  
TCD723719    TATTCTACGT AGTTAGCGGT ATAGAGAGAA GTTCATTTAA CCGATTGTTG  
TMI87197     GTTCCCCAGT TCCCCAGTTC CCCAGTTCCC CAGTTCCCCA GTTCCCCAGT  
TMI87199     GTTCCCCAGT TCCCCAGTTC CCCAGTTCCC CAGTTCCCCA GTTCCCCAGT  
TCD298424    GTTCCCCAGT TCCCCAGTTC CCCAGTTCCC CAGTTCACGT TCAATCATAA  
TCD316823    GTTCCCCAGT TCCCCAGTTC CCCAGTTCCC CAGTTCACGT TCAATCATAA  
TCD422011    GTTCCCCAGT TCCCCAGTTC CCCAGTTCCC CAGTTCCCCA GTTCCCCAGT  
TCD671445    GTTCCCCAGT TCCCCAGTTC ACGTTCAATC ATAATAGCCT CTCTTATTAT  
TCD723719    TATTCTACGT AGTTAGCGGT ATAGAGAGAA GTTCATTTAA CCGATTGTTG  
TCD674832    GTTCCCCAGT TCCCCAGTTC CCCAGTTCCC CAGTTCCCCA GTTCCCCAGT  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     310        320        330        340        350         
TCD139882    GTATAGAGAG AAGTTCATTT AACCGATTGT TGCGATATCC TCTGA.....  
TCD723719    CGATATCCTC TGA....... .......... .......... ..........  
TMI87197     TCCCCAGTTC CCCAGTTCCC CAGTTCCCCA GTTCACGTTC AATCATAATA  
TMI87199     TCCCCAGTTC CCCAGTTCCC CAGTTCCCCA GTTCACGTTC AATCATAATA  
TCD298424    TAGCCTCTCT TATTATTATG GGTATTCTAC GTAGTTAGCG GTATAGAGAA  
TCD316823    TAGCCTCTCT TATTATTATG GGTATTCTAC GTAGTTAGCG GTATAGAGAG  
TCD422011    TCACGTTCAA TCATAATAGC CTCTCTTATT ATTATGGGTA TTCTACGTAG  
TCD671445    TATGGGTATT CTACGTAGTT AGCGGTATAG AGAGAAGTTC ATTTAACCGA  
TCD723719    CGATATCCAC TGA....... .......... .......... ..........  
TCD674832    TCCCCAGTTC CCCAGTTCCC CAGTTCCCCA GTTCCCCAGT TCCCCAGTTC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     360        370        380        390        400         
TCD139882    .......... .......... .......... .......... ..........  
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TCD723719    .......... .......... .......... .......... ..........  
TMI87197     GCCTCTCTTA TTATTATGGG TATTCTACGT AGTTAGCGGT ATAGAGAGAA  
TMI87199     GCCTCTCTTA TTATTATGGG TATTCTACGT AGTTAGCGGT ATAGAGAGAA  
TCD298424    GAAGTTCATT TAACCGATTG TTGCGATATC CTCTGA.... ..........  
TCD316823    AAGTTCATTT AACCGATTGT TGCGATATCC TCTGA..... ..........  
TCD422011    TTAGCGGTAT AGAGAGAAGT TCATTTAACC GATTGTTGCG ATATCCTCTG  
TCD671445    TTGTTGCGAT ATCCTCTGAA A......... .......... ..........  
TCD723719    .......... .......... .......... .......... ..........  
TCD674832    CCCAGTTCCC CAGTTCCCCA GTTCCCCAGT TCCCCAGTTC CCCAGTTCCC  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     410        420        430        440        450         
TCD139882    .......... .......... .......... .......... ..........  
TCD723719    .......... .......... .......... .......... ..........  
TMI87197     GTTCATTTAA CCGATTGTTG CGATATCCTC TGA....... ..........  
TMI87199     GTTCATTTAA CCGATTGTTG CGATATCCTC TGA....... ..........  
TCD298424    .......... .......... .......... .......... ..........  
TCD316823    .......... .......... .......... .......... ..........  
TCD422011    A......... .......... .......... .......... ..........  
TCD671445    .......... .......... .......... .......... ..........  
TCD723719    .......... .......... .......... .......... ..........  
TCD674832    CAGTTCCCCA GTTCCCCAGT TCCCCAGTTC CCCAGTTCCC CAGTTCCCCA  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     460        470        480        490        500         
TCD139882    .......... .......... .......... .......... ..........  
TCD723719    .......... .......... .......... .......... ..........  
TMI87197     .......... .......... .......... .......... ..........  
TMI87199     .......... .......... .......... .......... ..........  
TCD298424    .......... .......... .......... .......... ..........  
TCD316823    .......... .......... .......... .......... ..........  
TCD422011    .......... .......... .......... .......... ..........  
TCD671445    .......... .......... .......... .......... ..........  
TCD723719    .......... .......... .......... .......... ..........  
TCD674832    GTTCCCCAGT TCCCCAGTTC ACGTTCAATC ATAATAGCCT CTCTTATTAT  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     510        520        530        540        550         
TCD139882    .......... .......... .......... .......... ..........  
TCD723719    .......... .......... .......... .......... ..........  
TMI87197     .......... .......... .......... .......... ..........  
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TMI87199     .......... .......... .......... .......... ..........  
TCD298424    .......... .......... .......... .......... ..........  
TCD316823    .......... .......... .......... .......... ..........  
TCD422011    .......... .......... .......... .......... ..........  
TCD671445    .......... .......... .......... .......... ..........  
TCD723719    .......... .......... .......... .......... ..........  
TCD674832    TATGGGTATT CTACGTAGTT AGCGGTATAG AGAGAAGTTC ATTTAACCGA  
 
             ....|....| ....|... 
                     560         
TCD139882    .......... ........ 
TCD723719    .......... ........ 
TMI87197     .......... ........ 
TMI87199     .......... ........ 
TCD298424    .......... ........ 
TCD316823    .......... ........ 
TCD422011    .......... ........ 
TCD671445    .......... ........ 
TCD723719    .......... ........ 
TCD674832    TTGTTGCGAT ATCCACTG 
 
 
D.3 Sequence Alignment: VNTR locus Sal02 
 
Multiple sequence alignment of the VNTR locus Sal02 sequences from ten Salmonella Typhi 
isolates. Sequences highlighted in Yellow and in Green indicate the forward and reverse 
primers respectively. Sequences highlighted in Purple indicate the tandem repeat region. 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                      10         20         30         40         50              
TCD152229    TCGATAGACA GCACCAGCAG AATACACAGT TGTTCCATCG GAACGCCCGG  
TCD186374    TCGATAGACA GCACCAGCAG AATACACAGT TGTTCCATCG GAACGCCCGG  
TCD402284    TCGATAGACA GCACCAGCAG AATACACAGT TGTTCCATCG GAACGCCCGG  
TCD428468    TCGATAGACA GCACCAGCAG AATACACAGT TGTTCCATCG GAACGCCCGG  
TCD671445    TCGATAGACA GCACCAGCAG AATACACAGT TGTTCCATCG GAACGCCCGG  
TCD537014    TCGATAGACA GCACCAGCAG AATACACAGT TGTTCCATCG GAACGCCCGG  
TCD146495    TCGATAGACA GCACCAGCAG AATACACAGT TGTTCCATCG GAACGCCCGG  
TCD281699    TCGATAGACA GCACCAGCAG AATACACAGT TGTTCCATCG GAACGCCCGG  
TCD316823    TCGATAGACA GCACCAGCAG AATACACAGT TGTTCCATCG GAACGCCCGG  
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TCD530747    TCGATAGACA GCACCAGCAG AATACACAGT TGTTCCATCG GAACGCCCGG  
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                      60         70         80         90        100             
TCD152229    AATGCCTTTA CCCACCGCCA GAATGACCGG CAGCATGGTC GCGGTGTGAG  
TCD186374    AATGCCTTTA CCCACCGCCA GAATGACCGG CAGCATGGTC GCGGTGTGAG  
TCD402284    AATGCCTTTA CCCACCGCCA GAATGACCGG CAGCATGGTC GCGGTGTGAG  
TCD428468    AATGCCTTTA CCCACCGCCA GAATGACCGG CAGCATGGTC GCGGTGTGAG  
TCD671445    AATGCCTTTA CCCACCGCCA GAATGACCGG CAGCATGGTC GCGGTGTGAG  
TCD537014    AATGCCTTTA CCCACCGCCA GAATGACCGG CAGCATGGTC GCGGTGTGAG  
TCD146495    AATGCCTTTA CCCACCGCCA GAATGACCGG CAGCATGGTC GCGGTGTGAG  
TCD281699    AATGCCTTTA CCCACCGCCA GAATGACCGG CAGCATGGTC GCGGTGTGAG  
TCD316823    AATGCCTTTA CCCACCGCCA GAATGACCGG CAGCATGGTC GCGGTGTGAG  
TCD530747    AATGCCTTTA CCCACCGCCA GAATGACCGG CAGCATGGTC GCGGTGTGAG  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     110        120        130        140        150         
TCD152229    CGGAAAGACT GGCGAACAAA TAGTGCGCGA AATAGAATAC CAGTACCAGT  
TCD186374    CGGAAAGACT GGCGAACAAA TAGTGCGCGA AATAGAATAC CAGTACCAGT  
TCD402284    CGGAAAGACT GGCGAACAAA TAGTGCGCGA AATAGAATAC CAGTACCAGT  
TCD428468    CGGAAAGACT GGCGAACAAA TAGTGCGCGA AATAGAATAC CAGTACCAGT  
TCD671445    CGGAAAGACT GGCGAACAAA TAGTGCGCGA AATAGAATAC CAGTACCAGT  
TCD537014    CGGAAAGACT GGCGAACAAA TAGTGCGCGA AATAGAATAC CAGTACCAGT  
TCD146495    CGGAAAGACT GGCGAACAAA TAGTGCGCGA AATAGAATAC CAGTACCAGT  
TCD281699    CGGAAAGACT GGCGAACAAA TAGTGCGCGA AATAGAATAC CAGTACCAGT  
TCD316823    CGGAAAGACT GGCGAACAAA TAGTGCGCGA AATAGAATAC CAGTACCAGT  
TCD530747    CGGAAAGACT GGCGAACAAA TAGTGCGCGA AATAGAATAC CAGTACCAGT  
 
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     160        170        180        190        200         
TCD152229    ACCAGTACCA GTACCAGTAC CAGTACCAGT ACCAGTACCA GTACCAGTAC  
TCD186374    ACCAGTACCA GTACCAGTAC CAGTACCAGT ACCAGTACCA GTACCAGTAC  
TCD402284    ACCAGTACCA GTACCAGTAC CAGTACCAGT ACCAGTACCA GTACCAGTAC  
TCD428468    ACCAGTACCA GTACCAGTAC CAGTACCAGT ACCAGTACCA GTACCAGTAC  
TCD671445    ACCAGTACCA GTACCAGTAC CAGTACCAGT ACCAGTACCA GTACCAGTAC  
TCD537014    ACCAGTACCA GTACCAGTAC CAGTACCAGT ACCAGTACCA GTACCAGTAC  
TCD146495    ACCAGTACCA GTACCAGTAC CAGTACCAGT ACCAGTACCA GTACCAGTAC  
TCD281699    ACCAGTACCA GTACCAGTAC CAGTACCAGT ACCAGTACCA GTACCAGTAC  
TCD316823    ACCAGTACCA GTACCAGTAC CAGTACCAGT ACCAGTACCA GTACCAGTAC  
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TCD530747    ACCAGTACCA GTACCAGTAC CAGTACCAGT ACCAGTACCA GTACCAGTAC  
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     210        220        230        240        250         
TCD152229    CAGTACCAGT ACCAGTACCA GTACCAGTAC CAGTACCAGT ACCAGTACCA  
TCD186374    CAGTACCAGT ACCAGTACCA GTACCAGTAC AATGACAGTT GCATCCGGCG  
TCD402284    CAGTACCAGT ACCAGTACCA GTACCAGTAC CAGTACCAGT ACCAGTACCA  
TCD428468    CAGTACCAGT ACCAGTACCA GTACCAGTAC AATGACAGTT GCATCCGGCG  
TCD671445    CAGTACCAGT ACCAGTACCA GTACAATGAC GGTTGCATCC GGCGAGAAAC  
TCD537014    CAGTACCAGT ACCAGTACCA GTACCAGTAC AATGACGGTT GCATCCGGCG  
TCD146495    CAGTACCAGT ACCAGTACAA TGACGGTTGC ATCCGGCGAG AAACCTTCCA  
TCD281699    CAGTACCAGT ACCAGTACCA GTACCAGTAC CAGTACAATG ACAGTTGCAT  
TCD316823    CAGTACCAGT ACCAGTACAA TGACGGTTGC ATCCGGCGAG AAACCTTCCA  
TCD530747    CAGTACCAGT ACCAGTACAA TGACGGTTGC ATCCGGCGAG AAACCTTCCA  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     260        270        280        290        300         
TCD152229    GTACCAGTAC CAGTACCAGT ACAATGACGG TTGCATCCGG CGAGAAACCT  
TCD186374    AGAAACCTTC CAGATGCGTA CTCATGGTAT TGGCGAA... ..........  
TCD402284    GTACCAGTAC CAGTACAATG ACGGTTGCAT CCGGCGAGAA ACCTTCCAGA  
TCD428468    AGAAACCTTC CAGATGCGTA CTCATGGTAT TGGCGAA... ..........  
TCD671445    CTTCCAGATG CGTACTCATG GTATTGGCGA A......... ..........  
TCD537014    AGAAACCTTC CAGATGCGTA CTCATGGTAT TGGCGAA... ..........  
TCD146495    GATGCGTACT CATGGTATTG GCGAA..... .......... ..........  
TCD281699    CCSGCGAGAA ACCTTCCAGA TGCGTACTCA TGGTATTGGC GAA.......  
TCD316823    GATGCGTACT CATGGTATTG GCGAA..... .......... ..........  
TCD530747    GATGCGTACT CATGGTATTG GCGAA..... .......... ..........  
 
 
             ....|....| ....|....| ....|.... 
                     310        320           
TCD152229    TCCAGATGCG TACTCATGGT ATTGGCGAA 
TCD186374    .......... .......... ......... 
TCD402284    TGCGTACTCA TGGTATTGGC GAA...... 
TCD428468    .......... .......... ......... 
TCD671445    .......... .......... ......... 
TCD537014    .......... .......... ......... 
TCD146495    .......... .......... ......... 
TCD281699    .......... .......... ......... 
TCD316823    .......... .......... ......... 
TCD530747    .......... .......... ......... 
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D.4 Sequence Alignment: VNTR locus TR4699 
 
Multiple sequence alignment of the VNTR locus TR4699 sequences from ten Salmonella 
Typhi isolates. Sequences highlighted in Yellow and in Green indicate the forward and 
reverse primers respectively. Sequences highlighted in Purple indicate the tandem repeat 
region. 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                      10         20         30         40         50              
TCD105056    TCGGGCAATT CGAGATAGGT AGAGAACAAA TTGCTGATCT TGGTGTTGGT  
TCD279436    TTGGGCAATT CGAGATAGGT AGAGAACAAA TTGCTGATCT TGGTGTTGGT  
TCD632685    TTGGGCAATT CGAGATAGGT AGAGAACAAA TTGCTGATCT TGGTGTTGGT  
TCD678093    TTGGGCAATT CGAGATAGGT AGAGAACAAA TTGCTGATCT TGGTGTTGGT  
TCD139882    TCGGGCAATT CGAGATAGGT AGAGAACAAA TTGCTGATCT TGGTGTTGGT  
TCD422011    TCGGGCAATT CGAGATAGGT AGAGAACAAA TTGCTGATCT TGGTGTTGGT  
TCD558851    TCGGGCAATT CGAGATAGGT AGAGAACAAA TTGCTGATCT TGGTGTTGGT  
TCD375103    TCGGGCAATT CGAGATAGGT AGAGAACAAA TTGCTGATCT TGGTGTTGGT  
TCD428468    TTGGGCAATT CGAGATAGGT AGAGAACAAA TTGCTGATCT TGGTGTTGGT  
TCD537014    TCGGGCAATT CGAGATAGGT AGAGAACAAA TTGCTGATCT TGGTGTTGGT  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                      60         70         80         90        100             
TCD105056    GTTGGTGTTG GTGTTGGTGT TGGGGTTCTT GATGTTAGCA TTTATGAAAA  
TCD279436    GTTGGTGTTG GTGTTGGTGT TGGTGTTGGT GTTGGTGTTG GTGTTGGTGT  
TCD632685    GTTGGTGTTG GTGTTGGTGT TGGTGTTGGT GTTGGTGTTG GTGTTGGGGT  
TCD678093    GTTGGTGTTG GTGTTGGTGT TGGTGTTGGT GTTGGTGTTG GTGTTGGTGT  
TCD139882    GTTGGTGTTG GTGTTGGTGT TGGTGTTGGT GTTGGTGTTG GTGTTGGTGT  
TCD422011    GTTGGTGTTG GTGTTGGTGT TGGTGTTGGT GTTGGGGTTC TTGATGTTAG  
TCD558851    GTTGGTGTTG GTGTTGGTGT TGGTGTTGGT GTTGGTGTTG GTGTTGGTGT  
TCD375103    GTTGGTGTTG GTGTTGGTGT TGGTGTTGGT GTTGGGGTTC TTGATGTTAG  
TCD428468    GTTGGTGTTG GTGTTGGTGT TGGTGTTGGT GTTGGTGTTG GTGTTGGTGT  
TCD537014    GTTGGTGTTG GTGTTGGTGT TGGTGTTGGT GTTGGTGTTG GTGTTGGTGT  
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             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     110        120        130        140        150         
TCD105056    AAATGGGCAG GTCCAAAACT ATACAGTGCC ATATTCAACT CCTGTATTAT  
TCD279436    TGGTGTTGGT GTTGGTGTTG GTGTTGGGGT TCTTGATGTT AGCATTTATG  
TCD632685    TCTTGATGTT AGCATTTATG AAAAAAATGG GCAGGTCCAA AACTATACAG  
TCD678093    TGGTGTTGGT GTTGGGGTTC TTGATGTTAG CATTTATGAA AAAAATGGGC  
TCD139882    TGGTGTTGGT GTTGGTGTTG GTGTTGGTGT TGGGGTTCTT GATGTTAGCA  
TCD422011    CATTTATGAA AAAAATGGGC AGGTCCAAAA CTATACAGTG CCATATTCAA  
TCD558851    TGGTGTTGGT GTTGGTGTTG GTGTTGGTGT TGGTGTTGGT GTTGGTGTTG  
TCD375103    CATTTATGAA AAAAATGGGC AGGTCCAAAA CTATACAGTG CCATATTCAA  
TCD428468    TGGTGTTGGT GTTGGTGTTG GTGTTGGTGT TGGGGTTCTT GATGTTAGCA  
TCD537014    TGGTGTTGGT GTTGGTGTTG GTGTTGGTGT TGGTGTTGGG GTTCTTGATG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     160        170        180        190        200         
TCD105056    CTTTGCCTGA TGGATATTCT AAATATAGTG TAACTATTGG TAGATACAGG  
TCD279436    AAAAAAATGG GCAGGTCCAA AACTATACAG TGCCATATTC AACTCCTGTA  
TCD632685    TGCCATATTC AACTCCTGTA TTATCTTTGC CTGATGGATA TTCTAAATAT  
TCD678093    AGGTCCAAAA CTATACAGTG CCATATTCAA CTCCTGTATT ATCTTTGCCT  
TCD139882    TTTATGAAAA AAATGGGCAG GTCCAAAACT ATACAGTGCC ATATTCAACT  
TCD422011    CTCCTGTATT ATCTTTGCCT GATGGATATT CTAAATATAG TGTAACTATT  
TCD558851    GTGTTGGTGT TGGTGTTGGT GTTGGGGTTC TTGATGTTAG CATTTATGAA  
TCD375103    CTCCTGTATT ATCTTTGCCT GATGGATATT CTAAATATAG TGTAACTATT  
TCD428468    TTTATGAAAA AAATGGGCAG GTCCAAAACT ATACAGTGCC ATATTCAACT  
TCD537014    TTAGCATTTA TGAAAAAAAT GGGCAGGTCC AAAACTATAC AGTGCCATAT  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     210        220        230        240        250         
TCD105056    GAGGTTA... .......... .......... .......... ..........  
TCD279436    TTATCTTTGC CTGATGGATA TTCTAAATAT AGTGTAACTA TTGGTAGATA  
TCD632685    AGTGTAACTA TTGGTAGATA CAGGGAGGTT A......... ..........  
TCD678093    GATGGATATT CTAAATATAG TGTAACTATT GGTAGATACA GGGAGGTTA.  
TCD139882    CCTGTATTAT CTTTGCCTGA TGGATATTCT AAATATAGTG TAACTATTGG  
TCD422011    GGTAGATACA GGGAGGTTA. .......... .......... ..........  
TCD558851    AAAAATGGGC AGGTCCAAAA CTATACAGTG CCATATTCAA CTCCTGTATT  
TCD375103    GGTAGATACA GGGAGGTTA. .......... .......... ..........  
TCD428468    CCTGTATTAT CTTTGCCTGA TGGATATTCT AAATATAGTG TAACTATTGG  
TCD537014    TCAACTCCTG TATTATCTTT GCCTGATGGA TATTCTAAAT ATAGTGTAAC  
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             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     260        270        280        290        300         
TCD105056    .......... .......... .......... .......... ..........  
TCD279436    CAGGGAGGTT A......... .......... .......... ..........  
TCD632685    .......... .......... .......... .......... ..........  
TCD678093    .......... .......... .......... .......... ..........  
TCD139882    TAGATACAGG GAGGTTA... .......... .......... ..........  
TCD422011    .......... .......... .......... .......... ..........  
TCD558851    ATCTTTGCCT GATGGATATT CTAAATATAG TGTAACTATT GGTAGATACA  
TCD375103    .......... .......... .......... .......... ..........  
TCD428468    TAGATACAGG GAGGTTA... .......... .......... ..........  
TCD537014    TATTGGTAGA TACAGGGAGG TTA....... .......... ..........  
 
 
             ....|.... 
                    
TCD105056    ......... 
TCD279436    ......... 
TCD632685    ......... 
TCD678093    ......... 
TCD139882    ......... 
TCD422011    ......... 
TCD558851    GGGAGGTTA 
TCD375103    ......... 
TCD428468    ......... 
TCD537014    ......... 
 
 
D.5 Sequence Alignment: VNTR locus Sal16 
 
Multiple sequence alignment of the VNTR locus Sal16 sequences from ten Salmonella Typhi 
isolates. Sequences highlighted in Yellow and in Green indicate the forward and reverse 
primers respectively. Sequences highlighted in Purple and in light Blue indicate the tandem 
repeat regions. 
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             ....|....| ....|....| ....|....| ....|....| ....|....|  
                      10         20         30         40         50              
TCD105056    TTGCAGTTAA TTTCTGCGAT CATTATTCTG AGCACCGCGT GCTGGATGTT  
TCD179358    TTGCAGTTAA TTTCTGCGAT CATTATTCTG AGCACCGCGT GCTGGATGTT  
TCD281699    TTGCAGTTAA TTTCTGCGAT CATTATTCTG AGCACCGCGT GCTGGATGTT  
TCD717480    TTGCAGTTAA TTTCTGCGAT CATTATTCTG AGCACCGCGT GCTGGATGTT  
TMI87513     TTGCAGTTAA TTTCTGCGAT CATTATTCTG AGCACCGCGT GCTGGATGTT  
TCD193597    TTGCAGTTAA TTTCTGCGAT CATTATTCTG AGCACCGCGT GCTGGATGTT  
TCD279436    TTGCAGTTAA TTTCTGCGAT CATTATTCTG AGCACCGCGT GCTGGATGTT  
TCD678877    TTGCAGTTAA TTTCTGCGAT CATTATTCTG AGCACCGCGT GCTGGATGTT  
TCD421690    TTGCAGTTAA TTTCTGCGAT CATTATTCTG AGCACCGCGT GCTGGATGTT  
TCD671445    TTGCAGTTAA TTTCTGCGAT CATTATTCTG AGCACCGCGT GCTGGATGTT  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                      60         70         80         90        100             
TCD105056    CTGGCGGACA TGACGAGGCG AGCAGCAGTG GCTGGCGGGA AACCACCATC  
TCD179358    CTGGCGGACA TGACGAGGCG AGCAGCAGTG GCTGGCGGGA AACCACCATC  
TCD281699    CTGGCGGACA TGACGAGGCG AGCAGCAGTG GCTGGCGGGA AACCACCATC  
TCD717480    CTGGCGGACA TGACGAGGCG AGCAGCAGTG GCTGGCGGGA AACCACCATC  
TMI87513     CTGGCGGACA TGACGAGGCG AGCAGCAGTG GCTGGCGGGA AACCACCATC  
TCD193597    CTGGCGGACA TGACGAGGCG AGCAGCAGTG GCTGGCGGGA AACCACCATC  
TCD279436    CTGGCGGACA TGACGAGGCG AGCAGCAGTG GCTGGCGGGA AACCACCATC  
TCD678877    CTGGCGGACA TGACGAGGCG AGCAGCAGTG GCTGGCGGGA AACCACCATC  
TCD421690    CTGGCGGACA TGACGAGGCG AGCAGCAGTG GCTGGCGGGA AACCACCATC  
TCD671445    CTGGCGGACA TGACGAGGCG AGCAGCAGTG GCTGGCGGGA AACCACCATC  
 
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     110        120        130        140        150         
TCD105056    ACGACCACCA TCACGACCAC CATTACGACC ATGACCATGA CCATGACCAT  
TCD179358    ACGACCACCA TCACGACCAC CATTACGACC ATGACCATGA CCATGACCAT  
TCD281699    ACGACCACCA TCACGACCAC CATCACGACC ACCATTACGA CCATGACCAT  
TCD717480    ACGACCACCA TCACGACCAC CATTACGACC ATGACCATGA CCATGACCAT  
TMI87513     ACGACCACCA TCACGACCAC CATCACGACC ACCATTACGA CCATGACCAT  
TCD193597    ACGACCACCA TCACGACCAC CATCACGACC ACCATTACGA CCATGACCAT  
TCD279436    ACGACCACCA TCACGACCAC CATCACGACC ACCATTACGA CCATGACCAT  
TCD678877    ACGACCACCA TCACGACCAC CATTACGACC ATGACCATGA CCATGACCAT  
TCD421690    ACGACCACCA TCACGACCAC CATTACGACC ATGACCATGA CCATGACCAT  
TCD671445    ACGACCACCA TCACGACCAC CATCACGACC ACCATCACGA CCACCATCAC  
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             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     160        170        180        190        200         
TCD105056    GACCATGACC ATCATGGTCA CATACATCCG GAAGGCGCAA CGTCAAAAGC  
TCD179358    GACCATGACC ATCATGGTCA CATACATCCG GAAGGCGCAA CGTCAAAAGC  
TCD281699    GACCATGACC ATGACCATGA CCATGACCAT GACCATGACC ATCATGGTCA  
TCD717480    GACCATGACC ATGACCATCA TGGTCACATA CATCCGGAAG GCGCAACGTC  
TMI87513     GACCATGACC ATGACCATGA CCATGACCAT GACCATGACC ATGACCATGA  
TCD193597    GACCATGACC ATGACCATGA CCATGACCAT GACCATGACC ATCATGGTCA  
TCD279436    GACCATGACC ATGACCATGA CCATGACCAT CATGGTCACA TACATCCGGA  
TCD678877    GACCATGACC ATGACCATGA CCATCATGGT CACATACATC CGGAAGGCGC  
TCD421690    GACCATGACC ATCATGGTCA CATACATCCG GAAGGCGCAA CGTCAAAAGC  
TCD671445    GACCACCATT ACGACCATGA CCATGACCAT GACCATGACC ATGACCATGA  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     210        220        230        240        250         
TCD105056    GTATCAA... .......... .......... .......... ..........  
TCD179358    GTATCAA... .......... .......... .......... ..........  
TCD281699    CATACATCCG GAAGGCGCAA CGTCAAAAGC GTATCAA... ..........  
TCD717480    AAAAGCGTAT CAA....... .......... .......... ..........  
TMI87513     CCATGACCAT CATGGTCACA TACATCCGGA AGGCGCAACG TCAAAAGCGT  
TCD193597    CATACATCCG GAAGGCGCAA CGTCAAAAGC GTATCAA... ..........  
TCD279436    AGGCGCAACG TCAAAAGCGT ATCAA..... .......... ..........  
TCD678877    AACGTCAAAA GCGTATCAA. .......... .......... ..........  
TCD421690    GTATCA.... .......... .......... .......... ..........  
TCD671445    CCATGACCAT GACCATGACC ATCATGGTCA CATACATCCG GAAGGCGCAA  
 
 
             ....|....| ....|.. 
                     260         
TCD105056    .......... ....... 
TCD179358    .......... ....... 
TCD281699    .......... ....... 
TCD717480    .......... ....... 
TMI87513     ATCAA..... ....... 
TCD193597    .......... ....... 
TCD279436    .......... ....... 
TCD678877    .......... ....... 
TCD421690    .......... ....... 
TCD671445    CGTCAAAAGC GTATCAA 
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D.6 Sequence Alignment: VNTR locus TR4500 
 
Multiple sequence alignment of the VNTR locus TR4500 sequences from ten Salmonella 
Typhi isolates. Sequences highlighted in Yellow and in Green indicate the forward and 
reverse primers respectively. Sequences highlighted in Purple indicate the tandem repeat 
regions. Sequences highlighted in light Blue indicate the 7bp insertion sequence identified in 
some Salmonella Typhi isolates. 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                      10         20         30         40         50              
TMI1647764   TCGTTGCTGC TCCGAAATAT TCTGTTTGTA TACTGTTTTC CGCTTCGGTT  
TCD537014    TCGTTGCTGC TCCGAAATAT TCTGTTTGTA TACTGTTTTC CGCTTCGGTT  
TCD197403    TCGTTGCTGC TCCGAAATAT TCTGTTTGTA TACTGTTTTC CGCTTCGGTT  
TCD185048    TCGTTGCTGC TCCGAAATAT TCTGTTTGTA TACTGTTTTC CGCTTCGGTT  
TCD173225    TCGTTGCTGC TCCGAAATAT TCTGTTTGTA TACTGTTTTC CGCTTCGGTT  
TCD678093    TCGTTGCTGC TCCGAAATAT TCTGTTTGTA TACTGTTTTC CGCTTCGGTT  
TCD619382    TCGTTGCTGC TCCGAAATAT TCTGTTTGTA TACTGTTTTC CGCTTCGGTT  
TCD409778    TCGTTGCTGC TCCGAAATAT TCTGTTTGTA TACTGTTTTC CGCTTCGGTT  
TCD179358    TCGTTGCTGC TCCGAAATAT TCTGTTTGTA TACTGTTTTC CGCTTCGGTT  
TMI83959     TCGTTGCTGC TCCGAAATAT TCTGTTTGTA TACTGTTTTC CGCTTCGGTT  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                      60         70         80         90        100             
TMI1647764   TTACCAGTCT CAACCTGGCT GTAAGTTCCC GCCGTTCCTT CTGGCCCATA  
TCD537014    TTACCAGTCT CAACCTGGCT GTAAGTTCCC GCCGTTCCTT CTGGCCCATA  
TCD197403    TTACCAGTCT CAACCTGGCT GTAAGTTCCC GCCGTTCCTT CTGGCCCATA  
TCD185048    TTACCAGTCT CAACCTGGCT GTAAGTTCCC GCCGTTCCTT CTGGCCCATA  
TCD173225    TTACCAGTCT CAACCTGGCT GTAAGTTCCC GCCGTTCCTT CTGGCCCATA  
TCD678093    TTACCAGTCT CAACCTGGCT GTAAGTTCCC GCCGTTCCTT CTGGCCCATA  
TCD619382    TTACCAGTCT CAACCTGGCT GTAAGTTCCC GCCGTTCCTT CTGGCCCATA  
TCD409778    TTACCAGTCT CAACCTGGCT GTAAGTTCCC GCCGTTCCTT CTGGCCCATA  
TCD179358    TTACCAGTCT CAACCTGGCT GTAAGTTCCC GCCGTTCCTT CTGGCCCATA  
TMI83959     TTACCAGTCT CAACCTGGCT GTAAGTTCCC GCCGTTCCTT CTGGCCCATA  
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             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     110        120        130        140        150         
TMI1647764   TTGTGGAGAT AATCCTGCAG TTCCTTCTCA TTCATGGTTT TAATATCGGG  
TCD537014    TTGTGGAGAT AATCCTGCAG TTCCTTCTCA TTCATGGTTT TAATATCGGG  
TCD197403    TTGTGGAGAT AATCCTGCAG TTCCTTCTCA TTCATGGTTT TAATATCGGG  
TCD185048    TTGTGGAGAT AATCCTGCAG TTCCTTCTCA TTCATGGTTT TAATATCGGG  
TCD173225    TTGTGGAGAT AATCCTGCAG TTCCTTCTCA TTCATGGTTT TAATATCGGG  
TCD678093    TTGTGGAGAT AATCCTGCAG TTCCTTCTCA TTCATGGTTT TAATATCGGG  
TCD619382    TTGTGGAGAT AATCCTGCAG TTCCTTCTCA TTCATGGTTT TAATATCGGG  
TCD409778    TTGTGGAGAT AATCCTGCAG TTCCTTCTCA TTCATGGTTT TAATATCGGG  
TCD179358    TTGTGGAGAT AATCCTGCAG TTCCTTCTCA TTCATGGTTT TAATATCGGG  
TMI83959     TTGTGGAGAT AATCCTGCAG TTCCTTCTCA TTCATGGTTT TAATATCGGG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     160        170        180        190        200   
TMI1647764   TAAATCACCC CCTGATTTGT TCAGATTTTC AACAGGGGGA CAGTTATTGC  
TCD537014    TAAATCACCC CCTGATTTGT TCAGATTTTC AACAGGGGGA CAGTTATTGC  
TCD197403    TAAATCACCC CCTGATTTGT TCAGATTTTC AACAGGGGGA CAGTTATTGC  
TCD185048    TAAATCACCC CCTGATTTGT TCAGATTTTC AACAGGGGGA CAGTTAGAGT  
TCD173225    TAAATCACCC CCTGATTTGT TCAGATTTTC AACAGGGGGA CAGTTATTGC  
TCD678093    TAAATCACCC CCTGATTTGT TCAGATTTTC AACAGGGGGA CAGTTAGAGT  
TCD619382    TAAATCACCC CCTGATTTGT TCAGATTTTC AACAGGGGGA CAGTTAGAGT  
TCD409778    TAAATCACCC CCTGATTTGT TCAGATTTTC AACAGGGGGA CAGTTATTGC  
TCD179358    TAAATCACCC CCTGATTTGT TCAGATTTTC AACAGGGGGA CAGTTATTGC  
TMI83959     TAAATCACCC CCTGATTTGT TCAGATTTTC AACAGGGGGA CAGTTAGAGT  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     210        220        230        240        250     
TMI1647764   CACGAGTCCG AGTCCAAGGG GCGCAAGCGC CCTGGTCGGC TGCCGCCTCC  
TCD537014    CACGAGTCCG AGTCCGAGTC CAAGGGGCGC AAGCGCCCTG GTCGGCTGCC  
TCD197403    CACGAGTCCG AGTCCGAGTC CAAGGGGCGC AAGCGCCCTG GTCGGCTGCC  
TCD185048    CCAAGGGGCG CAAGCGCCCT GGTCGGCTGC CGCCTCCTGA ACGTCAACGG  
TCD173225    CACGAGTCCG AGTCCGAGTC CAAGGGGCGC AAGCGCCCTG GTCGGCTGCC  
TCD678093    CCAAGGGGCG CAAGCGCCCT GGTCGGCTGC CGCCTCCTGA ACGTCAACGG  
TCD619382    CCAAGGGGCG CAAGCGCCCT GGTCGGCTGC CGCCTCCTGA ACGTCAACGG  
TCD409778    CACGAGTCCG AGTCCAAGGG GCGCAAGCGC CCTGGTCGGC TGCCGCCTCC  
TCD179358    CACGAGTCCG AGTCCAAGGG GCGCAAGCGC CCTGGTCGGC TGCCGCCTCC  
TMI83959     CCAAGGGGCG CAAGCGCCCT GGTCGGCTGC CGCCTCCTGA ACGTCAACGG  
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             ....|....| ....|....| ....|....| ....|....| ....|.... 
                     260        270        280        290               
TMI1647764   TGAACGTCAA CGGCTTTACG AACCTTTTTC CACTTCACCG CAA...... 
TCD537014    GCCTCCTGAA CGTCAACGGC TTTACGAACC TTTTTCACTT CACCGCA.. 
TCD197403    GCCTCCTGAA CGTCAACGGC TTTACGAACC TTTTTCCACT TCACCGCAA 
TCD185048    CTTTACGAAC CTTTTTCCAC TTCACCGCA. .......... ......... 
TCD173225    GCCTCCTGAA CGTCAACGGC TTTACGAACC TTTTTCCACT TCACCGCA. 
TCD678093    CTTTACGAAC CTTTTTCCAC TTCACCGCA. .......... ......... 
TCD619382    CTTTACGAAC CTTTTTCCAC TTCACCGCA. .......... ......... 
TCD409778    TGAACGTCAA CGGCTTTACG AACCTTTTTC CACTTCACCG CA....... 
TCD179358    TGAACGTCAA CGGCTTTACG AACCTTTTTC CACTTCACCG CA....... 
TMI83959     CTTTACGAAC CTTTTTCCAC TTCACCGCA. .......... ......... 
 
 
D.7 Sequence Alignment: VNTR locus Sal20 
 
Multiple sequence alignment of the VNTR locus Sal20 sequences from ten Salmonella Typhi 
isolates. Sequences highlighted in Yellow and in Green indicate the forward and reverse 
primers respectively. Sequences highlighted in Purple indicate the tandem repeat regions.  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                      10         20         30         40         50              
TCD619382    TCAGCCGACA CAACTTAACG AAGTGCCGTG GAACGAGCAG ACGCCAGAAC  
TMI83959     TCAGCCGACA CAACTTAACG AAGTGCCGTG GAACGAGCAG ACGCCAGAAC  
TCD105056    TCAGCCGACA CAACTTAACG AAGTGCCGTG GAACGAGCAG ACGCCAGAAC  
TCD111848    TCAGCCGACA CAACTTAACG AAGTGCCGTG GAACGAGCAG ACGCCAGAAC  
TCD179358    TCAGCCGACA CAACTTAACG AAGTGCCGTG GAACGAGCAG ACGCCAGAAC  
TCD316823    TCAGCCGACA CAACTTAACG AAGTGCCGTG GAACGAGCAG ACGCCAGAAC  
TCD110945    TCAGCCGACA CAACTTAACG AAGTGCCGTG GAACGAGCAG ACGCCAGAAC  
TCD185048    TCAGCCGACA CAACTTAACG AAGTGCCGTG GAACGAGCAG ACGCCAGAAC  
TCD298424    TCAGCCGACA CAACTTAACG AAGTGCCGTG GAACGAGCAG ACGCCAGAAC  
TCD678093    TCAGCCGACA CAACTTAACG AAGTGCCGTG GAACGAGCAG ACGCCAGAAC  
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             ....|....| ....|....| ....|....| ....|....| ....|....|  
                      60         70         80         90        100             
TCD619382    AACGCCAGCA AACGCTACAG CGCCAGCGTC AGGCGCAGCA GCAGCAGCAG  
TMI83959     AACGCCAGCA AACGCTACAG CGCCAGCGTC AGGCGCAGCA GCAGCAGCAG  
TCD105056    AACGCCAGCA AACGCTACAG CGCCAGCGTC AGGCGCAGCA GCAGCAGCAG  
TCD111848    AACGCCAGCA AACGCTACAG CGCCAGCGTC AGGCGCAGCA GCAGCAGCAG  
TCD179358    AACGCCAGCA AACGCTACAG CGCCAGCGTC AGGCGCAGCA GCAGCAGCAG  
TCD316823    AACGCCAGCA AACGCTACAG CGCCAGCGTC AGGCGCAGCA GCAGCAGCAG  
TCD110945    AACGCCAGCA AACGCTACAG CGCCAGCGTC AGGCGCAGCA GCAGCAGCAG  
TCD185048    AACGCCAGCA AACGCTACAG CGCCAGCGTC AGGCGCAGCA GCAGCAGCAG  
TCD298424    AACGCCAGCA AACGCTACAG CGCCAGCGTC AGGCGCAGCA GCAGCAGCAG  
TCD678093    AACGCCAGCA AACGCTACAG CGCCAGCGTC AGGCGCAGCA GCAGCAGCAG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     110        120        130        140        150         
TCD619382    CAGCAGCAGC AGCAGCAGTG GGCTCAAACG CAGCCTGTTC AGCAACCACG  
TMI83959     CAGCAGCAGC AGCAGCAGTG GGCTCAAACG CAGCCTGTTC AGCAACCACG  
TCD105056    CAGCAGCAGT GGGCTCAAAC GCAGCCTGTT CAGCAACCAC GCACGCAGCC  
TCD111848    CAGCAGCAGC AGCAGTGGGC TCAAACGCAG CCTGTTCAGC AACCACGCAC  
TCD179358    CAGCAGCAGC AGCAGTGGGC TCAAACGCAG CCTGTTCAGC AACCACGCAC  
TCD316823    CAGCAGCAGT GGGCTCAAAC GCAGCCTGTT CAGCAACCAC GCACGCAGCC  
TCD110945    CAGCAGTGGG CTCAAACGCA GCCTGTTCAG CAACCACGCA CGCAGCCGCG  
TCD185048    CAGCAGCAGC AGCAGCAGTG GGCTCAAACG CAGCCTGTTC AGCAACCACG  
TCD298424    CAGCAGTGGG CTCAAACGCA GCCTGTTCAG CAACCACGCA CGCAGCCGCG  
TCD678093    CAGCAGCAGC AGCAGCAGTG GGCTCAAACG CAGCCTGTTC AGCAACCACG  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|.. 
                     160        170        180        190               
TCD619382    CACGCAGCCG CGGGTAAACG AACAGCCGCA AACGCGCACG GTACAGT 
TMI83959     CACGCAGCCG CGGGTAAACG AACAGCCGCA AACGCGCACG GTACAGT 
TCD105056    GCGGGTAAAC GAACAGCCGC AAACGCGCAC GGTACAGTA. ....... 
TCD111848    GCAGCCGCGG GTAAACGAAC AGCCGCAAAC GCGCACGGTA CAGT... 
TCD179358    GCAGCCGCGG GTAAACGAAC AGCCGCAAAC GCGCACGGTA CAGT... 
TCD316823    GCGGGTAAAC GAACAGCCGC AAACGCGCAC GGTACAGT.. ....... 
TCD110945    GGTAAACGAA CAGCCGCAAA CGCGCACGGT ACAGT..... ....... 
TCD185048    CACGCAGCCG CGGGTAAACG AACAGCCGCA AACGCGCACG GTACAGT 
TCD298424    GGTAAACGAA CAGCCGCAAA CGCGCACGGT ACAGT..... ....... 
TCD678093    CACGCAGCCG CGGGTAAACG AACAGCCGCA AACGCGCACG GTACAGT 
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Appendix E 
Salmonella serotyping flowchart
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Appendix F  
 
Agarose gel electrophoresis 
 
F.1 10X TAE buffer (Tris: acetate: EDTA) 
48 g Tris (Merck) 
7.5 g EDTA (Sigma) 
Dissolve in 500 ml distilled H2O 
11 ml of glacial acetic acid (Merck) 
Adjust volume to 1L using distilled H2O 
 
 
F.2 1X TAE buffer  
100 ml of 10X TAE buffer 
900 ml of distilled dH20 
 
F.3 Loading dye: 0.25% Bromophenol blue 
0.25 g Bromophenol blue (Merck) 
40 g Sucrose (Merck) 
Dissolve in 100 ml distilled dH20 
 
F.4 SeaKem LE Agarose gel (1.5%) 
1.5 g SeaKem LE agarose 
100 ml 1X TAE buffer 
Dissolve agarose by boiling. Add 6 µl of ethidium bromide solution to the cooled agarose 
solution. Use 1 X TAE buffer as running buffer 
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Appendix G  
 
MLVA profiles identified through MLVA typing of Salmonella Typhi from SSA 
 
TR1 TR2 Sal02 Sal20 TR4699 MLVA profile* 
176 303 201 169 187 STyMT-48 
176 303 201 169 0 STyMT-49 
176 303 201 0 187 STyMT-50 
176 303 237 199 187 STyMT-51 
253 383 303 178 223 STyMT-52 
204 495 297 178 253 STyMT-54 
183 335 201 184 259 STyMT-55 
218 351 243 187 331 STyMT-56 
183 383 237 184 223 STyMT-57 
211 463 261 187 205 STyMT-58 
197 399 315 190 241 STyMT-59 
204 391 243 187 241 STyMT-60 
190 455 243 187 247 STyMT-61 
190 535 249 190 241 STyMT-62 
197 567 231 190 229 STyMT-63 
197 309 261 187 247 STyMT-64 
197 655 255 190 259 STyMT-65 
197 343 285 178 211 STyMT-66 
197 367 273 190 241 STyMT-67 
197 391 315 190 241 STyMT-68 
197 399 219 187 241 STyMT-69 
197 399 285 187 247 STyMT-70 
197 479 303 190 241 STyMT-71 
197 407 315 190 241 STyMT-72 
197 415 315 190 235 STyMT-73 
197 423 303 190 241 STyMT-74 
197 423 315 190 235 STyMT-75 
197 431 309 190 241 STyMT-76 
197 447 315 190 247 STyMT-77 
197 455 249 190 247 STyMT-78 
197 471 219 187 241 STyMT-79 
197 471 303 190 241 STyMT-80 
197 471 315 190 235 STyMT-81 
197 479 303 190 241 STyMT-82 
197 487 213 193 247 STyMT-83 
197 487 285 190 241 STyMT-84 
197 487 309 196 229 STyMT-85 
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197 487 309 196 241 STyMT-86 
197 495 255 190 247 STyMT-87 
197 495 297 190 241 STyMT-88 
197 503 225 187 241 STyMT-89 
197 503 249 190 241 STyMT-90 
197 503 255 190 247 STyMT-91 
197 503 279 196 247 STyMT-92 
197 503 285 190 241 STyMT-93 
197 511 255 190 247 STyMT-94 
197 511 255 190 259 STyMT-95 
197 511 309 190 241 STyMT-96 
197 519 249 190 241 STyMT-97 
197 519 303 190 259 STyMT-98 
197 527 209 190 247 STyMT-99 
197 527 237 187 229 STyMT-100 
197 527 243 187 235 STyMT-101 
197 527 249 190 247 STyMT-102 
197 527 255 190 247 STyMT-103 
197 527 309 190 247 STyMT-104 
197 527 315 190 247 STyMT-105 
197 535 243 190 235 STyMT-106 
197 543 249 187 253 STyMT-107 
197 543 255 190 247 STyMT-108 
197 551 249 190 247 STyMT-109 
253 359 273 178 271 STyMT-110 
197 551 255 190 247 STyMT-111 
197 559 249 190 247 STyMT-112 
197 567 243 190 253 STyMT-113 
197 567 249 190 247 STyMT-114 
197 567 249 190 253 STyMT-115 
197 567 249 190 259 STyMT-116 
197 567 255 190 247 STyMT-117 
197 567 261 187 274 STyMT-118 
197 567 315 190 235 STyMT-119 
281 519 267 190 271 STyMT-120 
197 575 237 190 229 STyMT-121 
197 575 249 187 253 STyMT-122 
197 575 249 190 259 STyMT-123 
197 575 455 190 253 STyMT-124 
197 583 237 190 229 STyMT-125 
197 583 249 187 259 STyMT-126 
197 583 249 190 241 STyMT-127 
197 583 249 190 247 STyMT-128 
197 583 249 190 253 STyMT-129 
  Appendix G 
163 
 
197 583 255 190 247 STyMT-130 
197 583 367 190 241 STyMT-131 
197 591 255 190 247 STyMT-132 
197 591 255 190 253 STyMT-133 
197 591 261 190 247 STyMT-134 
197 599 249 190 241 STyMT-135 
197 599 255 190 247 STyMT-136 
197 599 261 190 247 STyMT-137 
197 615 255 190 247 STyMT-139 
197 650 321 190 241 STyMT-140 
204 335 267 187 337 STyMT-141 
204 391 315 178 301 STyMT-142 
204 399 219 190 253 STyMT-143 
204 431 315 190 253 STyMT-144 
204 471 249 187 253 STyMT-145 
204 583 249 190 253 STyMT-146 
211 351 255 187 295 STyMT-147 
211 359 255 187 289 STyMT-148 
211 367 138 199 241 STyMT-149 
211 375 219 196 241 STyMT-150 
211 447 249 175 211 STyMT-151 
211 463 261 181 211 STyMT-152 
211 503 255 181 205 STyMT-153 
211 511 249 187 211 STyMT-154 
211 527 255 181 205 STyMT-155 
218 343 237 187 211 STyMT-156 
218 343 249 187 319 STyMT-157 
295 311 249 187 331 STyMT-158 
218 351 249 187 331 STyMT-159 
218 359 249 187 319 STyMT-160 
218 375 243 187 247 STyMT-161 
218 455 237 187 211 STyMT-162 
218 463 255 187 247 STyMT-163 
218 479 255 184 241 STyMT-164 
218 479 255 187 241 STyMT-165 
218 511 273 187 307 STyMT-166 
218 511 309 178 267 STyMT-167 
225 315 249 184 289 STyMT-168 
225 359 273 187 247 STyMT-169 
225 375 0 178 223 STyMT-170 
225 399 175 178 223 STyMT-171 
225 423 267 184 229 STyMT-172 
225 463 225 184 241 STyMT-173 
225 463 261 199 271 STyMT-174 
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225 503 273 178 295 STyMT-175 
225 543 231 199 223 STyMT-176 
225 543 249 187 223 STyMT-177 
232 335 261 184 259 STyMT-178 
232 335 261 187 232 STyMT-179 
232 335 261 187 259 STyMT-180 
232 335 263 187 187 STyMT-181 
232 351 303 178 229 STyMT-182 
232 359 219 181 313 STyMT-183 
232 375 163 184 241 STyMT-184 
232 399 583 193 205 STyMT-185 
232 407 273 184 295 STyMT-186 
232 415 151 184 229 STyMT-187 
232 423 231 187 223 STyMT-188 
232 423 261 184 223 STyMT-189 
232 455 219 178 247 STyMT-190 
232 455 261 184 247 STyMT-191 
232 487 261 178 229 STyMT-192 
232 503 201 184 259 STyMT-193 
232 503 261 187 253 STyMT-194 
232 543 255 184 247 STyMT-195 
232 551 0 184 247 STyMT-196 
232 551 267 184 241 STyMT-197 
232 559 261 184 241 STyMT-198 
232 559 267 184 241 STyMT-199 
232 575 261 187 223 STyMT-200 
232 650 261 184 247 STyMT-201 
239 359 285 181 265 STyMT-202 
239 367 279 181 265 STyMT-203 
239 375 285 187 289 STyMT-204 
239 383 0 184 247 STyMT-205 
239 383 168 184 253 STyMT-206 
239 383 267 181 253 STyMT-207 
239 391 163 184 253 STyMT-208 
239 391 267 181 253 STyMT-209 
239 399 213 187 247 STyMT-210 
239 399 279 178 283 STyMT-211 
239 431 285 178 229 STyMT-213 
239 439 267 178 235 STyMT-214 
239 455 0 184 259 STyMT-215 
239 455 237 187 271 STyMT-216 
239 455 291 178 211 STyMT-217 
239 463 291 190 235 STyMT-218 
239 503 285 178 229 STyMT-219 
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239 519 267 184 235 STyMT-220 
239 519 273 178 253 STyMT-221 
239 567 261 184 229 STyMT-222 
239 575 261 184 253 STyMT-223 
246 415 249 178 241 STyMT-224 
239 583 273 187 247 STyMT-225 
246 359 303 178 277 STyMT-227 
246 359 309 178 271 STyMT-228 
246 367 273 178 229 STyMT-229 
246 367 303 178 271 STyMT-230 
246 367 309 178 265 STyMT-231 
246 367 315 178 271 STyMT-232 
246 375 303 178 295 STyMT-233 
246 383 273 178 295 STyMT-234 
246 383 527 190 217 STyMT-235 
246 447 261 184 241 STyMT-236 
246 471 291 178 241 STyMT-237 
246 535 0 184 223 STyMT-238 
253 311 267 187 337 STyMT-239 
253 383 309 178 271 STyMT-240 
253 463 297 178 241 STyMT-241 
253 503 255 184 241 STyMT-242 
255 479 249 187 223 STyMT-243 
260 327 267 175 223 STyMT-244 
260 375 273 178 217 STyMT-245 
260 415 237 178 253 STyMT-246 
260 423 273 178 255 STyMT-247 
267 327 186 175 259 STyMT-248 
267 343 279 187 349 STyMT-249 
267 375 219 178 199 STyMT-250 
271 479 297 196 235 STyMT-251 
281 431 219 178 223 STyMT-252 
281 463 249 178 271 STyMT-253 
197 471 315 196 241 STyMT-254 
197 487 303 190 241 STyMT-255 
197 487 309 193 241 STyMT-256 
197 503 321 187 229 STyMT-257 
253 311 267 184 253 STyMT-258 
197 543 351 187 289 STyMT-259 
197 567 249 190 241 STyMT-260 
197 583 249 187 241 STyMT-261 
218 343 249 187 295 STyMT-262 
225 319 249 187 225 STyMT-263 
225 319 249 187 289 STyMT-264 
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225 511 249 184 235 STyMT-265 
232 351 303 178 289 STyMT-266 
246 359 309 178 277 STyMT-267 
246 359 321 178 211 STyMT-268 
246 383 309 178 271 STyMT-269 
197 261 0 190 253 STyMT-270 
197 309 303 190 235 STyMT-271 
197 319 249 187 253 STyMT-272 
197 343 243 190 259 STyMT-273 
176 303 201 169 253 STyMT-274 
239 519 0 184 253 STyMT-275 
239 543 0 184 253 STyMT-276 
197 591 249 190 247 STyMT-277 
* STyMT - Salmonella Typhi MLVA type 
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